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Abstract
The prevalence of allergic diseases, such as asthma, rhinitis, eczema and food
allergies has increased dramatically over the last few decades and is now a major
health and economic burden throughout the developed and developing worlds. Type
I (immediate) hypersensitivity reactions are mediated by immunoglobulin E (IgE)
responses directed against innocuous environmental antigens, such as pollen, house-
dust mites or animal dander. It is the resulting release of pharmacological mediators
by IgE-sensitised mast cells that cause the symptoms of asthma and allergic rhinitis.
The induction of IgE is dependent on CD4+ T cells of the Th2 phenotype which are
characterised by the production of specific cytokines (IL-4, IL-5 and IL-13). In
contrast, the presence of allergen reactive Thl cells, which secrete IFN-y, in non-
allergic healthy individuals suggests that Thl immunity is not damaging to the host
and is possibly associated with protective immunity.
It is clear with the high incidence of atopic disorders combined with existing
treatments, which are in general symptomatic, that there is a requirement for new
therapeutic agents. Since CD4+ T cells play an important role in the response to
allergens they are an obvious target for drug development and they can be targeted
directly, with the aim of inducing specific tolerance. A second strategy for inhibiting
the synthesis of Th2 cytokines may be achieved by promoting the induction of Thl
immunity.
Therefore, the main aim of this study was to investigate these different
approaches for the modulation of Th2 immunity to the major house dust mite
allergen Der p 1. Tolerance induction or the promotion ofThl responses were
attempted by intranasal delivery of antigen alone, by the systemic or mucosal
delivery ofDer p 1 in PLG polymer microparticles (MEA) and finally, by intranasal
administration with chitosan, an enhancer of epithelial permeability. In order to
investigate the efficacy of the regimens of vaccination, an adjuvant free model of
Th2 cytokine-mediated allergic inflammation was developed in vivo in H-2b mice.
Vaccination with microencapsulated antigen failed to elicit a Thl response or
induce tolerance despite altering the kinetics, dose and method of delivery. In fact,
the Th2 phenotype was usually exacerbated following administration of
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MEA/Der p 1 particles. Intranasal co-administration of antigen with chitosan
inhibited Th2 cytokine production but not as a result of the tolerance induction.
Similarly, high doses of soluble peptide delivered intranasally, failed to tolerise
allergen-specific Th2 immunity.
In conclusion, the redirection of the Th2 immune response and the induction
of tolerance were difficult to achieve. However, chitosan which was not as
extensively researched as the other approaches may prove to be of therapeutic value.
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Chapter 1
General Introduction
1.1 T Cell Subsets
There are two distinct T cell lineages - a:p and y:5. In mice and humans most
T cells (about 95-99%) express a:|3 T cell receptors, whereas the minority (about 1-
5%) express y:8 T cell receptors. In sheep the ratio of a:P to y:8 T cells is about
50:50. The a:P+ T cells can be further distinguished by the presence of a surface co-
receptor protein, either CD4 or CD8. In general, CD8+ T lymphocytes recognise
peptide fragments (epitopes) derived from endogenous proteins (i.e. proteins that are
synthesised within the cell or artificially introduced directly into the cytoplasm or the
nucleus). These are presented on the cell surface in association with MHC class I
molecules. CD4+ T lymphocytes recognise peptide epitopes derived from exogenous
or membrane proteins, which enter the cell via endocytosis or phagocytosis and are
primarily, degraded by lysosomal proteases. These are presented on the cell surface
bound to MHC class II molecules.
1.1.1 MHC Class I Molecules
MHC class I molecules consist of a heavy chain, p2-microglobulin and a
peptide. The heavy chain is 45 kDa and is encoded by the genes HLA-A, HLA-B and
HLA-C on chromosome 6 in humans and chromosome 17 in mice (H-2K, H-2D,
H-2L). The gene for p2-microglobulin is located on chromosome 15 in humans and
on chromosome 2 in mice. The peptide is usually eight to ten amino acids long and is
derived from cellular proteins or foreign antigens [1]. The MHC genes have
extensive polymorphism, which is vital for antigen presentation and recognition by T
cells. The two extracellular domains ai and a2, form the peptide-binding groove and
it is here where most of the polymorphic residues are located. Anchor residues
determine peptide binding to MHC molecules. The side chains of the residues are
buried in pockets within the MHC peptide-binding groove, usually one anchor
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residue is located at the carboxyl terminus and a second at a varying internal position
depending on the identity of the class I allele [2],
Cytoplasmic antigens are degraded into short peptide fragments by
proteasomes. These are large cylindrical complexes with a hollow core consisting of
the active sites of proteolytic subunits. Certain features ofproteasomes distinguish
them from most other enzymes. First, proteasomes are multicatalytic, i.e. they
contain independent active sites and may possess as many as five to nine different
activities [3]. Secondly, they degrade proteins in a processive fashion, i.e. one
molecule is degraded to completion before another is processed [4].
The delivery of peptides from the cytoplasm into the endoplasmic reticulum
is facilitated by TAP (transporter associated with antigen processing). TAP is
composed of two homologous integral membrane proteins, TAP1 and TAP2, that act
in an ATP-dependent manner. ATP hydrolysis is required for the TAP1/2 complex to
translocate peptides into the ER but is not required for peptide binding [5].
In the endoplasmic reticulum, newly synthesised MHC class I a chains bind
to calnexin, a chaperone protein which functions to retain the MHC class I molecule
in a partially folded state. B2-microglobulin then binds to the a chain, resulting in the
dissociation of the complex from calnexin and the subsequent association with a
second chaperone protein, calreticulin. Tapasin, a TAP 1-associated protein, forms a
bridge between the MHC class I molecules and the TAP complex, until the delivery
of a suitable peptide from the cytosol. Finally, peptide binding to the partially folded
heterodimer enables its release from the TAP/tapasin/calreticulin complex, allowing
the now fully folded MHC class I molecule to leave the ER and be transported to the
cell surface [6].
1.1.2 MHC Class II Molecules
In humans, class II molecules are encoded by the polymorphic HLA-DR,
HLA-DQ and HLA-DP genes and expressed as two noncovalent heterodimers of two
transmembrane polypeptides, the a-chain (35 kDa) and the P-chain (27 kDa) [7].
MHC class II molecules mainly present peptides derived from internalised proteins
that have entered the cell by endocytosis. This process leads to the containment of
the protein antigen in endosomes, which become increasingly acidic, as they progress
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deeper into the cell. The endosomal proteins are eventually degraded to peptides by
the action of acid proteases.
In the endoplasmic reticulum, MHC class II-associated invariant chain (Ii)
assembles with newly synthesised MHC class II molecules. This prevents premature
binding to peptides transported into the ER lumen by the TAP transporter, or to
endogenous peptides newly synthesised by the cell itself. Ii chain binds to the MHC
class II molecule with part of its polypeptide chain lying within the peptide-binding
groove thus preventing binding of other peptides. The invariant chain also targets the
delivery ofMHC class II molecules from the ER to an appropriate acidic endosomal
compartment, where peptide loading can occur. Over a period of 2-4 hours in this
compartment, the invariant chain is cleaved by proteases such as cathepsin S or
cathepsin L [8]. Initial cleavage generates a truncated form of the invariant chain that
remains bound to the MHC class II molecule and is retained within the endocytic
compartment. Subsequent cleavage releases the MHC class II molecule from the
membrane-associated fragment of Ii, leaving a short fragment of Ii, called CLIP
(class Il-associated invariant chain peptide) still bound to the MHC class II molecule.
The class II-like molecule DM, binds to the MHC/CLIP complex, catalysing the
release ofCLIP which enables subsequent binding of antigenic peptides, before
transportation to the cell surface. The DM molecule also binds to and stabilises
empty MHC class II molecules that would otherwise aggregate [9]. Invariant chain-
deficient mice (Ii"7") mice have impaired ability to present MHC class II-restricted
antigens, and reduced numbers ofCD4+ T cells [10]. In contrast, DM"7" mice have
normal amounts of class II molecules at the cell surface, but most of these are
associated with invariant chain-derived CLIP peptides. These mice contain large
numbers of CD4+ T cells, which is indicative of positive selection in the thymus [11].
1.1.3 Presentation of Exogenous Antigens on MHC Class I Molecules
The concept that MHC class I-restricted presentation is only associated with
the cytoplasmic degradation of cellular (endogenous) proteins, and is considered
inaccessible to exogenous antigens, is not strictly true. Certain exogenous elements
can gain entry into this so-called endogenous pathway by a mechanism termed cross-
presentation [12, 13, 14 reviews]. Class I-restricted presentation of exogenously
derived antigen is particularly important for priming CTL responses, especially to
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proteins expressed within extra-lymphoid (peripheral) compartments. This cross-
presentation was first implicated in studies examining CTL induction in response to
minor histocompatability antigens [15]. Cross-priming has subsequently been shown
to occur for viral proteins [16], protein-coated spleen cells [17] and tumour antigens
[18], Bevan proposed that cross-presentation may provide the immune system with a
mechanism to detect and respond to tissue-tropic viruses that do not infect APCs
[19]. Bennett et al. showed that CTL induction by cross-priming with cell associated
ovalbumin required the active involvement ofCD4+ helper T cells. Most importantly,
the involvement of this CD4+ population was only effective when both the helper and
CTL determinants were recognised on the same APC [20]. An earlier study using
OVA bound to latex beads, suggested that class Il-restricted T cell help was
important for CTL induction but did not address the APC requirements [21],
Cross-priming in the context of T cell priming has just been discussed but the
cross-presentation of exogenous antigens can also contribute to T cell tolerance,
specifically CD8+ T cell deletion. This mechanism is often referred to as cross-
tolerance. An early study by von Boehmer and Hafen showed that maturing CD8+ T
cells could be tolerised to minor histocompatability antigens expressed on thymic
epithelial cells, even when such cells did not carry the restricting MHC class I
elements [22], It was thought that APCs of haematopoietic origin were involved,
resulting in thymic cross-tolerance. Peripheral cross-tolerance has also been
demonstrated in transgenic rat insulin promoter (RIP)-mOVA mice [23]. OVA-
specific CD8+ T cells were adoptively transferred into RIP-mOVA mice which
initially resulted in T cell activation (in those lymph nodes draining OVA-expressing
tissues) but eventually led to T cell deletion.
This deletion ofCD8+ T cells via cross-presentation raised a conceptual
paradox. The cross-presentation of peripheral exogenous antigens occurs by
professional APCs which usually results in immunogenic rather than tolerogenic T
cell responses. This was demonstrated by Ohashi et al. and Oldstone et al. who found
that naive CD8+ T cells ignored lymphocytic choriomeningitis virus (LCMV)
proteins expressed exclusively by pancreatic [l-cells (i.e. non-professional APCs) but
became autoaggressive when the virus was able to access professional APCs [24,
550]. A possible explanation for the existence of some models that show ignorance
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of islet antigens whereas others observe tolerance is the effect of antigen dose. Kurts
et al. demonstrated that the concentration of self antigen was critical in the induction
of ignorance vs tolerance [25]. There was no detectable cross-presentation when low
concentrations of ovalbumin were expressed in the pancreatic islets of transgenic
mice, with the CD8+ T cell compartment remaining ignorant ofOVA. However, in
mice expressing higher doses ofOVA cross-presentation was detectable resulting in
peripheral deletion of OVA-specific CD8+ T cells. This phenomenon was confirmed
by reconstituting the bone marrow compartment with cells incapable of presenting
OVA, which resulted in a conversion from deletional tolerance to ignorance.
Exogenous antigens can gain access to the MHC class I-restricted pathway by
a number ofmechanisms. Regurgitation involves antigen degradation by
phagocytosis with subsequent release of fragments for binding to cell surface class I
[26]. A number of groups have demonstrated that the heat shock protein gp96 can
mediate cross-presentation [27, 28]. As yet, the APCs targeted by gp96 have not
been identified but the overexpression of certain proteins in transgenic models or
viral infection could promote increased expression of this stress-induced protein, thus
facilitating class I presentation. Access via the cytosolic pathway is another
mechanism. In this case, antigens in the extracellular fluids can be internalised into
phagocytes by phagocytosis (large particles) [29, 30], or macropinocytosis (large
scale fluid phase uptake involving small particles/soluble antigens). Dendritic cells
and macrophages have been implicated in the macropinocytosis mechanism [31, 32].
1.2 CD4+ T Cells
1.2.1 The Thl /Th2 Paradigm
The T helper 1 (Thl) and Th2 patterns of cytokine production were originally
described among mouse CD4+ T cell clones [33, 34] and later among human T cells
[35]. Since then, multiple parameters ofT cell activation have been discovered that
influence Thl /Th2 development:
23
• Type ofAPCs present at site of antigen exposure
• Antigen dose
• Antigen structure, particularly the affinity of the processed peptides for MHC and
TCR
• Levels of costimulation (positive or negative signals) during T cell priming
• Genetic background
• Pathogen derived materials
• Presence of cytokines in the priming milieu (see figure 1.1, pg 25).
Usually, Thl /Th2 priming (directly or indirectly) is influenced by several of the
above factors. In addition, there is strong evidence suggesting that Thl and Th2 cells
are not derived from distinct lineages, but develop from the same Th-cell precursor
under the influence of environmental and genetic factors acting at the level of antigen
presentation. When first stimulated by antigen on APCs, naive CD4+ T cells initially
produce IL-2, and then differentiate into phenotypes that secrete other cytokines. IL-
3 has also been implicated in the differentiation and growth of various lymphocyte
lines [36], However, unlike IL-2, IL-3 appears to primarily influence immature
lymphocyte differentiation. The environmental and genetic factors that influence Thl
/Th2 differentiation act mainly by determining the predominance of a given cytokine
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1.2.2 Contribution of Cells During T Cell Priming
IL-12 and IFN-y stimulate differentiation into Thl cells, whereas
IL-4 induces Th2 cell differentiation [37]. In a primary response, the frequency of
antigen-specific T cells is very low (e.g. 1 in 1(f) so other cell types may supply the
appropriate cytokine for differentiation. IL-12 is made by many cell types, but
particularly by macrophages in response to certain microbial products [38, 39].
Natural killer (NK) cells synthesise IFN-y in response either to IL-12 [40] or antigen-
mediated cross-linking of antibody bound to Fc receptors [41].
There has been some discussion in the last few years concerning which cell
type produces IL-4 and is thus involved in initial Th2 development. Possible
candidates include mast cells/basophils, [42] eosinophils [43], the LECAM-ldu"
subset ofCD4+ T cells [44], the CD4+NK1.1+ T cell subset [45] or naive T cells
themselves [46, 47].
CD4+NK1.1+ T cells were prime candidates for a while based on the fact that
on recognition of the conserved MHC class I-like CD1 molecule, they released bursts
of IL-4. However, a later study showed that early IL-4 production in the lymph nodes
and development of Th2 responses against L. major infection, originated from a
CDd^NKl.l" T cell population that was [Lm independent (beta2-microglobulin-
deficient mice have been shown to contain strongly reduced numbers ofNK1.1+T
cells) [48].
1.2.3 Costimulation
Two signals are required for the optimal activation of nai've T cells. One
signal is delivered by the engagement of the TCR by Ag-MHC complexes on APCs;
the other signal is the ligation of CD28 on T cells by either B7.1 (CD80) or B7.2
(CD86) molecules on APCs [49, 50]. CD28 is expressed by resting and activated T
cells. CTLA-4 is expressed on the activation ofT cells and is related to CD28.
However, CTLA-4 binds the B7 molecules with a higher affinity than CD28 and
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studies suggest that it is predominantly a negative regulator ofT cell proliferation
[50-52],
A number of studies have suggested that CD28 ligation plays an important
role in Th cell differentiation [49, 53] and in particular can selectively regulate Thl
and Th2 induction. Thompson et al. hypothesised that the strength of the TCR signal,
in conjunction with the strength of costimulatory signals delivered by CD28, can
influence the generation ofThl and Th2 cells. This hypothesis was supported by in
vivo [47, 54] and in vitro [55-58] studies from the Bottomly group. In one of their
later studies, they investigated whether the costimulatory requirements of Thl and
Th2 generation in vitro might vary with either a strong or weak TCR signal in the
presence or absence ofB7 costimulatory molecules [58], In this system, Th2 cells
were generated using altered peptide ligands (Ag peptides with a single amino acid
substitution at a position known to contact the TCR) or with low doses ofwild-type
peptide. Th2 cells were dependent on a weak TCR signal and CD28/B7 interactions,
as disruption ofCD28/B7 interactions inhibited the priming of Th2 cells, and cross-
linking CD28 with anti-CD28 antibody augmented the priming of Th2 cells.
Studies in various disease models have proposed that the molecules
themselves may play a role in T cell differentiation, with B7.1 favouring Thl
induction and B7.2 favouring Th2 induction [59-61]. In an in vivo model of
experimental allergic encephalomyelitis, Thl cells are associated with disease
phenotype. Kuchroo et al. demonstrated that anti-B7.1 treatment (resulting in Th2
expansion) ameliorated the disease whereas anti-B7.2 exacerbated the disease [59].
Similar results have been observed in allergic asthma mouse models [61] and also in
atopic asthmatic subjects [62],
Larche et al. examined the requirements ofCD80 and CD86 on allergen-
induced T cell proliferation and cytokine production in peripheral blood and
bronchoalveolar lavage from atopic asthmatic subjects. Administration ofCTLA-4-
Ig fusion protein or anti-CD86 mAb to allergen-stimulated PBMC cultures inhibited
proliferation and IL-5 and IL-13 production. Antigen presentation by airway APCs
(from BAL) and allergen-induced proliferation from airway T cells was also CD86
dependent. These results supported those ofKeane-Myers et al. who found that
administration of anti-B7.2 antibody to OVA-treated A/J mice abolished allergen-
28
induced airway hyperresponsiveness, pulmonary eosinophilia and elevation in serum
IgGl and IgE levels. Lung IL-4 and IL-5 mRNA and bronchoalveolar lavage fluid
IL-4 and IL-5 protein levels were also reduced with no significant changes in IFN-y
message or protein levels. This observation concerning IFN-y was in contrast to the
results ofTsuyuki et al. [63], They observed an increase in IFN-y levels in in vitro-
activated lung T cells after anti-B7.2 administration in a similar model of antigen
exposure using SV129mice. These differences were thought to be due to mouse
strain differences (the A/J strain has an inherent susceptibility to develop Th2
responses, so pathways associated with IFN-y production may be redundant in these
mice) and also in cytokine measurement. In Keane-Myers study, cytokines were
measured in BAL fluids taken at the time ofmeasurement of the allergic response,
whereas in Tsuyuki's study, IFN-y levels were derived from isolated lung cells
stimulated in vitro with anti-CD3 Abs.
In contrast, treatment with anti-B7.1 mAb had no effect on allergen-induced
airway hyperresponsiveness, IgE production or cytokine production, however, it
significantly suppressed pulmonary eosinophilia. This finding was consistent with
that of Harris et al. who demonstrated that blockade of B7.1 with a mutant form of
CTLA-4-Ig (which specifically blocked B7.1 signalling) reduced Ag-induced tissue
eosinophilia [64],
A study by Mathur et al. compared the effect of S. mansoni sensitisation and
challenge in wild-type mice, CD28KO mice and mice treated with monoclonal
antibodies to CD80 and CD86 [65]. Previous related studies had shown that
administration ofCTLA-4-Ig after primary immunisation with S. mansoni antigens
could cause immune deviation from a Th2-like response to a Thl-like response [66],
However, the ability ofCTLA-4-Ig to inhibit the interaction of both CD28 and
CTLA-4 to both CD80 and CD86 meant that the specific roles of the B7 molecules in
the induction ofT lymphocyte-mediated asthmatic airway inflammation remained
unclear. The study in 1999 by Matur et al. addressed these issues and suggested that
CD28, not CTLA-4 was the essential B7 receptor for the induction and progression
of Th2-mediated allergic airway inflammation in the S. mansoni model. In addition,
antibody treatment directed against either CD80 or CD86 alone had a partial and
similar inhibitory effect on the development of allergic inflammation. This is in
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agreement with Schweitzer and colleagues who reported that CD80 and CD86
costimulatory signals were basically equivalent because both could elicit IL-4 as well
as IFN-y by anti-CD3-stimulated CD4+ T cells [67]. Similarly, Heligmosomoides
polygyrus-infected mice seem relatively resistant to the effect of treatment with
antibodies to either B7 ligands [68], However, the immune and inflammatory
reactions could be blocked when antibodies to both molecules were used together.
These results are in contrast to the previous studies already discussed [61, 63,
64], who all suggest that either CD80 or CD86 is the dominant costimulatory
molecule involved in allergic airway inflammation. However, the latter two studies
did observe a reduction in eosinophilic recruitment into airways after treatment with
only the anti-CD80 antibody.
Most investigators agree that the requirements for costimulatory molecules
during immune responses are quite complex and depend on the system studied. There
are clear differences in the kinetics of expression and also on which cell type these
molecules are expressed. Lung macrophages [64] and lung B cells [63] have been
shown to predominantly express B7.2 following inhalational exposure to OVA of
mice of two different genetic backgrounds. Mathur et al. demonstrated by reverse
transcriptase/PCR and FACs analysis that both CD80 and CD86 were expressed on
lung cells from naive animals and were upregulated within 24 hours of antigen
challenge. They also found that both B7 molecules were expressed on eosinophils
from the allergic lung with greater expression of CD80 than CD86 on these
inflammatory cells.
Although treatment with antibodies to either CD80 or CD86 resulted in a
partial reduction in the development of allergic airways in the study by Mathur et al.,
only anti-CD86 treatment significantly depressed systemic production of IgE [65],
Treatment with anti-CD86 mAbs has previously been shown to result in deficiencies
in germinal centre formation and isotype switching [69], Thus, while local
lymphocyte responses to antigen may be driven equally by CD28/CD80 or
CD28/CD86 ligation, CD86 seemingly plays the predominant role in systemic B cell
response in the mouse.
Recently, another member of this costimulatory family has been identified.
Inducible co-stimulator (ICOS) is a homodimeric protein of relative molecular mass
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55K-60K exhibiting 20% homology with CD28. However, unlike CD28, ICOS is not
present on nai've T cells; instead it is upregulated after T cell activation and retained
on many memory T cells. Hutloff et al. proposed that ICOS was involved in the late
phase of activation because nearly all ICOS+ T cells expressed CD45RO (a cell
surface marker on memory/effector T cells) [70].
In humans, ICOS binds B7h, a molecule expressed by APCs with homology
to CD80 and CD86 [71]. Murine homologues of ICOS and B7h (B7RP-1) have also
been identified [72]. Data from ICOS-deficient mice have shown that this molecule
plays a critical role in T-B cell interactions, is essential for germinal centre formation
and humoral immune responses [73, 74], The inability of ICOS-deficient mice to
generate germinal centres is due to their impaired ability to upregulate CD40 ligand
[75], This was overcome by CD40 stimulation, which suggests that ICOS
costimulation is mediated, at least in part, via regulation of the CD40-CD154
(CD40L) pathway [74],
A study by McAdam et al. implicated murine ICOS in the differentiation of
CD4+ T cells [75]. TCR-transgenic T cells differentiated into the Th2 phenotype,
expressed significantly more ICOS than cells differentiated towards the Thl
phenotype. Engagement of ICOS is particularly effective in costimulating IL-10 and
IL-4 but not IL-2 production. In addition, T cell differentiation, in the presence of an
ICOS antagonist, lead to the development ofmore Thl than Th2 cells. In support of
this, Coyle and colleagues investigated the roles of ICOS and CD28 in the regulation
of Th2-mediated mucosal inflammatory responses. They found that both molecules
regulate the outcome of the immune response but play separate key roles: CD28
primes T cells whereas ICOS regulates effector responses. The investigators
proposed that T cells first become primed by a CD28-B7-dependent mechanism,
which lead to upregulation ofCXCR5 and subsequent migration to the edge of the B
cell rich follicle. ThP (primed) cells then encounter antigen-bearing B cells which
present peptides to the antigen-specific ThP cells through B7RP-1. This signal
specifically facilitates Th2 cytokine production, thus upregulating CD40 ligand and
leading to B cell expansion. In addition, B7RP-1-ICOS interactions would also
deliver a signal for the upregulation ofCCR3, CCR4 and CCR8. As the ligands for
these receptors - eotaxin, MDC and 1-309 - are induced during allergic inflammation
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from epithelial cells and monocytes and have been implicated in mediating Th2
accumulation in the lungs [76, 77], ICOS-mediated costimulation of effector cells
would then provide the signals for these effector cells to migrate from secondary
lymph nodes into the airways. However, anti-ICOS or ICOS-Ig administration were
given 30 minutes before antigen challenge so the results may be due to antibody
competition rather than a downregulation ofmucosal inflammation.
However, recent studies are challenging the fact that ICOS-mediated
signalling is only associated with Th2 responses. Hancock and colleagues have
shown that blockade of ICOS signalling leads to increased heart allograft acceptance
and reduced evidence of chronic rejection [78]. Although acute allograft rejection is
not Th2-mediated, it is dependent on a Thl-mediated inflammatory response that
leads to the destruction of graft tissue. They found that ICOS was induced on host
mononuclear cells that were progressively infiltrating the graft. Treatment with anti-
ICOS or ICOS-Ig fusion protein suppressed intragraft T cell activation and cytokine
expression and prolonged allograft survival in a manner similar to that in ICOS"7"
allograft recipients. The combination of anti-ICOS therapy and cyclosporin A led to
permanent engraftment.
Another study has implicated ICOS in the immunopathogenesis ofEAE [79].
After the induction of experimental allergic encephalomyelitis in SJL mice with
proteolipid protein (PLP), brain ICOS mRNA and protein were upregulated on
infiltrating CD3+ T cells before disease onset. ICOS blockade during the efferent
immune response (9-20 days after immunisation) abrogated disease, but blockade
during antigen priming (1-10 days after immunisation) exacerbated disease. It was
proposed that deficient IL-13 expression by antigen-specific T cells was the cause of
disease exacerbation. ICOS blockade during antigen priming lead to excessive PLP-
specific splenocyte proliferation and IFN-y expression, increased brain IFN-y mRNA
and decreased plasma PLP-specific IgGl.
Thus, it is now clear that manipulation of the ICOS-B&RP-l pathway has
important therapeutic implications beyond the Th2 field.
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1.2.4 Antigen Dose and Affinity of Binding to the T Cell Receptor
Early in vivo studies showed that both a high and low amount of antigen
primed for DTH, whereas a moderate level stimulated antibody production [80],
These results were further supported in BALB/c mice infected with Leishmania
parasites. Mice infected with very low numbers of the parasites produced a healing
DTH response but in mice infected with higher doses, the result was a non-healing
antibody response [81]. Fully differentiated Thl cells are stimulated by moderate but
not high doses of antigen, whereas Th2 cells respond over a wider range of
concentrations [82], In the differentiation of nai've CD4+ T cells, Constant et al.
demonstrated that low doses of priming antigen favoured development ofTh2-like
cells, with high doses favouring Thl-like cells [56]. In the same year, Pfeiffer et al.
showed that signals delivered via the TCR could influence CD4 T cell
differentiation. This was investigated by measuring the strength ofbinding of the
immunodominant peptide of huCol IV to purified MHC class II molecules and by
examining the effect of peptide modification on CD4 T cell subset differentiation.
Peptide/MHC class II complexes that interacted strongly with the T cell receptor,
favoured generation ofThl-like cells, while those that bound weakly favoured
priming of Th2-like T cells [47].
Grakoui et al examined the role of the peptide/MHC ligand in CD4+ T cell
differentiation into Thl or Th2 cells using a TCR alphabeta transgenic mouse
specific for haemoglobin Hb(54-76)I-Ek. Two altered peptide ligands ofHb(64-76)
were found to induce Th2 cytokines at low concentrations and Thl cytokines at high
concentrations. However, the authors argued that the potential to develop into Thl or
Th2 cells was independent of antigen dose. They proposed that the basis for the
observed effects on the Thl/Th2 balance shown by the altered peptide ligands and
the amount of antigen dose, involved the modification of soluble factors in bulk




Several experiments suggest that certain epitopes can preferentially induce
one of the two subsets of Th cells. Liew et al showed that a repetitive peptide of L.
major selectively activated Th2 cells and enhanced disease progression [83]. In
contrast, a recombinant 403 amino acid protein from L. brasiliensis, preferentially
stimulated human PBMCs to express a Thl-type cytokine profile and to produce IL-
12 [84], The house dust mite allergen Der p 1 can cleave CD23 (the low affinity
receptor for IgE) leading to exacerbation of the allergic Th2 response by disrupting
the IgE regulatory pathway [85, 86]. Der p 1 can also cleave the a subunit of the
human IL-2 receptor (CD25) leading to a disruption in IL-2 production and
expansion of IFN-y-producing Thl cells, thus biasing Th2 cell induction [87]. The
properties of Der p 1 are discussed in greater detail later in this chapter.
1.2.6 Environmental Factors
Environmental factors can take effect before and/or after birth. Early clinical
information suggests that Thl responses are suppressed systemically during
pregnancy, and more recent data shows that Th2 cytokines are expressed in the
placenta [88]. This may be essential for foetal survival, as inflammatory responses,
NK cells and the Thl cytokines IL-2, IFN-y and TNF are all harmful for placental
maintenance, whereas IL-10 promotes foetal allograft survival. Supporting this, are
studies using CD4+ and CD8+ T-cell clones, generated from the decidua ofwomen
suffering from unexplained recurrent abortions. These clones showed significantly
reduced IL-4 and IL-10 production compared to those generated from the decidua of
women with voluntary abortion [89], In mice, Leishmania major infection is
eliminated by a strong Thl response but persists longer in pregnant mice [90, 91].
Holt et al. suggested that early postnatal exposure to high levels of allergen,
exemplified by "birth during the pollen season", maximised the risk for subsequent
expression of allergen reactivity to that allergen in adult life [92]. Subsequent studies
have shown that initial T cell priming to a variety of allergens can occur prenatally
[93, 94] via ingestion or inhalation by the mother [95]. Prescott et al. demonstrated
that Th2-skewed responses to common environmental allergens, comprising IL-4,
IL-5, IL-6, IL-9 and IL-13 were present in virtually all newborn infants and were
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dominated by high level production of IL-10. Szepfalusi and co-workers
demonstrated that the transfer of inhalant and nutritive allergens across the human
placenta was indeed possible [96]. A second study by the same group showed that
foetal T cell priming with inhalant allergens occurs predominantly early in
pregnancy, likely before the gestational age of 20 weeks. This conclusion was based
on the fact that lymphoproliferative reactivity to inhalant allergens (rBet v 1 and rPhi
p 1) was comparable in cells derived from cord blood samples of term newborns and
of unborn (preterm) babies with a gestational age from 20 to 37 weeks.
The decrease of childhood infections such as mycobacterial infection (Thl-
orientated) in the developed world as a result of vaccination schedules, is thought to
favour Th2 priming, as the cytokines produced during these types of infection are
antagonistic to Th2 development [97], This "hygiene hypothesis" was based on a
number of studies in vitro and in vivo. IL-12 and IFN-y production by macrophages
and NK cells in response to Mycobacterium tuberculosis, was able to shift the
development of allergen-specific T cells from the Th2/Th0 to the Thl profile in vitro
[98]. These results were substantiated in mice showing that IFN-y produced during
the Thl response against BCG suppressed the development of local inflammatory
Th2 responses in the lung [99]. In Japanese school children, positive tuberculin
responses correlated with a lower incidence of asthma, lower serum IgE levels, and
cytokine profiles biased towards Thl responses. Also, expression of atopy in 12 year
old children was most prevalent among those who had previously failed to develop
Thl-dependent delayed tuberculin hypersensitivity in response to bacillus Calmette-
Guerin (BCG) vaccination during infancy [100].
In addition, it has been shown that blockade of endogenous production of
IL-12 in naturally resistant murine strains (C3H/HeJ), renders them susceptible to the
development of allergen-induced AHR and eosinophilic inflammation [101].
A number of environmental chemicals have been implicated in the prevalence
and incidence of allergic diseases during the last few decades [102], Ozone in
particular has been demonstrated as a modulator of the T cell effector response
toward the Th2 phenotype [103, 104], A recent study by Neuhaus-Steinmetz et al,
investigated the effect of repeated ozone exposure on the development of immune
responses towards ovalbumin. When OVA-sensitised mice were additionally
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exposed to ozone, the allergen-specific Th2 response was enhanced in both the IgE-
high and IgE-low responder strains [105].
1.2.7 Role of Stat 4 and Stat 6 in Thl/Th2 Development
Differentiation-inducing signals are delivered by the actions of IL-12 and
IL-4 on specific receptors expressed by activated T cells, through specific STAT
(signal transducers and activators of transcription) factors [106-108], Cytokine
receptors consist of at least two chains that dimerise after binding of the appropriate
cytokine. This dimerisation brings together the Janus kinases (JAKs) that are
associated in the cytoplasm with the cytokine receptor chains. These JAKs activate
each other and phosphorylate the receptor which enables the STATs to bind and in
turn become phosphorylated themselves. The phosphorylated STATs dimerise and
translocate to the nucleus to initiate gene transcription.
STAT6 is activated by IL-4 and IL-13 to induce Th2 development [109-111].
Studies in STAT6-deficient mice have shown that Th2 cells were unable to develop
and production of IgE and IgGl by B cells was virtually abolished [112, 113].
STAT4 is activated by IL-12 to induce Thl development [107, 108], Experiments on
Stat 4-deficient T cells have shown that they only produce negligible amounts of
IFN-y [114],
Another transcription factor associated with murine Th2 cells is GATA3
which controls the expression of the IL-5 gene [115], Conversely, a specific T box
transcription factor - T-bet has been found to direct Thl lineage commitment. T-bet
expression was found to correlate with IFN-y expression in Thl and NK cells [563].
1.2.8 Markers on Thl and Th2 Cells
As well as producing different cytokines, polarised human Thl and Th2 cells
preferentially express certain activation markers. For example, CD30 (a member of
the TNF receptor family) is mainly expressed in Th2- and Tc2-like cells in vitro and
in vivo [116, 117]; crosslinking ofCD30 enhances proliferation of T and B cells.
Lymphocyte activation gene 3 (LAG-3), a member of the immunoglobulin
superfamily, preferentially associates with Thl-like cells [118], LAG-3 expression is
upregulated by IFN-y and down regulated by IL-4 [119], in contrast, CD30 is
dependent on IL-4 and its expression is therefore prevented in fully differentiated,
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IL-4 receptor-lacking Thl effectors. Other molecules associated with human Thl
cells are CD26 (acts as exopeptidase by cleaving N terminal X-Pro or X-Ala
dipeptides from polypeptides), CCR5 and CXCR3. Thl reactions depend upon IFN-
y-induced CXC chemokines interferon-inducible protein (IP)-10, interferon T cell-
alpha chemoattractant (iTAC) and monokine induced by interferon-gamma (MiG),
which bind to the chemokine receptor CXCR3. In contrast, CD62L [120], CCR3
(eotaxin and MCP-3 receptor), CCR4 and CCR8 preferentially associate with human
Th2 cells during different phases of their differentiation and activation [121]. CD62L
binds CD34, GlyCAM-1 and MAdCAM-1 which are expressed on the endothelium.
Interaction ofCD62L with its ligands mediates specific homing of naive T cells to
lymphoid organs by a rolling mechanism along the endothelium. The c-mafproto-
oncogene is a Th2-specific transcription factor that activates the IL-4 promoter in
mice [122, 123],
T1/ST2 is constitutively and stably expressed on the surface of murine Th2
cells. This was first shown by Xu et al who used differential display PCR to compare
a panel of Thl and Th2 clones [124], They also found that an antibody against the
extracellular domain ofST2-L lysed Th2 cells in a complement-mediated fashion. A
second study by Lohning et al, showed expression of T1/ST2 on Th2 cells at the
single cell level and that this expression was independent of IL-4, IL-5 or IL-10
[125]. Mast cells have also been found to express high levels of T1/ST2 [126],
A few studies have suggested that T1/ST2 is more than just a stable Th2
marker in that it is required for Th2 effector responses. Antibodies to ST2-L have
been used in a number of disease models. Anti-ST2-L was found to increase
resistance to Leishmania major infection in BALB/c mice and exacerbated collagen-
induced arthritis in DBA/1 mice [124]. Furthermore, administration of either amAb
to T1/ST2 or a T1/ST2 fusion protein attenuated eosinophilic inflammation in the
airways in a murine model ofTh2-dependent allergic airway inflammation, and
suppressed IL-4 and IL-5 production in vivo following adoptive transfer of Th2 cells
[125, 127], However, a study by Hoshino et al disputed this hypothesis. T1/ST2"'"
mice were generated and found to exhibit normal Th2 responses to helminth
infection and in a mouse model of asthma. In addition, differentiation and function of
mast cells was found to be unaffected [128],
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1.2.9 Stability ofThl/Th2 cells
In vitro
After one round of stimulation of naive murine TCR-transgenic CD4+ T cells
with antigen, APC and IL-12, Thl cells can be readily converted to Th2 populations
by a second round of stimulation with antigen, APC and IL-4 [129, 130]. Analysis of
cytokines after one round of stimulation with IL-12 only showed the presence ofThl
cytokines, however, analysis at the single cell level showed the existence of
heterogeneous populations, with the majority of cells neither producing IFN-y nor
IL-4 [131]. Thus, this Thl to Th2 conversion may actually represent either the
development of Th2 cells from undifferentiated precursor T cells, or expansion of a
small number of contaminating, differentiated Th2 cells. After repeated stimulation
under Thl-polarising conditions, this ability to reverse to the Th2 phenotype is lost
indicating a stable Thl phenotype.
In contrast, reversal to a Thl phenotype after only one round of Th2
stimulation is relatively harder [130], The Th2 population becomes relatively
resistant to phenotype reversal by IL-12 stimulation [129, 132], However, Th2—>Thl
phenotype reversal is not impossible, as shown by Murphy et al [131]; primary
populations of Th2 cells gave rise to Thl cells upon antigenic stimulation in IL-12
but it was noted that numbers of IL-4-producing cells remained the same. They
hypothesised that Thl cells were produced from either uncommitted precursor T
cells or the expansion of a rare previously committed Thl population. This
reversibility was only possible after early differentiation to the stable Th2 phenotype;
after a number of restimulations in the presence of IL-4, the ability to become Thl-
committed was completely lost.
Human populations behave slightly differently. Short-term Th2 cells derived
from mitogen-stimulated cord blood cells can still be induced to produce IFN-y if
restimulated in the presence of IL-12 [133], This suggests that basic differences exist
in the differentiation of Th populations or in the regulation of IL-12 receptor
expression, in mouse and human culture systems [129, 132, and 134],
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In vivo
Thl/Th2 phenotype reversibility in vivo is even more resistant to change. For
example, in mice infected with Leishmania major, the healing Thl response and non¬
healing Th2 response are very resistant to reversal even after anti-IFN-y, anti-IL-4
and IL-12 treatment. Reversal (Th2—»Thl) is only possible within the first week of
infection or after treatment with a combination of IL-12 and a parasiticidal drug
[135]. Recently, Janssen et al. showed that an established in vivo Th2 response could
be modulated by treatment with a Thl-skewing peptide, which resulted in decreased
airway eosinophilia and antigen-specific IL-4 and IL-5 production [136].
1.2.10 Adoptive Transfer
Reversibility ofThl/Th2 populations after adoptive transfer is possible in the
recipient, even after reversibility in the host is no longer possible. Transfer of LN
cells from a non-healing Th2 BALB/c mouse into T and B cell-deficient C.B-17 scid
mice along with anti-IL-4, resulted in a stable dominant protective Thl response
[137]. This can probably be attributed to the existence of different
microenvironments between the host and recipient. Thus, adoptive transfer
experiments have the potential for reversing Thl/Th2 responses that are difficult to
reverse in situ.
1.3 CD8+ T Cells
CD8+ T cells have been classically associated with cytolytic function. All
viruses and some bacteria multiply in the cytoplasm of infected cells and thus, are
not accessible to antibodies. A mechanism has therefore evolved in which infected
cells are programmed to undergo apoptosis by cytotoxic T cells. The cytotoxic T cell
recognises foreign peptides bound to MHC class I molecules that are transported to
the surface of an infected cell. Cytotoxic T cells release a number of effector
molecules to initiate apoptosis of the target cell. The calcium-dependent release of
specialised lytic granules upon antigen recognition is the initial step. These granules
are modified lysosomes that contain a number of proteins, that function once
released. Perforin polymerises to form transmembrane pores in the target cell
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membranes, which allows water and salts to pass rapidly into the cell. Once the
integrity of the cell membrane is destroyed, the cell dies rapidly. Granzymes, which
comprise of serine proteases, activate apoptosis once in the cytoplasm of the target
cell. The granzymes are unable to defragment the DNA directly but act by cleaving
the ubiquitous cellular enzyme CPP-22. This is believed to play an essential role in
the apoptosis of all cells. As well as the destruction of cellular DNA, viral DNA is
also degraded which prevents the assembly of virions and thus spread of the virus to
neighbouring cells. The apoptotic cells are then phagocytosed by other cells in the
vicinity [138, 139],
Cytotoxic T cells are very discriminate in their killing so 'innocent' bystander
cells are spared. By orientating their Golgi apparatus and microtubule-organising
centre, the secretory apparatus is focused at the point of contact with the target cell.
Thus, the cytotoxic T cells kill target cells one by one in this manner. Targets are
killed rapidly because cytotoxic proteins are stored in inactive forms in the lytic
granules. Cytotoxins are synthesised and located in the lytic granules on the first
encounter of a naive cytotoxic precursor T cell with specific antigen. These stocks
are constantly replenished by ligation of the T-cell receptor which induces de novo
synthesis of the proteins, enabling the CD8 T cell to kill many targets in succession.
A calcium-independent mechanism of killing also exists for CD8+ and some
CD4+ T cells. This involves the binding of Fas in the target cell membrane by Fas
ligand, which is expressed in the membranes of activated cytotoxic T cells and Thl
cells. Activation of Fas also leads to apoptosis in the target cell [140].
Cytotoxic T cells also contribute to host defence by releasing IFN-y, TNF-a
and TNF-P [141], IFN-y directly inhibits viral replication, induces the upregulation
ofmore MHC class 1 expression on APCs and leads to macrophage activation,
recruiting them to sites of infection as effector cells and APCs. TNF-a and TNF-(3
are also involved in macrophage activation and can kill some target cells through
their interaction with TNFR1.
Studies have demonstrated that CD8+ T cells can be sub-divided into Tel and
Tc2 subsets in humans and mice [551, 552], These CD8+ T cell subsets can be
derived under similar conditions as those needed to generate Thl and Th2 subsets:
IL-12 and IFN-y promote Thl and Tel induction whilst IL-4 induces Th2 and Tc2
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generation. Evidence suggests that Tel and Tc2 cells are stable and retain their
cytokine profile [142].
CD8 T cells have been identified in vivo in a number of infectious diseases.
Tc2-like cells have been isolated from patients with lepromatous leprosy and from
HIV-infected individuals with Job's-like syndrome (high IgE levels) [143], whereas
Tel-like cells have been isolated from patients with tuberculoid leprosy. Both Tel
and Tc2 subsets have cytotoxic activity but this differs depending on the disease
model [144] and may depend on cytokine exposure prior to the cytotoxicity assay
[145],
1.3.1 CD8+ T Cells in Allergic Inflammation
Earlier in this chapter, the effect of viral and bacterial infections on the
induction of a Thl response was discussed. However, viral/microbial infections
and/or their products may have bidirectional effects on the development of allergy
and asthma.
McMenamin et al. demonstrated in aerosol-exposed rats during the early
sensitisation phase, that CD8+ IFN-y-producing cells may provide the initial source
of T cell-derived IFN-y and thus, play a critical role in preventing the induction of
allergic responses [146]. Early studies with CD8+ T cells have implicated them in the
suppression of IgE production. Renz et al showed that allergen-reactive CD8 T cells
from sensitised mice when adoptively transferred to pre-sensitised recipient mice,
caused a significant reduction specific serum IgE [147]. Furthermore, measurement
of in vitro Ig production indicated that mononuclear cells from recipients of CD8
cells (CD8ova > CD8PBS) produced less IgE and IgGl antibodies, whereas IgG2a
production was enhanced. Airway hyperresponsiveness and immediate-type skin
reactions were also prevented. This suggested that CD8+ T cells play a role in the
negative regulation of IgE production and AHR. However, other studies have
demonstrated that CD8+ T cells have the potential to stimulate IgE-class switching
and promote allergic inflammation. Rats depleted ofCD8+ T cells or nude rats
reconstituted with CD4+ but not CD8+ T cells prior to immunisation, failed to mount
an IgE response [148]. In vitro studies analysing T cell subsets in allergic patients
revealed that twice as many CD4+ T cells and six times as many CD8+ T cells
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produced IL-4 compared with non-allergic controls. Other studies have demonstrated
that IL-13 was the major IgE-synthesis-inducing cytokine from Thl and CD8+ T
cells [149]. Furthermore, CD8+ T cells have been observed at sites of allergic
inflammation [150], although they were not the major subset present.
Hamelmann et al. studied the role ofCD8+ T cells in allergic airway
sensitisation. The depletion of CD8+ T cells before aerosolised OVA sensitisation in
BALB/c mice, prevented the development of airway hyperresponsiveness despite the
production of allergen-specific IgE. The requirement for the induction ofAHR was
confirmed in cell transfer experiments; transfer of nonprimed CD8+ T cells restored
the ability to develop AHR in CD8 T cell-depleted mice [151]. However, a later
study by Haczku using Brown-Norway rats found that purified CD4+ T cells from
sensitised donors induced AHR in naive recipients, while sensitised CD8+ and naive
CD4+ cells failed to do so [152].
Virus-specific CD8+ T cells have also been reported to induce a switch to IL-
5 production and induce eosinophilia [153]. Transgenic mice expressing an H-2Db-
restricted TCR specific for the epitope 31-44 of the lymphocytic choriomeningitis
virus (LCMV), were immunised with OVA to produce a Th2 response and then
challenged intranasally with LCMV glycoprotein 33-41 peptide. The bystander CD4+
response to OVA was able to switch the virus peptide-specific CD8+ T cells to IL-5
production and furthermore, when those IL-5-producing CD8 cells were challenged
via the airways with virus peptide, significant eosinophilia was induced. These
results provided a possible link between virus infection and exacerbation of asthma.
Production of IL-5 by virus-reactive CD8+ T cells is dependent on CD4+ bystander T
helper activity. Virus peptide-reactive CD8+ T cells were found to secrete IL-5,
leading to eosinophilia when mice were challenged via the airways.
A number of respiratory viruses can exacerbate asthma in humans, the most
common being rhinovirus. This effect has now been demonstrated in animal models,
with Suzuki et al reporting that an infection with influenza A virus lead to increased
airway responsiveness and allergen-specific IgE production in aerosolised, antigen-
exposed mice [154], Other studies reported an increase in OVA-specific IgGl
antibodies leading to anaphylactic shock after OVA-induced sensitisation was
combined with influenza A virus or RSV infection in mice [155]. Infections with
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RSV were also found to increase allergen-induced airway hyper-reactivity in mice
[156],
Perhaps it is not surprising that considering the existence of different Tc
subsets, CD8+ T cells have been implicated in both the moderation and exacerbation
of allergic inflammation.
1.4 Allergy and Asthma
When an adaptive immune response occurs in an exaggerated or
inappropriate form, the term hypersensitivity is applied. Hypersensitivity reactions
are the result of normally beneficial immune responses acting inappropriately, and
sometimes cause inflammatory reactions and tissue damage. Hypersensitivity is not
manifested on first contact with the antigen, but usually appears on subsequent
contact. Type I hypersensitivity is characterised by an allergic reaction that occurs
immediately following contact with the antigen, referred to as the allergen. The term
'allergy' means 'changed reactivity' of the host when meeting an 'agent' on a second
or subsequent occasion. In recent years 'allergy' has become synonymous with type I
hypersensitivity.
For an allergic response to occur, a naive individual first becomes sensitised
by mounting an antibody or T cell response to the allergen. This adaptive response
takes time and does not usually cause any symptoms. Allergic responses are
characterised by the enhanced ability of B cells to produce IgE antibodies, driven by
the production of IL-4 and IL-13 by Th2 cells. When a sensitised individual is
challenged with antigen, a bimodal response ensues consisting of a classical Type I
hypersensitivity reaction followed by a type IV reaction with Th2 cytokine
characteristics. The early phase response peaks at 10-15 minutes and resolves after
approximately 1 hour. It is mediated by the cross-linking of allergen specific IgE on
the surface ofmast cells.
The late phase response begins at about 3 hours, peaks at 6-9 hours and
resolves by 24 hours. Once IgE has bound to FcsRI on mast cells and basophils,
degranulation can be triggered by IgE crosslinking. This relies upon a degree of
conformational integrity within the allergen molecule (or fragment) and the presence
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of at least two contiguous epitopes in order to bridge adjacent IgE molecules. This
causes an influx of calcium ions into the mast cells and basophils resulting in their
degranulation. Degranulation results in the release of preformed mediators, the major
one in man being histamine. There is also an induction of synthesis of newly formed
mediators from arachidonic acid, leading to the production ofprostaglandins and
leukotrienes, which have a direct effect on the local tissues. In the lung they cause
immediate bronchoconstriction (which is mediated by eosinophil infiltration to the
site of allergen challenge), mucosal oedema and hypersecretion leading to asthma
[157, 158],
Most allergens are relatively small, highly soluble protein molecules that are
inhaled in desiccated particles such as pollen grains or mite faeces. The allergen
elutes from the particle because it is readily soluble and diffuses into the mucosa.
Typical symptoms of an allergic reaction include rhinitis (runny nose and sneezing),
asthma and in severe cases, systemic anaphylaxis in response to an insect bite or
sting, or even a food product in highly sensitised individuals. Once an individual is
sensitised, each subsequent exposure to the allergen often leads to worsening of
symptoms because antibody levels and effector T cell responses increase.
Other common hypersensitivity reactions are termed type IV or delayed
hypersensitivity because they take time to manifest. Examples of these reactions are
contact dermatitis, graft rejection, rheumatoid arthritis and diabetes mellitus. The
reactions are T cell mediated either by inflammatory (Thl) cells that are mainly
induced by macrophages, or cytotoxic CD8+ T cells.
Over the years, a number of studies have supported the hypothesis that
allergen-specific Th2 cells have a pathogenic role in allergic disorders:
• Allergens preferentially expand Th cells showing a Th2-like profile [159, 160]
• Th2-like cells accumulate in the target organs of allergic patients [161, 162]
• Allergen challenge results in local activation and recruitment of allergen-specific
Th2-like cells [163, 164]
• Atopic asthma is associated with activation in the bronchi of the IL-3, 4 and 5
and GM-CSF gene cluster, a pattern compatible with predominant activation of
the Th2 like T cell population [564]
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development of allergen-induced allergic airway responses. Furthermore, the
adoptive transfer of Th2 clones into the lungs of naive mice induced AHR [176],
The excessive production of airway mucus glycoproteins is a consistent
finding in the lungs of asthmatic subjects, especially in those that have died as a
result of asthma [177], IL-4 has been directly implicated in mucus production as
shown in IL-4 transgenic mice, which exhibit profound increases in mucus-
containing cells in the airway epithelium [178]. In contrast, blockade of the IL-4
receptor results in ablation ofmucus-containing cells [179].
Goblet cell hyperplasia is thought to be mediated by mast cell and eosinophil
recruitment since these effector cells release the potent mucus secretogues LT,
hydroxyeicosatetraenoic acid (15-HETES) and platelet-activating factor (PAF).
1.4.1 IL-4
IL-4 is a key cytokine in the development of allergic inflammation. It is
associated with induction of the c isotype switch and secretion of IgE by B
lymphocytes [565]. IL-4 further enhances IgE-mediated immune responses by
upregulating IgE receptors on the cell surface: the low affinity receptor (FCsRII;
CD23) on B lymphocytes and mononuclear phagocytic cells and the high affinity IgE
receptor FCsRI on mast cells and basophils [566]. The role ofmast cells and
basophils in the allergic response is discussed on page 45.
An additional mechanism by which IL-4 contributes to airway obstruction in
asthma is through the induction ofmucin gene expression and the hypersecretion of
mucus [567]. IL-4 increases the expression of eotaxin and other inflammatory
cytokines from fibroblasts that might contribute to inflammation and lung
remodelling in chronic asthma [568]. IL-4 induces the expression ofVCAM-1 in the
asthmatic lung thus promoting cellular inflammation [569]. Through the interaction
ofVCAM-1, IL-4 is able to direct the migration of T lymphocytes, monocytes,
basophils and eosinophils to inflammatory loci. In addition, IL-4 inhibits eosinophil
apoptosis and promotes eosinophilic inflammation by inducing eosinophil
chemotaxis and activation through increased expression of eotaxin (discussed in
more detail on page 52) [570],
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• Successful specific immunotherapy is associated with the down-regulation of
allergen-reactive Th2 cells and/or up-regulation of allergen-reactive Thl cells
[165, 166] [167]
Asthma is a chronic inflammatory disease of the lung that has increased in
prevalence in recent years. It is characterised by the continued presence of increased
numbers of Th2 lymphocytes, eosinophils, neutrophils and mast cells, along with
epithelial desquamation, goblet cell hyperplasia and thickening of the submucosa
[169]. This in turn, leads to variable airflow obstruction and AHR (airway
hyperresponsiveness) [ 170].
The allergic asthma reaction can be divided into an early (within minutes)
bronchospastic response followed by a late (hours) inflammatory response. The
immediate reaction can be characterised by rapid onset ofmucosal oedema, increases
in airway smooth muscle tone and airway narrowing due to the release of vasoactive
mediators by mast cells. The late phase response is associated with the migration of
neutrophils, eosinophils and lymphocytes from the blood into the lung parenchyma
and airway epithelium. Mast cells have also been implicated in the late phase
response. Support for this has come from a study in which the administration of
sodium nedocromil, a mast cell stabiliser, was found to inhibit both the early and late
phase responses [172], They may also act indirectly by the release of cytokines such
as IL-4 which leads to an increase in Th2 lymphocytes and eosinophil infiltration
[173].
Studies in asthmatics have shown an increase in T cell activation, with
increased expression of the IL-2 receptor, MHC class II antigens and very late
activation antigen-1 (VLA-1) in blood, BAL and bronchial biopsies [174], As
mentioned earlier, Th2 cells produce IL-4, IL-13, IL-5, IL-9, IL-6 and IL-10 which
are important in the stimulation of IgE production, mucosal mastocytosis and
eosinophilia.
A link between CD4+ T cells in the development ofAHR was first
demonstrated in 1994 by Gavett and colleagues [175]. In a murine model of
ovalbumin sensitisation, depletion ofCD4+ T cells in sensitised mice by specific
monoclonal antibodies, prior to local lung antigen challenge, prevented the
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The ability of IL-4 to drive differentiation of naive ThO lymphocytes into Th2
lymphocytes has already been discussed. IL-4 is also able to prevent apoptosis ofT
lymphocytes. This inhibition of apoptosis of is thought to be mediated by the ability
of IL-4 to maintain levels of the survival-promoting protein Bcl-2 in T cells [571]. It
was found that the co-culture ofT cells with IL-4 downregulates Fas expression on
the cell surface thus preventing apoptosis through the interaction of Fas (CD95) and
Fas ligand.
1.4.2 IL-5
IL-5 is essential for the maturation of eosinophils in the bone marrow and
their release into the blood [545], In humans, IL-5 acts only on eosinophils and
basophils, in which it causes maturation, growth, activation and survival [572,573].
This specificity occurs because only those cells possess the IL-5 receptor. The role of
IL-5 in eosinophilia is discussed in more detail on page 51.
1.4.3 IL-9
IL-9 is a T cell derived cytokine with pleiotropic effects on various cell types
[180]. Preferential production of IL-9 by Th2 cells has [181, 182] been implicated in
the in vitro stimulation of activated T cells [183], enhancement of immunoglobulin
production in B cells [184, 185] and the proliferation and differentiation ofmast cells
[186]. In addition, IL-9 has been shown to effect IgE-mediated responses by up-
regulating the a chain of the high affinity IgE receptor [187].
IL-9 has been proposed as a candidate gene for asthma. The gene for IL-9 is
located within human chromosome 5q31-33 which is associated with asthma and
bronchial hyperresponsiveness [188, 189]. Studies with inbred strains ofmice
demonstrated that bronchial hyperresponsiveness is genetically linked to
chromosome 13, which shows homology with human chromosome 5q31 -33 [190].
The hyporesponsive B6 strain ofmice express undetectable levels of IL-9 protein in
the steady state but the hyperresponsive D2 strain ofmice have significant IL-9
protein levels in the lung. Thus, there appears to be a tight genotype-phenotype
correlation. In naive B6 mice, intratracheal instillation of recombinant murine IL-9
induced eosinophilia with an elevation in total serum IgE [191]. Furthermore,
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transgenic mice over-expressing IL-9, showed enhanced eosinophil infiltration,
elevated total serum IgE, mast cell hyperplasia and airway hyperresponsiveness [192,
193], In humans, the in vivo expression of IL-9 was found to be significantly up-
regulated in bronchial biopsy specimens obtained from subjects with asthma,
compared with those from controls and from subjects with non-atopic lung disease
[194].
IL-9 can stimulate mucin transcription and the production of chemokines by
respiratory epithelial cells. The expression of IL-9 in transgenic mice resulted in the
upregulation of eotaxin and MCP-5, which have chemotactic activity on eosinophils
[195]. Also, Levitt et al have shown an induction of IL-5Ra by IL-9 in mice
suggesting that IL-9 has a direct effect in eosinophilia [191]. Mucus overproduction
is often observed in airway inflammation and is the leading cause of airway
obstruction in asthma [196]. Longphre et al blocked the ligand-receptor interactions
of IL-5, IL-13 and IL-9 in dog airway fluid and found that only IL-9 stimulated
mucin synthesis [197],
1.4.4 IL-13
IL-13 consists of 132 amino acids and has a molecular mass of 12 kDa. The
gene for human IL-13 is located on chromosome 5q 31 in the same region as the
genes encoding IL-3, IL-4, IL-5, IL-9 and GM-CSF [198], IL-13 shows 25%
homology with IL-4 and shares some structural characteristics and functional
properties with the cytokine. Both the IL-4R and IL-13R share the IL-4Ra chain and
promote STAT 6 activation.
IL-13 production was found to be independent of IL-4 as observed in IL-4
deficient mice, after challenge with Onchocerca volvulus antigen [199]. IL-13 in
contrast to IL-4 does not support the proliferation of activated human and mouse T
cells and failed to induce the differentiation of naive CD4+ cord blood T cells
towards a Th2 phenotype [133].
The expression ofCD23, CD71 (on activated leukocytes), CD72 (on B cells),
slgM and class II MHC antigens can all be upregulated by IL-13. In addition, IL-13
has growth-promoting and anti-apoptotic effects on normal B cells activated by anti-
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IgM or anti-CD40 mAbs. The production of IgM, IgG and IgA can also be enhanced
by IL-13.
The physiological effects of IL-13 are contradictory. On one hand,
IL-13 has been shown to induce IgE synthesis independently of IL-4, [200] and
unlike IL-4, is produced by nai've CD45RA+ T cells, implying that it is important for
the initiation of IgE production. The role of IL-13 in allergic asthma has also been
examined [201, 574], Mice were immunised intraperitoneally with ovalbumin and
subsequently challenged intratracheally with the protein in order to induce an allergic
phenotype. IL-13 production was blocked by the administration of a soluble IL-
13a2-IgGFc fusion protein, which specifically bound and neutralised IL-13,
subsequently causing a complete reversal of allergen-induced AHR. As well as
allergic responses, parasitic worm infections are also characterised by the induction
of a Th2 response. Originally, IL-4 was thought to be the major cytokine responsible
for worm clearance but more recent studies using Nippostrogylus brasiliensis (a
gastrointestinal nematode) infected IL4"7" mice, have demonstrated that these animals
were able to expel the parasite [202], suggesting that another T cell mediator is
required for efficient worm clearance. A study using IL-13"7"mice, showed that these
animals were unable to clear the N. brasiliensis infection efficiently, even though a
strong Th2 response was observed [203], Furthermore, treatment of the infected IL-
13"7" mice with exogenous IL-13, resulted in a decreased worm burden. CD8+ T cells
have been shown to produce IL-13 [149], which supports the view that these cells are
responsible for exacerbation of asthma following viral infection [153]. Furthermore,
IL-13 can induce VCAM-1 expression on endothelial cells, which results in the
adhesion and subsequent extravasation of T cells, monocytes and eosinophils to sites
of allergic inflammation [204],
IL-13 is also capable of antagonising a Thl response. IL-13 has the capacity
to downregulate the production ofRANTES in vitro by airway-derived smooth
muscle and endothelial cells [205]. In vivo, IL-13 inhibits LPS-induced lethal shock,
collagen-induced arthritis, EAE and diseases in which TNF-a produced by
macrophages plays a major role [206, 207].
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1.4.5 Antigen Presentation in the Airways
Dendritic cells are bone marrow-derived professional APCs and are probably
the most important antigen presenting cell in the airways. The DCs form an extensive
network below the basement membrane of the airway epithelium that ensures
accessibility to inhaled antigens [208, 209]. The density of DCs is highest in the
upper airways with a decline in number further down the airways [210], which
suggests that these APCs may play a sentinel function in detecting the presence of
foreign antigens [211]. Dendritic cells are stellate with many fine dendrites. This
shape combined with excellent motility are the characteristics that make DCs
excellent at capturing antigens and selecting antigen-specific T cells. DCs display
large amounts ofMHC-peptide complexes on their surface which are typically 10-
100 times higher on DCs than on other APCs like B cells and monocytes. Chemokine
receptors expressed by immature DCs, promote their migration to inflamed tissues,
where antigens are captured and maturation is induced. Maturing DCs upregulate
CCR7 which drives their migration to the T-cell areas of the draining lymph nodes
where antigen is presented to naive T cells [212], Lambrecht et al, reported a
requirement for DCs in the development of chronic eosinophilic airway
inflammation in response to inhaled antigen in sensitised mice [213],
DC numbers in the airways have been shown to be elevated in a number of
asthmatics compared to normal controls [214] and also, the proportion of DCs
expressing the alpha subunit of the FcsRl is significantly increased in asthmatics
[215]. Steroid treatment dramatically inhibits the recruitment ofDCs into the
respiratory tract epithelium during acute inflammation [216].
Another cell type implicated in airway inflammation is the alveolar
macrophage (AM) [217, 218]. Alveolar macrophages from asthmatic patients express
an enhanced capacity to present antigen to autologous T-lymphocytes [219], than
those from normal subjects, and also express elevated levels of ICAM-1 and LFA-1
[220]. Stimulated AMs from asthmatics produce more GM-CSF, TNF-a, IL-8 and
leukotrienes than AMs from nonasthmatics [221, 222], and it has been shown that
AMs influence the production of IL-5 by CD4+ T cells [223, 224], However, resident
pulmonary alveolar macrophages (PAM) have been shown to play an important role
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in the maintenance of immunological homeostasis in the lung via downmodulation of
local T cell responses in the steady state [225].
1.4.6 Eosinophils
Eosinophils are present in relatively low numbers in healthy individuals, but
their numbers increase dramatically in certain diseases, particularly parasite
infections and allergic conditions [226]. The recruitment of eosinophils into the lung
followed by their release of chemotactic factors results in chronic thickening and
inflammation of the airways. This recruitment of eosinophils to sites of allergic
inflammation is a complex process and is mediated by a number of cytokines and
chemokines. The induction of airway eosinophilia is also dependent on CD80 (B7-1)
costimulation [64],
IL-5 is probably the most important cytokine to be implicated in eosinophil
development, migration and function [227-229]. Experiments with IL-5 deficient
mice have established that blood and airway eosinophilia is dependent on IL-5 [230].
IL-5 specifically facilitates the terminal differentiation and proliferation of
eosinophils [227], as well as the survival, viability, and antibody-dependent
cytotoxicity ofmature eosinophils [228]. In addition, IL-5 can induce migration of
mouse and human eosinophils [229].
Activation of the endothelium is an important step in the inflammatory
process. The endothelium can be activated by a variety of proinflammatory
mediators such as IL-ip [231, 232] and TNF-oc [233] to induce the expression of
ICAM-1. VCAM-1 is induced primarily by IL-4. The initial attachment of
eosinophils is thought to be mediated through E-selectin and VCAM-1 /VLA-4
interaction [234, 235]; and the upregulation of adhesion molecules such as ICAM-1
and VCAM-1 enhances the attachment of eosinophils and thus exacerbates airway
inflammation. The rolling of eosinophils on the endothelium is mediated primarily
by P-selectin. After cellular activation by exposure to chemoattractants such as
platelet-activating factor [236] or eotaxin, [237-239] eosinophils adhere firmly to the
endothelium through adhesion molecules of the integrin family. These include the
CD18 family (P2 integrins) and very-late-antigen-4 (VLA-4) molecules (Pi
integrins). The p2 integrins interact with intercellular adhesion molecule 1 (ICAM-1)
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on endothelial cells, whereas the Pi integrins interact with vascular-cell adhesion
molecule 1 (VCAM-1). The subsequent transendothelial migration process relies
heavily upon ICAM-1/CD11/18 [240]. Upregulation ofCD1 lb and shedding of L-
selectin during transendothelial migration was also observed [232].
IL-3 and GM-CSF are also implicated in the production and effector function
of eosinophils [241, 242]. IL-3 and GM-CSF stimulate bone marrow progenitors in
vitro to form colonies of cells that include eosinophils. They also promote
inflammatory changes in eosinophils characterised by prolonged viability, enhanced
functional properties and hypodensity. Hypodense eosinophils have been found in
the peripheral blood of patients with chronic helminthic infections, bronchial asthma
and hypereosinophilic syndrome. Upon activation, the eosinophil releases preformed
toxic cationic proteins such as major basic protein, eosinophil cationic protein [243]
and eosinophil peroxidase [244], In addition, the eosinophil generates oxidative
products, hyperhalous acids, lipid mediators (platelet activating factor and
leukotriene C4) and cytokines (IL-3, IL-5 and GM-CSF) that all contribute to the
eosinophil's proinflammatory functions. The production ofPAF and leukotriene C4
are dependent on expression of phospolipase A2 by eosinophils [245]. These are
characteristics of eosinophils that make them excellent candidates for defending the
host against invading pathogens but contribute enormously to the symptoms of
chronic inflammatory diseases such as asthma.
Eosinophil movement within inflamed tissues is promoted by IL-5 in
conjunction with the chemokines - RANTES, MlP-la (macrophage inflammatory
protein) [246], MCP-3 (monocyte chemoattractant protein) [247], lipid mediators
such as PAF (platelet-activating factor) and leukotriene B4 [236, 248, 249]], and
eotaxin.
Eotaxin was first identified in 1994 by Jose et al when eosinophil
chemoattractant activity was purified from the BAL fluid of sensitised guinea pigs
after challenge with ovalbumin [239]. Microsequencing revealed a novel 73 amino
acid C-C chemokine that exhibited 53% homology with human MCP-1, 44% with
guinea pig MCP-1, 31% with MlP-la, and 26% with human RANTES. Human
eotaxin was cloned shortly after [250, 251] and more recently, another C-C
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chemokine was cloned which showed chemotactic activity for eosinophils and
basophils. This chemokine was termed eotaxin-2 and only exhibited 39% homology
with eotaxin-1 and was much less potent [252, 253].
Eotaxin is constitutively expressed in a number of tissues and may regulate
the basal tissue homing of eosinophils. On exposure of a tissue in a sensitised animal
to allergen, there is an upregulation of eotaxin mRNA and an early appearance of
protein. However, eotaxin will be unable to induce eosinophil recruitment to any
extent if circulating cell numbers are low. Collins et al proposed that the secretion of
1L-5 acts in an autocrine fashion in that it (IL-5) circulates in the blood and
stimulates the release of a rapidly mobilizable pool of bone marrow eosinophils
[237]. The synergism of IL-5 and eotaxin will then induce a rapid recruitment of
eosinophils from the bone marrow into the affected tissue [254], The specificity and
potency of eotaxin for eosinophils are the result of its high affinity interaction with
the P-chemokine receptor, CCR3, which is highly expressed in human and mouse
eosinophils [255, 256].
Eosinophilic infiltration of tissues is usually followed by elimination of these
cells by apoptosis. Inhibition of apoptosis of eosinophils by certain cytokines (IL-5,
GM-CSF) increases the survival of eosinophils and thus, exacerbates eosinophilia.
Recent work has suggested that Bc1-xl (an anti-apoptotic protein) may be involved in
the anti-apoptotic pathway mediated by cytokines in eosinophils [257].
1.4.7 IgE
The presence of IgE was first identified in 1966 by Ishizaka et al. [258]. IgE
is a 188 kDa immunoglobulin with a very short half-life in serum of two days [259].
In normal, non-atopic individuals, IgE is present at a concentration of 5 xlO"5 mg/ml
in serum, but in allergic subjects or those with a parasitic infection, the levels are
significantly elevated.
IgE, like IgM, lacks a hinge region but each isotype has an extra heavy chain
domain and also show a wide distribution ofN-linked carbohydrate groups [260].
IgE can bind to two classes of receptor - the high affinity (FcsRl) and low affinity
receptor (FcsRII, CD23). CD23 is found on activated B cells, but several cell types
including, T cells, eosinophils, follicular dendritic cells, neutrophils and
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macrophages, also express CD23 [261]. As mentioned before, CD4+ T cells in atopic
individuals secrete high levels of IL-4 which promotes IgE synthesis by B cells. The
synthesis of IgE is thought to be controlled by a feedback inhibition mechanism that
is mediated by IgE-containing complexes binding to CD23 on B cells, which
prevents further IgE synthesis [262], In CD23 knockout mice, the feedback inhibition
is absent and thus, IgE levels are increased in response to T cell-dependent antigens
[263], CD23 cleavage from the cell surface is thought to involve proteolysis but the
mechanism has not been fully elucidated [264], Its cleavage results in the formation
of soluble trimeric CD23 (sCD23) molecules that retain their ability to bind IgE and
thus exacerbate allergic symptoms. Monomeric forms of CD23 can be inhibitory.
As well as binding to specific IgE receptors, IgE can bind to other structures,
e.g. FcyReceptors [265] and Mac-2 [553], Receptor-bound IgE has an extended half-
life.
1.4.8 Mechanism of Class Switching
IgE production by B cells is preceded by an isotype class switch from IgM to
IgE. Studies in vitro, have demonstrated that stimulation of B cells with anti-IgM
antibodies or LPS in the presence of IL-4 is sufficient to induce the class switch to
IgE [266], The two signals required for the switch to IgE production are delivered by
T cells to B cells through a complex series of interactions. Synthesis of IgA and IgM
antibodies by naive B cells on initial exposure to antigens, is followed by an
expansion ofmemory B cells recognising antigen fragments. On subsequent
exposure to the same antigen, the IgM on the B cell surface binds the antigen and the
antigen-receptor complex is internalised. Endosomal processing leads to antigenic
peptide fragments associated with MHC class II molecules being presented to T
cells. Subsequent recognition by the TCR complex leads to two crucial events:
1) secretion of IL-4 and IL-13 and
2) expression of the CD40 ligand.
Signals transmitted following binding of IL-4 to its receptor on the B cell induces
transcription of the Cs heavy chain gene locus [267]. CD40L on the T cell, engages
CD40, a 50 kDa integral membrane glycoprotein member of the TNF receptor
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superfamily, that is constitutively expressed on B cells, macrophages, dendritic cells
and endothelial cells [268]. This oligomerisation of CD40 triggers deletional switch
recombination to IgE. Expression ofB7 (CD80) on B cells is increased following
CD40 activation and this serves as a co-receptor for CD28 on T cells, leading to
optimal T cell activation and secretion of cytokines [269].
A number of studies have revealed the importance ofCD40-CD40L interactions
in isotype switching. It was shown that monoclonal antibodies directed against
CD40, eliminated the need for T cells in IL-4-driven isotype switching to IgE in vitro
[270], Patients that had X-linked hyper-IgM syndrome (X-HIM) were deficient in
CD40L and were found to have defects in isotype switching and thus lacked serum
IgG, IgA and IgE [271, 272], Similarly, mice with a targeted disruption of the
CD40L gene [273], lacked serum IgE and failed to undergo isotype switching in vivo
and in vitro following immunisation with T cell-dependent antigens but were capable
ofmounting IgM and IgG responses to T cell-independent antigens.
High levels of antigen-specific IgE is obviously detrimental in allergic disease
but in parasitic infections, the presence of IgE is very beneficial. Mast cells have
been implicated in the clearance of parasites. This has been demonstrated in w/wv
mutant mice, which have a profound mast-cell deficiency caused by a maturation of
the gene c-kit [274]. These mutant mice had impaired clearance of the intestinal
nematodes Trichinella spiralis and Strongyloses species. This clearance was
impaired to an even greater extent in IL-3-deficient w/wv mice because they failed to
produce basophils as well as lacking functional mast cells.
1.4.9 Neurotrophins
Recently, neurotrophins have been implicated as mediators of inflammation
and hyperresponsiveness. Neurotrophin receptors are expressed on nerve cells as
well as on immune cells, including monocytes, mast cells, B cells and T cells. Nerve
growth factor (NGF) has several immunological functions such as induction ofmast
cell degranulation, induction of cytokine synthesis, and regulation of antibody
production [275], Additionally, NGF is a chemoattractant and activation factor for
eosinophils [276]. In one study, high levels ofNGF that correlated with high serum
IgE levels and amounts of eosinophilic cationic protein, were found in patients with
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severe allergic bronchial asthma. Furthermore, NGF serum levels correlated with
total IgE antibody titres [277]. A more recent study found a significant increase in
the neurotrophins NGF, BDNF (brain-derived neurotrophic factor) and neurotrophin-
3 in the BAL fluid of human volunteers 18 hours after segmental allergen
provocation [278],
1.4.10 Genetic Background
The possibility that atopic subjects have a genetic dysregulation at the level
of Th cell-derived IL-4 is supported by several observations. First, CD4+ T cell
clones from atopic individuals produce noticeable amounts of IL-4 and IL-5 in
response to bacterial antigens, such as PPD and streptokinase, that usually evoke
responses with a Thl-like cytokine profile in non-atopic individuals [279]. Second,
atopic donors have a higher frequency of IL-4 producing T cells than normal subjects
[280]. Also, T cell clones generated from neonatal cord blood lymphocytes from
new-borns with atopic parents showed higher levels of IL-4 than those born with
non-atopic parents [281].
Since 1989 when Cookson and coworkers first reported that they had
identified a locus containing an atopy gene on chromosome 1 lq [282], there have
been important advances in incriminating specific loci in the human genome that
harbour genes that contribute to asthma and allergy [283 for review].
Atopy, (ie. the predisposition of some individuals to produce IgE after contact
with low levels of innocuous allergens), has been linked to the FcsRIp gene found on
chromosome 11 (the 1 lql3 region) [282], Mutations in these genes could lead to
increased signal transduction after allergen binds to IgE, and consequently to
increased secretion of IL-4. One such mutation (Leu-181) was associated with atopy
[284] and asthma [285] in some populations but not in others.
On chromosome 5q there are many candidate genes for asthma and allergy
such as IL-4 and (h-andrenergic receptor genes. A specific polymorphism in the IL-4
gene (IL-4 C-589T) has been identified in a region of the gene that binds
transcription factors and influences gene expression [286], This polymorphism has
been shown to correlate with high serum IgE levels and enhanced IL-4 gene
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expression. A number of variants in the P2-adrenergic receptor gene have been
identified that alter receptor function. The most prevalent of these are the Arg-16 -»
Gly and the Gln-27 —> Glu polymorphisms, which influence the downregulation of
the receptor in response to the agonist. The Gly-16/Gln-27 haplotype was associated
with bronchial hyperresponsiveness (BHR) and asthma severity [287], The Gln-27
allele was associated with high total serum IgE [288].
Chromosome 5q also contains genes for IL-5, IL-9, IL-13, GM-CSF [289,
290] and CD14 [291 ]. CD 14 is found on the surface ofmonocytes and macrophages
and is also present in a soluble form (sCD14). CD 14 acts as the high-affinity receptor
for bacterial LPS (lipopolysaccharide, also known as endotoxin) and is a key
molecule in the initiation of the nonspecific innate immune response to bacterial
infection. Baldini et al. identified aC^T base change, 159 bases upstream of the
transcription start site for CD 14. They then studied children from the general
population and showed the T genotype to be significantly associated with high levels
sCD14 and low levels of IgE. Activation ofmonocytes and macrophages through
CD14 causes the release of a complex mixture of cytokines which modulate the
specific immune response and which have been shown to inhibit the production of
IgE [292, 293],
Another potentially important candidate gene is the IL-4 receptor a (IL-4Ra)
gene, located on chromosome 16q. One variant of the IL-4Ra gene (Gln576Arg) has
been associated with increased signal transduction and high IgE levels, including the
hyper-IgE syndrome [294].
The pro-inflammatory cytokine tumour necrosis factor (TNF) shows
constitutional variation in the level of secretion which is linked to polymorphisms
within the TNF gene complex and the surrounding MHC (located on chromosome
6p) [295]. TNF is prominent in asthmatic airways [296]. One study identified a
higher incidence of asthma in subjects possessing allele 1 of the LTa Ncol
polymorphism. However, linkage was not associated with IgE production, indicating
that the association of the TNF polymorphisms with asthma is independent of atopy.
Chromosomes 13q and 12q have also been linked to asthma and related
phenotypes but not the linked regions contain no known candidates [297].
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Overall, a combination of genetic factors along with the environmental
factors mentioned earlier, can contribute to the pathogenesis of allergic disease and
predispose any given individual to allergy. Atopic diseases have increased in
prevalence over the last few decades and now affect approximately 20-30% of the
general population in developed countries, (see figure 1.2, pg 59).
1.4.11 T Cell Receptor-a and Human Leukocyte Antigen-DR
Inhaled allergen sources such as house dust mite (HDM) or grass pollens are
complex mixtures ofproteins. Der p I and Der p II (major allergens from HDM) have
four major B cell epitopes [298, 299] and peptide mapping of Der p II has shown that
T cell clones from different individuals may also react to common T cell epitopes
[300],
The human leukocyte antigen (HLA) and T cell receptor (TcR) genes are
candidates for germ-line influences on specific allergen responses. The association of
HLA haplotypes and ragweed allergy was the first human Ir (immune response) gene
to be recognised [301], and HLA-DR restriction of IgE reactions to allergen is well
documented [302, 303]. However, the HLA genes on their own do not account for
the differences in an individual's IgE reactions to allergen [302], Polymorphisms in
the TcR genes influence the peripheral TcR repertoire [304, 305] and may affect the
immune response to antigen. The Va8 region of TcR-(3 has previously been
demonstrated to be in excess in T cell clones reacting to HDM [306]. A later study
showed that both Va8.1 *2 and HLA-DRB1 * 1501 were positively associated with
IgE titres in Der p II [307]. The epitopes ofDer p I recognised by human and mouse
T cells will be discussed later in the chapter.
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Figure1.2-ThePathogen sisfAll gyandsthma AdaptedfromParronchietl[168].
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1.5 House Dust Mite Allergy
Approximately 20% of the developed world's population suffers from allergy
to house dust mite (HDM). House dust mites are arthropods that measure between
170 - 350 pm in length and thrive in warm and humid conditions. In the United
Kingdom, three species, Dermatophagoides pteronyssinus, D. farinae and
Euroglyphus maynei, commonly flourish in the indoor environment. The mites
produce faecal pellets that vary in size between 10 - 40 pm; this makes them ideal
respirable vehicles for delivery to the respiratory tract. Der p 1 has been identified as
being one of the major allergens found at high concentrations in mite faeces. It is
highly water soluble with a molecular weight of 25 kD. It was found that
approximately 75% of the serum IgE antibodies to D. pteronyssinus in sensitive
patients were directed against Der p 1 [308].
Der p 1 has been cloned and sequenced and found to consist of 222 amino
acids. It also has a high degree ofhomology at the nucleotide and amino acid level
with actinidin and papain, which belong to the group of cysteine proteases [309]. The
two crucial amino acid residues (cysteine and histidine) known to be an integral part
of the active site of papain and actinidin are also conserved in Der p 1 (as cysteine
residue 34 and histidine residue 170). As well as being an immunogenic protein in its
own right, the protease activity ofDer p 1 is also thought to contribute to the
pathogenesis of airway inflammation. This enzymic activity is thought to cause
disruption of intercellular tight junction (TJs), which are the principal components of
the epithelial paracellular permeability barrier. Specifically, Der p 1 led to the
cleavage of the TJ adhesion protein occludin in confluent airway epithelial cells
resulting in increased epithelial permeability to a variety of allergens [310].
1.5.1 Cleavage of CD23 and CD25
A few years ago, two groups showed that Der p 1 could cleave CD23, the low
affinity receptor for IgE, by proteolysis, [85, 86], As mentioned elsewhere, cleavage
of CD23 results in the formation of soluble CD23 (sCD23) molecules that retain their
ability to bind IgE and thus exacerbate allergic symptoms.
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More recently, Der p 1 has also been shown to proteolytically cleave the a
subunit of the human IL-2 receptor (CD25) from peripheral blood T cells [87]. As
mentioned before, IL-2 plays a pivotal role in the development ofThl cells and thus
a disruption in this signalling pathway would consequently bias the immune response
towards Th2 induction.
1.5.2 Epitopes of Der p 1 Recognised by Human T Cells
The antigen and restriction specificity ofT cell responses to Der pi have been
identified using cDNAs and various peptides. Five regions of the protein, residues
45-67, 94-104, 107-119, 110-131 and 117-143 have been identified that contain T
cell epitopes restricted by several different HLA class II molecules [299]. T cell
clones specific for residues 45-67 and 117-143 recognised antigen in association with
HLA-DR7, whilst those T cells reactive with amino acids 94-104 were restricted by
HLA-DR2, -DRwl 1 (DR5) and -DR8 [311]. Within the region 101-131 ofDer pi,
three overlapping epitopes are present that are similar to those determined in H-2b
mice. The T cell epitopes 110-131 and 110-119 are restricted by DRB1*0101 and
DPB1 *0402, respectively. The T cell epitope 107-119 was HLA-DP restricted and
could be presented to T cells bound to HLA-DPB1*0401, -DPB1*0402 and -
DPBl*0501-bearing accessory cells.
1.5.3 Epitopes of Der p 1 Recognised by Murine T Cells
When primed with Der p 1, mice of the H-2b haplotype (e.g. C57BL/6,
BALB/b) were found to be the highest responders. H-2k mice had intermediate
responses whilst H-2d, H-28 and H-2 k mice responded poorly (Hoyne - PhD. thesis).
The murine T-cell epitopes have been identified using overlapping synthetic
peptides. H-2b mice recognise three distinct epitopes at residues 21-49, 78-100 and
110-131. The strongest response was observed to a 110-131 peptide which contains






1.6 Immunotherapeutic Strategies for Atopic Diseases
With such a high incidence of atopic disorders in the developed world, it is
clear that suitable therapies are needed. This can be approached in a number ofways.
Corticosteroids are a commonly used anti-inflammatory which require continuous
administration to be effective in reducing symptoms, are associated with undesirable
side effects and most importantly, have no effect on the underlying inflammatory
process. Therefore, it is preferable to target the allergen-specific T cells which are
central to the induction and regulation of allergic responses. Allergen-specific T cells
can be targeted either directly or indirectly. Non-allergen-specific immunotherapy




T cells can be functionally inactivated or tolerised by a number of different
mechanisms, including clonal deletion, the induction of anergy (which occurs when
antigen binds to the TCR but the T cells no longer proliferate) or the induction of
linked suppression.
1.6.1.2 Anergy
Anergy was first defined in vitro as a state of functional unresponsiveness. It
occurs when antigen binds to the TCR in the absence of adequate costimulation,
mediated through the interaction ofCD28 and its ligands, CD80 and CD86. This has
been demonstrated by in vitro experiments, firstly, by incubating influenza virus-
specific human T cell clones with the relevant virus-specific haemagglutinin peptide
alone, in the absence ofAPC [312], Treatment resulted in an inability to respond to
rechallenge with antigen 24 hours later. A second study by Higgins at al. investigated
the effect of an epitope located in the group 1 allergen ofDer p on HLA-DP-
restricted T cell clones. Pretreatment of the T cell clones with the Der p 1 peptide
p( 101 -119) rendered them nonresponsive to an immunogenic challenge with the
whole D. pteronyssinus allergen [311].
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In vivo studies in mice have subsequently been developed and have shown
that T cell responses to allergens can be inhibited by the subcutaneous, intranasal or
oral administration of allergen-derived synthetic peptides. One murine study utilised
peptides from the cat allergen Fel d 1. Mice were pre-treated subcutaneously with
high dose peptide prior to a parenteral challenge with the same peptide in Freund's
complete adjuvant. This resulted in the tolerisation of T cells, as evidenced by
decreased production of IL-2, IL-4 and IFN-y from lymph node and spleen cells
cultured with the peptide. In addition T cell proliferation was decreased in the
peptide-tolerised animals [313]. A later study by Hoyne et al. administered Der p 1
peptide intranasally. Four days after the peptide treatment, rapid but transient
activation ofMHC class II-restricted CD4+ T cells was observed (by upregulation of
the activation molecules CD25) however, by day 14, IL-2 and IFN-y secretion by T
cells were down-regulated as well as proliferation [314],
This so-called peptide treatment has been used in humans as a possible means
of therapy. Peptide therapy has a considerable safety advantage over traditional
therapies with crude extract or native allergens. Because the peptides are smaller than
the whole allergen, there is reduced IgE cross-linking by allergen-specific peptides,
with the desired effects on T cells unaltered [315]. Disadvantages of this approach to
immunotherapy include the fact that large amounts of IL-4 and IL-5 are still
produced during initiation of a peptide vaccine, that could lead to initial worsening of
symptoms. In addition, most allergens contain multiple T cell epitopes that are
restricted by different MHC class II antigens. Thus, the total T cell response to the
native protein is limited to a few immunodominant epitopes but tolerance induction
is avoided because non-immunodominant epitopes have made themselves available
after in vivo processing of native allergen [316].
The modulation ofproliferative and cytokine responses has been
demonstrated following peptide immunotherapy in bee venom-allergic subjects
[317]. Proliferative and cytokine Thl and Th2 responses from isolated peripheral
blood mononuclear cells were suppressed after bee venom peptide immunotherapy.
Following whole allergen challenge, there was a change in the PLA2-specific
IgE:IgG4 ratio in favour of IgG4. However, the number of subjects in the experiment
was small and comparisons were not made in relation to a placebo group. Akidis et
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al. also found a reduction in T cell proliferative responses to allergen after ultra rush
bee venom immunotherapy [318], However, responses could be restored following
addition of exogenous IL-2 or IL-15, which suggested that the T cells were in a state
of anergy. Even when proliferation was restored, the anergy effect resulted in the
production of a stronger Thl phenotype.
The precise mechanisms underlying the induction of anergy still need to be
fully elucidated. However, it is known that peptide-mediated anergy is associated
with compound changes in the T cell phenotype characterised by the down-
regulation of the TCR/CD3 receptor complex and enhanced expression of CD2 and
CD25 [319, 320]. Anergic cells have an inability to release intracellular calcium
upon restimulation; and altered signalling pathways may be utilised by anergic T
cells [321, 322], Studies ofpeptide anergised PLA2-specific cloned CD4+ T cells
have identified abrogation of the activity of p561ck and ZAP-70 tyrosine kinases
[323],
Expression of the costimulatory molecules CD80 and CD86 does not seem to
affect the induction of anergy. No changes in their expression were observed on ThO
or Th2 cells that had become unresponsive after modulation. Also, in the absence of
APCs, stimulation with peptide, induced anergy in human Th2 cells irrespective of
CD80 and CD86 [320]. However, CD28 expression may be down-regulated [324],
1.6.1.3 Clonal Deletion
In the periphery, a mature T cell will be stimulated to proliferate and produce
effector cells if it encounters an antigen for which its receptor is specific. However,
when a developing T cell encounters the antigen it recognises in the thymus, it
undergoes apoptosis. This is the basis of negative selection and has been
demonstrated in experiments involving transgenic mice. High dose antigen treatment
in OVA-TCR transgenic mice, induced clonal deletion by apoptosis [325]. Self
peptides bound to selfMHC molecules on thymic cells and developing cells with
receptors specific for these peptides, will be deleted from the repertoire. This form of
tolerance is incredibly important because it prevents the body reacting to self
antigens. Breakdown in clonal deletion leads to autoimmune disease.
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Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) plays a key role in
immunologic self-tolerance in the periphery. CTLA-4 (CD152) is a CD28
homologue expressed on activated T cells, and upon interaction with CD80 or CD86
on APCs, exerts a downregulatory or attenuating effect on T cell-mediated immune
responses [326, 327], CTLA-4-deficient mice develop a severe lymphoproliferative
disorder and die from autoimmune-like disease within one month after birth [52,
328]. In the murine models ofmultiple sclerosis and insulin-dependent diabetes
mellitus, the autoimmune responses were exacerbated after administration of anti-
CTLA-4 antibody [329, 330]. Perez et al. demonstrated the requirement of CTLA-4
for in-vivo peripheral tolerance induction [331].
1.6.1.4 Linked Suppression and Regulatory T Cells
In addition to clonal anergy or deletion, there is accumulating evidence to
suggest that another tolerance mechanism exists involving T cell mediation, termed
linked suppression. A phenotypically and functionally distinct population ofT cells
has been identified and termed regulatory T (T reg) cells. This subset of cells were
implicated in the control of intestinal inflammation and have been suggested to play
a pivotal role in intestinal homeostasis [332], These cells express a particular cell
surface phenotype (CD25+CD45RBloCD4+), determined through studies
investigating inflammatory bowel disease [333] and autoimmune gastritis [334, 335].
Colitis induced in SCID mice by the transfer ofCD45RbhlCD4+ T cells was
prevented by the co-transfer ofmurine Trl clones derived from CD4+ T cells
expressing a transgenic TCR specific for OVA. Immunosuppression was dependent
on the antigen-induced activation ofTrl cells in vivo as these cells only inhibited
colitis in recipients receiving OVA in their drinking water. In contrast, the effector
function ofTrl cells was not antigen-specific as they could inhibit the function of T
cells responding to unknown intestinal antigens, a phenomenon termed antigen-
driven bystander suppression (Groux, O'Garra et al. 1997).
In the colitis model, immune suppression was dependent on TGF-P [336] and
production of IL-10 [337], along with the ligation ofCTLA-4 [338], The role of
CTLA-4 in immune suppression was also shown by Takahashi et al. by blocking
CTLA-4 in vivo [339]. CTLA-4 has a 10 to 100-fold higher affinity for CD28 than
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B7.1/2. The authors suggested that T cells stimulated via CTLA-4 and the TCR may
physically interfere with the interaction of other T cells with APCs by competing for
the costimulatory molecules on the APCs, as they are predominantly expressing
CTLA-4 [340]. Alternatively, the signals via the TCR and CTLA-4 may activate
CD25+CD4+ T cells to deliver to the other T cells a negative signal for activation and
proliferation. This is currently under investigation.
There is evidence of a role of cell-cell contact in bystander suppression.
Hoyne et al. have proposed a mechanism in which the differentiation ofCD4+ T cells
into regulatory phenotypes, may be induced by the interaction of two receptors -
Notch-1 (expressed on T cells) and Serrate-1 (expressed by APCs), that also
determine cell fates during thymic T-cell differentiation [341]. The expression and
function of Delta-1 (a second ligand for Notch), was also investigated in a murine
model ofT cell tolerance to Der p 1 in vivo by using in-situ hybridisation and virus-
mediated gene transfer [342]. The intranasal delivery ofhigh dose peptide induced
the transient expression of Delta-1 on inhibitory CD4+ T cells. Ligation of the Notch-
1 receptor on neighbouring T cells by Delta-1+ regulatory T cells inhibited clonal
expansion thus implicating Notch/Delta signalling as an important factor in the
underlying mechanisms of linked suppression.
1.6.1.5 Redirection of Allergen-Specific Th2 Responses
As mentioned earlier, the Th2 response is quite resistant to a reversal in
cytokine patterns once established; and after long-term stimulation, this reversibility
is completely lost. However, recent findings indicate that regardless of prior
commitment, memory CD4+ T cells may retain the capacity to be further influenced
during effector cell development [343, 344].
1.6.1.6 Altered Peptide Ligands
Several studies suggest that certain epitopes can preferentially induce one of
the Th subsets. The chosen response can be induced by altering either the antigenic
peptide or the MHC class II molecule. High MHC class II peptide density on the
APC surface favours Thl responses, while lower ligand densities favour Th2
responses [47], This is logical as allergens are presented to the human immune
system at very low doses, leading to IgE synthesis. Moreover, desensitisation is
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generated by injecting successively higher doses of allergen. Kumar et al. showed
that stimulation with a high affinity ligand resulted in IFN-y production whilst low
affinity ligands induced IL-4 production [345], A single MHC polymorphism may
dictate Thl/Th2 selection by determining the level of peptide presented to a given
TCR on APCs [346].
Slightly later studies showed the enhancement of IFN-y production from
human ThO cells by stimulation with an altered dominant T cell epitope ofDerp 2
[347]; and similarly, a replacement of the arginine residue at position 21 by lysine in
a peptide derived from the D.farinae group 1 allergen, resulted in increased IFN-y
production associated with a rise in IL-12 [348],
More recently Janssen et al. defined four modulatory peptide analogues of
ovalbumin (OVA323-339) with comparable MHC class II binding affinity. These
peptide analogues were used for immunotherapy by subcutaneous injection in OVA-
sensitised mice before OVA challenge. Treatment with a Th2-skewing peptide
dramatically increased airway eosinophilia upon OVA challenge but treatment with a
Thl-skewing peptide analogue resulted in a significant decrease in airway
eosinophilia and OVA-specific IL-4 and IL-5 production [136].
1.6.1.7 Use ofAdjuvants and Incorporation of Peptides
Peptides and proteins can be administered along with adjuvants that
preferentially induce a Thl response. Examples are the use of recombinant M. bovis
(BCG) against L. major [349], M. tuberculosis [350] and measles virus [351]. Live
recombinant Salmonella has been administered orally to elicit antigen-specific Thl-
type responses in both mucosal and systemic tissues, in the absence of IL-4 and IL-5.
In the laboratory, a common adjuvant administered in mice to induce a Thl response,
is Complete Freund's Adjuvant. However, because of its undesirable inflammatory
side effects, CFA is not suited for use in human vaccines. The main component of
this adjuvant are mycobacterial cell walls that induce high IL-12 production by
macrophages, with subsequent upregulation of IFN-y [352], In contrast, Incomplete
Freund's Adjuvant, alum, acellular Bordetella pertussis toxin and cholera toxin act
by inducing Th2 responses [353-355].
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Immune stimulating complexes (ISCOMS) act as antigen carriers. They are
generally 40 nm in diameter and consist of cholesterol, phospholipids, the chosen
antigen and the adjuvant component, Quillaja saponins. Studies with ISCOMS have
shown that they can upregulate both Thl and Th2 responses [554-556]. As well as
this, ISCOMS have also been shown to induce CD8+ cytotoxic T cells, when gpl60
envelope glycoprotein from HIV was incorporated and given subcutaneously in mice
[356],
Other antigen carriers include liposomes and MEA (microencapsulated
antigen) particles which will be discussed in more detail later in this thesis.
Liposomes can simply be portrayed as spherical vesicles consisting of one or more
phospholipid bilayers surrounding an aqueous cavity. As well as drug delivery and
gene therapy [357, 358], liposomes can be employed as an adjuvant to enhance the
immunogenicity of small antigens [359, 360].
1.6.1.8 Plasmid DNA Gene Therapy
Plasmid DNA vaccines usually consist of naked DNA (i.e. DNA that has
been freed of all the proteins in the usual DNA-protein complexes) coding for the
gene of interest inserted into a plasmid. Plasmids are circular DNA molecules,
usually found in bacteria and some yeasts. Although plasmids are not usually
essential for cell growth and division, they often confer traits (e.g. antibiotic
resistance) on the host organism, which can be a selective advantage under certain
conditions. A plasmid can reproduce itself in bacteria but not in other cell types
unless the appropriate transcriptional elements are present [361]. When DNA
encoding an antigen is injected intramuscularly or intradermally, host cells take up
the foreign DNA, express the gene of interest and synthesise the corresponding
protein. The protein then enters the MHC class I pathway, where subsequent peptide
fragments of the protein are carried to the cell surface and cell-mediated immunity in
the form of cytotoxic CD8+ T cells is induced, against later rechallenge with whole
protein [362],
DNA vaccines have many advantages over standard vaccines. The immunity
they induce is long lasting [363], they can induce the expression of antigens that
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resemble native epitopes more closely because the manufacture of live attenuated
vaccines and killed vaccines often alters their structure and thus lowers the
antigenicity.
Gene therapy has been investigated quite extensively over the past ten years.
One of the first reports of gene therapy was by Wolff and colleagues in 1990. They
reported that non-replicating DNA plasmids encoding the reporter genes
chloramphenicol acyltransferase, luciferase and (3-galactosidase, could be
internalised and expressed in muscle cells following i.m. injection without the need
of any transfection vehicle [364], Since then, gene therapy has been used in a number
of animal disease models, for example, HIV, HSV and Leishmania major infection
[365-367],
Gene therapy is now being investigated as an approach for the treatment of
allergic disorders. An initial study in 1996, showed that mucosal IFN-y gene transfer
(by intratracheal instillation) resulted in significant expression of IFN-y in the
pulmonary epithelium, as well as an inhibition in both Ag- and Th2-cell-induced
pulmonary eosinophilia and airway hyperreactivity [368], A second study in the
same year reported an inhibition of specific IgE to Der p 5 allergen after
intramuscular injection ofpDNA encoding Der p 5 in mice. Furthermore, this
suppression of the IgE response could be adoptively transferred with CD8+ cells to
naive and subsequently rechallenged recipients, suggesting that active suppression of
this IgE response was involved [369], At around the same time, it was found that
certain bacterial DNA motifs were able to favour Thl responses [370, 371]. This
motif- an unmethylated CpG dinucleotide flanked by two 5' purines and two 3'
pyrimidines, rapidly stimulated B cells to produce IL-6 and IL-12, CD4+T cells to
produce IL-6 and IFN-y, and NK cells to produce IFN-y both in vivo and in vitro
[370]. A study in 1998 by Broide et al, demonstrated that immunostimulatory
sequences (ISS) containing a CpG DNA motif, significantly inhibited airway
eosinophilia and reduced responsiveness to inhaled metacholine [372], A single dose
of ISS was found to inhibit eosinophilia as effectively as seven daily injections of
corticosteroids. Moreover, whilst IL-5 levels were reduced with both ISS and steroid
treatment, only the ISS could induce allergen-specific IFN-y production and redirect
the immune response toward a Thl type.
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More recently, Hertz and colleagues delivered a DNA vaccine encoding
murine IL-5 modified to contain a promiscuous foreign Th epitope to break or bypass
immunological tolerance to IL-5. In established models of experimental asthma, Th-
modified IL-5-vaccinated mice induced an immune response directed against IL-5
that reduced both pulmonary lymphocyte infiltration and eosinophilia, reduced the
levels of Th2 cytokines, and inhibited the development ofAHR [577].
CpG-DNA acts as a "pathogen-associated" molecular pattern that is
recognised by TLR-9 (Toll-like Receptor 9) [575]. Dendritic cells are major
expressors of TLR-9. Interactions between CpG-DNA and TLR-9 rapidly activate
antigen-presenting dendritic cells through the ancient Toll/IL-1 -receptor signalling
pathway to upregulate costimulatory molecules and to produce Thl-polarising
cytokines, such as IL-12 and IL-18. Thus, interactions between CpG-DNA and TLR-
9 effectively bridge innate and acquired immunity [576].
Some concerns exist however, over the safety of DNA vaccines. One major
factor is whether plasmid DNA can insert itself into the host genome; if so, then
insertional mutagenesis would be a concern. There is evidence against integration of
the DNA into the host chromosome [363], although it is difficult to prove
conclusively that integration cannot happen. The evidence to date suggests that
increased pDNA antigen expression occurs for a limited time period so, how would
this affect the immune system? It may lead to host tolerance or an attack on tissues
expressing that antigen but this has yet to be proven [168].
1.6.2 Non-Allergen-Specific Immunotherapies
It has been proven in IL-4-deficient mice that Th2 responses are probably not
critical for survival and protection [373], however, it has been shown that a Th2
environment is critical for foetal survival in pregnancy [88]. In addition, Th2
responses play an important part in the balance between developing allergic or
autoimmune responses. Therapies that target the Th2 pathway have been developed
even though they may be detrimental to health.
It has been mentioned earlier, that transcription factors such as the c-maf
oncogene are selectively transcribed; and signalling by IL-4 through STAT6 occur in
Th2 cells. This makes them likely candidates for manipulating Th2 responses.
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Shimoda and Takeda have shown that knock out of the STAT6 gene results in
deficient Th2 responses [112, 113].
The Th2 cytokines IL-4 and IL-5 can be antagonised by soluble receptors
[374], antibodies [375, 376], mutant proteins [377] and even by a specific gene
transcription inhibitor [378]. Renz et al used lymphocytes from allergen-sensitised
mice and restimulated them in vitro with the sensitising allergen in the presence of
either a soluble murine sIL-4R, a dimeric sIL-4Rig fusion protein (sIL-4R/Fc) or
anti-IL-4 antibody. Both the monomeric and dimeric sIL-4R inhibited allergen-
specific IgE and IgGl similar to that observed in the presence of the
anti-IL-4 antibody. In kinetic experiments, Renz found that newly induced IgE
production was the major target of the sIL-4Rs, demonstrating the efficacy of sIL-4R
in inhibiting the early stages of the IgE B cell maturation pathway [374].
Two humanised monoclonal antibodies specific for IL-5 have been
investigated as potential therapies for asthma. SCH55700 (reslizumab) is a
humanised monoclonal antibody with activity against IL-5 from various species
[578]. SB240563 9 (mepolizumab) is also a humanised antibody with specificity for
human and primate IL-5 [579, 580].
In a dose-dependent manner, SCH55700 inhibited total cell and eosinophil
influx into BAL fluid, bronchi, and bronchioles of allergic mice for up to 8 weeks
after a single 10 mg/kg dose and for 4 weeks after a single 2 mg/kg dose. In allergic
guinea pigs, SCH55700 caused a dose-dependent decrease in pulmonary eosinophilia
and inhibited the development of allergen-induced airway hyperresponsiveness to
substance P. it also inhibited the accumulation of total cells, eosinophils, and
neutrophils in the lungs of guinea pigs exposed to human IL-5. SCH55700 had no
effect on the numbers of inflammatory cells in unchallenged animals or in animals
challenged with GM-CSF, and had no effect on the levels of circulating total
leukocytes [578]. A rising single dose phase I clinical trial was conducted with
SCH55700 in patients with severe persistent asthma who remained symptomatic
despite intervention with high-dose inhaled or oral steroids. The two highest doses of
SCH55700 significantly decreased peripheral blood eosinophils, with inhibition
lasting up to 90 days after the 1 mg/kg dose. There was also a trend toward
improvement in lung function at the higher doses 30 days after dosing, with mean
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FEVi increasing by 11.2 and 8.6% in the 0.3 and 1.0 mg/kg groups, respectively,
versus 4.0% in the placebo group [581].
Preclinical studies with SB240563 in cynomolgus monkeys indicated that
peripheral blood eosinophils were decreased as a result administration of the
antibody [579, 580]. SB240563 has also been tested in asthmatic persons in a clinical
single dose safety and activity study [582], Patients with mild asthma were
administered with a single intravenous dose of the antibody at either 2.5 or 10 mg/kg,
or placebo. Patients were challenged with allergen 2 weeks before and 1 and 4 weeks
after dosing. Peripheral blood and sputum eosinophil levels were measured, and
early-phase and late-phase asthmatic responses were assessed by measuring the
percentage fall in FEVi induced by allergen challenge. Both doses of SB240563
caused a significant reduction in peripheral blood eosinophils. Eosinophil counts
were reduced in the 10 mg/kg dose group by approximately 65% for up to 8 weeks.
Post challenge sputum eosinophils were also reduced in the 10 mg/kg dose group.
In a rat model of allergic lung inflammation, eosinophil influx into the lung
was significantly diminished by the use ofmonoclonal antibodies against various
integrins [379], Anti-CD4 monoclonal antibody therapy has also been demonstrated
as a therapy for rheumatoid arthritis and psoriasis [380] as well as in transplantation
models [381].
IgE antibodies can also be targeted. In recent years, anti-human IgE
antibodies have been developed that bind to membrane IgE on B cells and soluble
IgE but not with basophil or mast cell bound IgE [382, 383], In another study, IgE
antibody treatment not only neutralised serum IgE but also inhibited eosinophil
recruitment in Der p 1-sensitised mice and the production of IL-4 and IL-5, by
inhibiting IgE-CD23-facilitated presentation to T cells [384], Studies using anti-IgE
antibodies in asthmatic patients have been shown to be effective in reducing serum
IgE and look promising for the future [385, 386].
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1.7 Mucosal Immunity
1.7.1 Antigen Uptake and Processing in the Gut Associated Lymphoid Tissue
(GALT)
With an area of over 300 m2, the gastrointestinal tract is the largest mucosal
surface in man. The vast majority of cells comprising the intestinal epithelium are
absorptive enterocytes that are designed to absorb nutrients, but to exclude foreign
macromolecules and microorganisms. Enterocyte apical surfaces are coated by rigid,
closely packed microvilli [387] that are coated by the filamentous brush border
glycocalyx, a thick (400-500 nm) layer ofmembrane-anchored glycoproteins [388].
The glycocalyx is an effective diffusion barrier that contains large, negatively
charged integral membrane mucin-like molecules, [388], absorbed pancreatic
enzymes and stalked intramembrane glycoprotein enzymes responsible for terminal
digestion [389]. This thick, highly glycosylated layer prevents direct contact ofmost
macromolecular aggregates, particles, viruses and bacteria with the microvillous
membrane [390]. Thus, the glycocalyx serves two complimentary roles - protection
against invading pathogens whilst providing a highly degradative microenvironment
to promote the digestion and absorption of nutrients.
The GALT can be divided into a number of layers [391, review], the first of
which consists of intraepithelial lymphocytes (IELs) which reside within the
epithelium itself, above the basement membrane. The IEL population chiefly consists
ofCD8+ T cells, with CD4+ T cells being the predominant LPL population. Beneath
this layer, in the lamina propria located between the epithelium and submucosa,
reside the lamina propria lymphocytes (LPLs). Finally, organised lymphoid tissue in
the form ofPeyer's Patches are present within the gut epithelium in the small
intestine [392],
The Peyer's Patches have a specialised epithelium known as M cells, which
deliver samples of foreign material by vesicular transport from the lumen directly to
intra-epithelial lymphoid cells and to organised mucosal lymphoid tissues. Most M
cells lack the thick glycocalyx seen in other enterocytes and therefore, in its absence,
uptake of foreign materials is improved [393]. Hydrophobic particles and cationic
macromolecules adhere much more avidly to M cells than to enterocytes. Several
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investigators have observed M cell-selective adherence and uptake of polystyrene or
latex beads [394], PLG microparticles [395] and liposomes [396, 397]. Antigen is
endocytosed by the M cell on the apical surface, transcytosed to the basolateral side
by vesicular transport and presented to the underlying follicle-associated epithelium.
Below the FAE lies an extensive network of dendritic cells and macrophages
intermingled with CD4+ T cells and B cells from the underlying follicle [398], These
subepithelial cell populations reinforce the idea that M cells serve as gateways to
immune inductive sites, where endocytosis and killing of incoming pathogens as well
as processing, presentation and perhaps storage of antigen occurs. The APCs present
the antigen along with MHC class II to T cells, which subsequently migrate via the
efferent lymphatics along with IgA-committed B cells sensitised to the antigen,
through the mesenteric lymph nodes to the thoracic duct and hence into the
circulating blood to other parts of the body (mucosal and non-mucosal), (see figure
1.3 pg 76).
The cytokine milieu in the lymphoid tissue microenvironment strongly
influences the generation of T cells which provide help to induce and differentiate
IgA+ B cells [399]. Mature (antigen responsive) B lymphocytes expressing
membrane IgM switch to surface IgA production, under the control of Th2 cytokines
including TGF-(3, IL-4, IL-5 and IL-10 [400], This switching occurs in the germinal
centres of the organised mucosa-associated lymphoid tissues (O-MALT). When IgA+
cells leave the O-MALT they migrate to distant mucosal sites to undergo terminal
differentiation from soluble IgA+ B cells to IgA-secreting plasma cells under the
regulation of IL-5 and IL-6 [401, 402], The IgA antibodies are secreted as dimers
associated with a single J chain which then diffuses across the basement membrane
and is subsequently bound by the poly-Ig receptor (plgR) on the basolateral surface
of the epithelial cell. The bound complex undergoes transcytosis in which it is
transported in a vesicle through the cell to the apical surface. Here, the plgR is
cleaved enzymatically, releasing the extracellular portion of the receptor still
attached to the Fc region of the dimeric IgA. This fragment of the receptor, called the
secretory component, is thought to help protect the dimeric IgA from proteolytic
cleavage [403]. IgA antibodies are important in preventing the attachment of bacteria
or toxins to epithelial cells or the absorption of foreign substances, and provide a first
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line ofdefence against a variety ofpathogens. In fact, 70-90% ofall Ig secreted in





As discussed earlier, immunologic tolerance provides the immune system
with self-nonself discrimination and is crucial to prevent pathogenic reactivities
against self-antigens. Most of the population have lifelong clinical and
immunological tolerance to both food antigens and their gut flora. However, a
sizeable minority of the population (5%) suffer from adverse reactions to foods, of
which 40% are thought to have a known immunological basis. Food-allergic diseases
are a feature of childhood and may represent a breakdown or failure of oral tolerance
induction or maintenance.
Oral exposure to antigens has several potential outcomes:
1) induction of systemic immunological hyporesponsiveness (tolerance),
2) systemic priming, and/or
3) the induction of local secretory IgA responses in the absence ofmeasurable
systemic immune responses.
The oral administration of antigens is a classical method of inducing antigen-specific
peripheral immune tolerance [404], The mechanisms of oral tolerance include active
suppression, clonal anergy and clonal deletion. The dose of antigen, duration, and
route of antigen administration seem to be crucial factors for determining which of
these mechanisms will be the main operator [see 557 & 558 for reviews]. Orally
administered antigens rapidly gain access to mucosal and systemic lymphoid tissues,
and regulatory cells have been demonstrated in the Peyer's patches and mesenteric
lymph nodes within 24 hours after a single feeding of antigen [405], and in the
spleen after 4-7 days. Oral tolerance to systemic challenge is well established within
5-7 days [404, 406], and recent work suggests that antigen-specific suppression after
a feed is demonstrable at 24-48 hours (Strobel and Mowat unpublished). Thereafter,
tolerance seems to be long-lasting, with suppression ofDTH being demonstrable for
up to 17 months after a single feed [407], although the accompanying suppression of
antibody responses is more short-lived and is lost after 3-6 months.
Friedman et al. were some of the first investigators to delineate the effect of
antigen dose on the induction of tolerance mediated by either anergy or active
suppression [408]. In this study, the investigators fed hen egg white lysozyme to
mice and guinea pigs, and myelin basic protein to rats using low dose or high dose
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regimens. A single feeding of high dose antigen (5-20 mg or 0.5 mg g"1 body weight
in mice) induced tolerance characterised by anergy with little or no active
suppression and increased secretion of IL-4. The most important change in anergic T
cells is their inability to produce IL-2: this prevents them from proliferating and
differentiating into effector cells when they encounter antigen, even if the antigen is
subsequently presented by professional APCs. The anergic state can be reversed if
the cells are cultured in IL-2. Anergy was confirmed by an increase in the frequency
of IL-2-secreting cells following culture in recombinant IL-2. In contrast, a low dose
(lmg or O.lmg g"1 body weight in mice) intermittent feeding schedule, induced
tolerance characterised by antigen-driven active suppression with increased secretion
of transforming growth factor p (TGF-P) and IL-4 with minimal anergy. The in vivo
relevance of bystander suppression was confirmed by the demonstration that
injection of anti-TGF-p mAb into animals reversed oral tolerance induced by low-
dose antigen [409], In addition, feeding myelin basic protein (MBP) suppressed
experimental autoimmune encephalomyelitis (EAE) induced not only by MBP but
also by proteolipid protein (PLP) [410].
TGF-P is a potent immunosuppressive and anti-inflammatory cytokine, which
plays an important role in the local function of the gut, as it serves as a switch factor
for IgA production in the mucosa [411] and may also be involved in the homing
mechanism of cells to high endothelial venules [412], TGF-p is produced by both
CD4+ and CD8+ GALT-derived T cells [413,414] and is an important mediator of
the active suppression component of oral tolerance. The importance of TGF-P in the
maintenance of immune homeostasis is demonstrated in TGF-p-deficient mice,
which have inflammation affecting multiple organ systems [415]. Chen et al. isolated
T cell clones from the mesenteric lymph nodes of SJL mice that had been orally
tolerised to myelin basic protein [413]. These clones were CD4+ and were
structurally identical to Thl encephalitogenic CD4+ clones in T cell receptor usage,
MHC restriction and epitope recognition. However, they produced TGF-P with
various amounts of IL-4 and IL-10 and suppressed EAE induced with either MBP or
proteolipid protein. Thus, there appears to be a unique CD4+ T-cell subset that
induces mucosal helper T-cell function and downregulatory properties for Thl and
other immune cells. In contrast to Thl and Th2 cells, these cells (termed Th3 or Tr -
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T regulatory cells) provide help for IgA production and primarily secrete TGF-p.
Th3/Tr cells appear distinct from Th2 cells since CD4+TGF-(3-secreting cells that
suppress a form of collitis have been generated from IL-4-deficient animals [336].
A regulatory population of T cells has also been identified in a nasal tolerance
induction model. Shi et al. studied nasal tolerance induction as a strategy to prevent
Experimental Autoimmune Myasthenia Gravis (EAMG) in Lewis rats and found that
acetylcholine receptor (AchR) administration by the nasal route was as effective as
oral administration at only 1/500 of the dose [416]. A later study using the same
model suggested that suppression was independent ofCD8+ and involved Ag-
specific CD4+ Th3 cells producing TGF-p.
It is now clear that oral tolerance can affect CD8+ as well as CD4+ T cell
functions and can be adoptively transferred by both these subsets [417, 418]. A
recent study by Grdic et al. addressed the role ofCD8+ T cells in oral tolerance and
whether evidence for compartmentalisation of control of the tolerant state could be
observed [419], They found that feeding KLH antigen to mice induced tolerance that
was highly compartmentalised, requiring CD8+ T cells for local suppression of IgA
responses, while CD4+ T cells were responsible for systemic hyporesponsiveness
with Thl and Th2 cell function equally affected. These findings confirmed those of
earlier study by Garside et al. who found that the production ofThl and Th2-
dependent cytokines were equally affected [420]. Garside also found that oral
tolerance could be induced in IL4"/_ mice suggesting that Th2 cells were not essential
in the induction of oral tolerance. However, a subsequent study by the same group
showed that high dose tolerance induction with ovalbumin was dependent on CD4+ T
cells, as depletion of this population completely abrogated the tolerance [421].
The induction of anergy in high dose oral tolerance specifically affects
antigen-specific Thl lymphocytes (characterised by diminished production of IgG2a,
IL-2 and IFN-y) with intact Th2 responses (IgGl and IL-4) [422]. The anergic state
is probably the result of aberrant presentation of antigen by APCs lacking
costimulatory molecules such as B7.1/B7.2 and intercellular adhesion molecule
(ICAM-1) [423].
There are several candidates for the tolerogenic APC. Dendritic cells are
obvious candidates due to their abundance throughout the intestinal wall, Peyer's
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Patches and draining lymphoid tissues [409, 414, 424]. Administration of the growth
factor Flt3L (ligand offms-like tyrosine kinase) to mice expands the number ofDCs
in the intestine and other lymphoid organs, and increases the susceptibility to
tolerance induction by feeding OVA [425]. B cells are unlikely to be involved in oral
tolerance as peripheral T cell tolerance can be induced in B-cell-knockout mice
[426],
The lining of the intestinal epithelium consists of enterocytes which express
low levels ofMHC class II. Epithelial cells lines have been shown to be capable of
processing and presenting protein antigen to CD4+ T cell hybridomas in vitro [427],
In support of this, recent studies have shown that orally administered ovalbumin can
be detected in murine enterocytes 5-10 minutes after a feed [428]. However, as
enterocytes do not express ICAM-1 or B7.1 [423]. It seems likely that presentation of
antigen by these cells would normally lead to anergy of naive CD4+ T cells.
In addition, studies have demonstrated that epithelial cells may present
antigen to CD8+ T cells in the context of the CD1 molecule, a nonclassical MHC that
is only distantly related to the MHC class I molecules [429]. Furthermore, the
membrane protein gpl80 expressed on epithelial cells has been reported to act as a
cofactor together with CD1 in stimulating CD8+ T cell activation [430]. Thus, the
surface expression of the CD8 molecule is critical for interactions between epithelial
cells and gut T cells, in particular for the activation of a regulatory CD8+ population.
Therefore, in addition to Peyer's Patches [424], the gut epithelium is also a prime site
for the induction of tolerance.
Clonal deletion is rarely found in peripheral tolerance to nominal antigens
and has not been described during oral tolerance induction in normal animals. Clonal
deletion can be induced in transgenic animals but unphysiologically large doses of
antigen were required to demonstrate such effects [325].
So far, therapeutic applications of oral tolerance have mainly been concerned
with the treatment of autoimmune diseases [reviewed in 557], Therefore, it has been
proposed that mucosal tolerance is superior in suppressing Thl-biased immune
responses. As already discussed, this may be due to preferential activation of
lymphocytes producing cytokines that can be attributed to Th2-like cells (eg. IL-4,
IL-5 and IL-10), which down-regulate Thl-based inflammatory processes.
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Although not as abundant as Thl studies, a few studies on Th2 tolerance
induction do exist. In 1998, Wu et al. investigated the effects of continuous low-dose
oral administration of ovalbumin [431]. TCR-transgenic mice were immunised intra-
peritoneally with OVA in alum and pertussis toxin. Seven days later the mice
received lOOpg OVA/day for fourteen days orally before receiving a second
challenge ofOVA in alum/pertussis toxin one day later. This immunisation protocol
induced Ag-specific unresponsiveness of Th2 cells without affecting the Thl
response, which resulted in suppression ofAg-specific IgE production. It was found
that oral treatment induced down-regulation of the expression ofAg-specific TcR as
well as B7.2 expression on APCs but did not cause clonal deletion of the T cells. A
recent study by Russo et al. exposed different strains ofmice to 1% ovalbumin
dissolved in drinking water for 5 consecutive days [432]. This regimen ofOVA
administration induced Ag-specific unresponsiveness in all the mouse strains tested,
characterised by reduced (almost absent) airway eosinophilic inflammation, airway
hyperreactivity and mucus production; there were also low levels ofTh2-type
cytokines in bronchoalveolar lavage fluid and decreased OVA-specific IgGl and IgE
production. Tolerance in this model was not associated with IL-10 and TGF-(3
production or with immune deviation toward the Thl pathway. However, the
tolerance was short-lived as challenge at day 14 after oral treatment increased
allergic responses.
Experimental tolerance induction is usually induced in naive lymphocytes.
However, in the disease state the immune system has already met the causing antigen
and accordingly has developed active immune responses. Hence, studies of tolerance
induction in primed animals would be more clinically relevant. A few studies do
exist that report the effect of antigen feeding after antigen immunisation with mixed
results. For example, feeding low doses of antigen after immunisation led to
worsening of experimental autoimmune encephalitis [433] and similarly, was not
effective in decreasing ongoing clinical EAE [434], In contrast, feeding antigen
seven days after immunisation produced dose-dependent suppression ofT cell
responses, although serum IgG levels were unaffected [435]. A recent study by
Chung et al. investigated the effect of single or multiple feeding regimens on the
induction ofAg-specific unresponsiveness in primed animals [436], The results of
81
this study indicated that the early phases of the immune response could be tolerised
by orally administered antigen. However, once memory was established to a
particular antigen, feeding the same antigen was not effective in inducing tolerance.
On a similar theme, Hurst et al. investigated the effects of ongoing Thl and
Th2 responses during the establishment of aerosol-induced IgE tolerance [437]. They
found that concurrent, secondary Th2 lung responses to keyhole limpet hemocyanin
or primary responses to Nippostrongylus larvae orAspergillus fumagatus extract
prevented establishment of IgE tolerance to aerosolised OVA. Intranasal rIL-4 given
before OVA aerosolisation also prevented establishment of tolerance, whereas
concurrent Thl responses to influenza virus or Mycobacterium bovis BCG had no
effect. These results suggested that normal IgE and IL-4 unresponsiveness following

































Fig. 1.4. Immunoregulation after oral antigen administration.




2.1 Purification ofDer p 1
The house dust mite allergen Der p 1 (D. pteronyssinus) was affinity purified from
spent mite medium (a kind gift from Dr. WR Thomas, Western Australian Institute
for Child Health, Perth, Australia).
2.1.1 Preparation of the anti-Der p 1 antibody-coupled column
The 4C1 mAb (Indoor Biotechnologies Ltd, UK) recognises a cross-reacting epitope
on all three Group I allergens {Der p I, DerfI and Der m 1). Briefly, 100 mg 4C1
mAb was coupled to 7 g cyanogen bromide activated Sepharose 4B (Amersham
Pharmacia Biotech, Uppsala, Sweden #17-0430-01) according to manufacturer's
instructions. The 4C1-sepharose was poured into a 20 ml column and equilibrated
with PBS (pH 7.4).
2.1.2 Preparation ofMite Extract
Typically, the mite extract was prepared by extracting 100-150 g of the spent mite
medium in 1 litre of PBS by stirring overnight at 4°C. The extract was centrifuged
for 25 minutes at 3000 rpm and the pellet discarded. The supernatant was then passed
through successive (5pm, 3pm, 0.8pm and 0.45pm) nitrocellulose filters (#7195 004,
#7193 004, #7188 004, #7404 004, Whatman International, Maidstone, UK) under
suction.
2.1.3 Extraction of Der p 1
The filtered supernatant was applied to the 4C1 column at a flow rate of
84
-20 ml/hour. The column was then washed with 400 ml PBS containing 0.5M NaCl.
The bound Der p 1 was eluted with dT^O (pH 11 with ammonium hydroxide, A-
6899). Fractions (2.2 ml) were collected into tubes containing 0.8 ml 0.2M Na2HPC>4,
pH 7 at a flow rate of 20 ml/hour. The column was re-equilibrated with 400 ml of
PBS containing 0.01% NaN3 (S-2002) to prevent bacterial growth.
The absorbance of each fraction was measured at 280 nm to assess the concentration
ofDer p 1. Fractions containing Der p 1 were pooled and dialysed extensively
against PBS (Oxoid). After dialysis the allergen was concentrated using Aquacide
(Calbiochem, La Jolla, CA, USA). Aliquots ofDer p 1 were stored at -20°C until
use.
2.1,4 Assessment of Purity
The purity was assessed by SDS-PAGE on a 13% acrylamide gel. A resolving gel
(see materials and buffers) was poured into the apparatus. Butanol (500 pi) was
layered onto the gel to ensure that the gel remained level. After the gel had set, the
butanol was washed off with dF^O and a stacking gel (see materials and buffers) was
then applied to the top of the apparatus. A plastic comb was pushed into the gel and
left to set.
Der pi (5 or 10 pg) was diluted in 10 pi PBS and 10 pi of reducing loading buffer
(see materials and buffers) added. Molecular weight (MW) markers (Gibco BRL,
Paisley, U.K.) were also prepared by diluting 2 pi ofMW markers in 10 pi PBS, and
then adding this to 10 pi loading buffer. The samples and MW markers were boiled
for 5 minutes.
The gel was placed in a gel tank filled with SDS-Tris Glycine electrophoresis buffer
(see materials and buffers). The comb was removed and samples and MW markers
added to the wells. A voltage of 100 volts was applied for 30 minutes followed by
200 volts until the dye front was close to the bottom.





Female, 6-8 week-old, C57BL/6 and Balb/b mice were either obtained in house or
from Harlan Olac Ltd. (Bicester, UK). They were housed in specific pathogen free
conditions, and given food and water ad lib.
2.2.2 Generating a Th2-type response to Der p 1
2.2.2.1 Adjuvant Protocol
Imject® Alum (Pierce, Chester, UK) - an aqueous solution of aluminium hydroxide
(45 mg/ml) and magnesium hydroxide (40 mg/ml) was used to generate a Th2-type
response. Briefly, 100 pi of alum was added dropwise to 10 pg Der p 1/100 pi saline
and then shaken for 30 minutes to enable effective adsorption of the immunogen.
Mice were immunised s.c. on day 0 and then i.p. on days 14 and 28. The dose
volume in each case was 200 pi containing 2 pg Der p 1.
2.2.2.2 Non-Adjuvant Protocol
Mice were immunised s.c. on day 0 with 10 pg Der p 1 in saline and then i.p. on days
2, 4, 6, 8, 10,12 and 14 with the same amount. On days 34, 37 and 40, mice were
given 25 pg Der p 1 in 50 pi saline by intra-tracheal instillation to induce lung
eosinophil infiltration. Mice were anaesthetised with 250-300 pi avertin (i.p.) and the
upper jaw rested over a wire. A small weight was placed on the lower jaw to open
the airways and a bevelled 25G needle was placed into the trachea where upon the
chosen solution was administered. Mice were then sacrificed on day 41.
A more detailed comparison of the two methods of immunisation for Th2 induction
is shown in the next chapter.
General comment about the protocols adopted within this thesis
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Throughout this thesis there was not always consistency in the protocols that were
adopted. Although every effort was taken to try and make the experiments
comparable, this was not always possible due to time constraints and limited supplies
ofhigh quality, low endotoxin Der p 1. The protocols adopted are described in detail
throughout the thesis with reasons given for any deviation from standardised
protocols.
2.2.3 Collection of serum
Blood was collected into eppendorfs where it was left at room temperature for 30
minutes and then at 4°C for at least an hour to allow clot formation. Blood was
removed from the clot and centrifuged for 5 minutes at 5000 rpm. Sera was then
removed from the red blood cell pellet and frozen at -70°C until use.
2.3 Measurement of Lung Eosinophilia
2.3.1 BAL Fluid
Mice were anaesthetised with 0.5 ml avertin i.p. The peritoneum was carefully
opened to avoid damage to the diaphragm and the mice killed by cutting the para¬
aortic artery. The diaphragm was carefully cut and then the thorax opened. The lungs
and trachea were carefully removed from the thoracic cavity to avoid puncture. A
3 cm length of plastic tubing was placed in the trachea and held by forceps whilst
0.5 ml of ice cold saline injected into the lungs. These were squeezed gently a few
times and the BAL fluid removed and placed on ice. The BAL was centrifuged at
1200 rpm for 5 minutes. The supernatant was removed and frozen at -20°C for later
cytokine analysis by ELISA. The cell pellet was washed with PBS and then
resuspended in 0.5 ml PBS.
2.3.2 Cytospins
The resuspended cell pellet (100 ql) was added to a poly-L-lysine (PLL)-coated glass
slide and was spun at 300 rpm for 3 minutes. The slide was air-dried o/n.
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2.3.3 Staining of Cytospins
To evaluate the levels of eosinophils in BAL samples, cytospin slides were fixed for
2 minutes in methanol. Slides were removed and placed in Diff-Quick I solution
(eosin G in phosphate buffer - pH 6.6) for 3 minutes after which they were placed in
Diff-Quick II solution (thiazine dye in phosphate buffer pH 6.6) for 2 minutes as a
counterstain. The slides were then washed in approximately 5 changes of H2O until
the water appeared clear. Slides were left to air-dry before viewing under the
microscope. Diff-Quick solutions were obtained from Dade Behring, CH-3186,
Dudingen.
2.3.4 Lung Tissue
Once the BAL fluid had been removed from the lungs they were placed in ice cold
PBS. They were blotted dry on tissue paper and weighed. The tissue was then
chopped into small pieces and made up to a 5% suspension in Hank's Balanced Salt
Solution (HBSS) (without phenol red, calcium or magnesium) containing 10 mM
HEPES (pH 7.4) and homogenised using a Polytron homogeniser. The homogenate
was centrifuged for 10 minutes at 3000 rpm. The supernatant was discarded and the
cell pellet was lysed by hypertonic shock using ice-cold buffers (0.2% NaCl for 10
seconds and then 1.6% NaCl/Dextrose). The homogenate was centrifuged again (10
minutes at 3000 rpm), the supernatant discarded and the pellet resuspended to a 5%
suspension in HBSS/HTAB (HBSS containing 0.5% HTAB, pH 7.4). This was
homogenised again and freeze thawed three times in liquid nitrogen and warm water.
Samples were stored at -20°C until assayed.
2.3.5 Eosinophil Peroxidase Assay
The homogenates were centrifuged for 5minutes at 3000 rpm. Each supernatant
(75 pi) was placed in a 96 well flat-bottomed plate and diluted to Vi and % in
HBSS/HTAB. A standard curve using eosinophils isolated from the lungs of IL-5
transgenic mice [559] was included. Substrate (150 pi) was added to each sample
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and left at room temp, in the dark for 30 minutes. Plates were read at 490 nm in a
Biorad ELISA reader.
2.4 Cell Culture
2.4.1 Cell Culture Medium
Cells were cultured with complete RPMI cell culture media, (see "Materials and
Buffers" for composition).
2.4.2 Incubation
Cells were kept in an incubator at 37°C, 95% humidity and in an atmosphere of 5%
CO2 in air.
2.4.3 Preparation of cell suspensions
2.4.3.1 Spleen
Spleens were excised from mice and collected into ice-cold HBSS (containing P/S).
Tissues were macerated between 2 frosted glass slides until a homogenous cell
suspension was obtained. The suspension was placed in 15 ml Falcon tubes and left
to settle for 5 minutes, after which the supernatant was transferred to a clean tube and
centrifuged for 7 minutes at 1400 rpm. The supernatant was discarded and the pellet
resuspended with 1 ml ice cold Tris-NH4C1 red blood cell lysis buffer and left on ice
for 5 minutes. Complete media (4 ml) was added and suspension centrifuged again
for 7 minutes at 1400 rpm. The supernatant was discarded and the pellet resuspended
in 5 ml complete media and left on ice until use. Cell suspensions were counted
using a haemocytometer chamber with trypan blue exclusion.
2.4.3.2 Lymph Nodes and Peyer's Patches
Lymph nodes and Peyer's Patches were pressed through a 70 pm sterile gauze by a
plunger of a 1 ml plastic syringe into 5 ml HBSS (containing P/S). This was
transferred to a 5 ml Falcon tube and centrifuged for 7 minutes at 1400 rpm. The
89
supernatant was discarded and the pellet was resuspended in 1 ml complete media.
Cells were counted as described above.
2.4.4 Restimulation of Cells
For cell proliferation and cytokine determination, cells were cultured in triplicate at a
density of 5 x 103 in 200 pi per well in 96-well flat-bottomed plates (for spleen) and
at 2 x 10? in 200 pi per well in 96-well round bottomed plates (for lymph nodes and
Peyer's Patches). Antigens were added to the cultures at the concentrations indicated.
As a positive control, cells were either stimulated with 1 pg/ml Concanavalin A or
anti-CD3/CD28. For anti-CD3/CD28 stimulation, 96 well flat-bottomed plates were
coated with anti-CD3 in sterile PBS (50 pl/well at 5 pg/ml) and left at 37°C for 1
hour. The plates were washed thoroughly with PBS (200 pl/well x 3). Cells were
then cultured with 2.5 pg/ml anti-CD28.
2.5 Measurement of Proliferation
Earlier experiments involve the addition of 0.5 pCi/well of [3H]-thymidine (ICN,
Basingstoke, Hampshire, UK) at 66 hours. Plates were then harvested or frozen six
hours later. Later experiments added [3H]-thymidine at 72 hours and an incubation
of 18 hours before freezing or harvesting. The figure legends make clear which
thymidine protocol was used. The cells were harvested onto fibreglass filters
(Wallac, Crownhill, Buckinghamshire, UK) using a 96 well Tomtec plate harvester
(Wallac). The filter mat was sealed into a plastic bag (Wallac) with 10 ml of
'Betaplate™ Scint' liquid scintillation fluid (Fisons, Loughborough, Leicestershire),
placed in a holding cassette and counted on a 1205 Betaplate™ scintillation counter
(Wallac) allowing 20 seconds of counting for each sample.
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2.6 ELISA (Enzyme Linked Immunosorbant Assay)
2.6.1 Cytokine Detection From Cell Culture Supernatants
Cytokine secretion was analysed by detecting soluble protein aliquots of
supernatants collected from cultures at 48 hours (for IFN-y,) and 72 hours (for IL-5,
IL-13 and IFN-y). Figure legends make clear at which time supernatants were
removed.
Briefly, anti-cytokine capture antibodies were diluted to the appropriate
concentration (see table on page 92) in ELISA binding buffer and added (50 pl/well)
to 96 well flat-bottomed plates with enhanced protein binding capacity (Corning,
NY, USA). The plates were sealed and incubated overnight at 4°C.
The plates were washed 3 times with ELISA wash buffer and blotted dry on
tissue. Blocking buffer A was added to each well (200 pi) and left at room
temperature for 1 hour.
Plates were washed as before, the samples and standards (diluted in blocking
buffer A) added (50 pl/well) and incubated overnight at 4°C.
The plates were washed again (three short washes and two longer washes)
and 50 pi of biotinylated detection antibody (diluted in blocking buffer A) at the
appropriate concentration was added to each well and then incubated for two hours at
room temperature.
Plates were washed again (three short and two long washes) before the
addition of Streptavidin-alkaline phosphatase conjugate (Amersham Life Sciences,
Amersham, UK); this was diluted 1:2000 and 50 pi was added to each well. The
plates were incubated at room temperature for 30 minutes.
Plates were washed again (three short and two long washes) and 100 pi
substrate solution was added to the wells. The plates were left to develop in the dark
and were read at different time intervals (between 20 - 60 minutes depending on how
quickly the reaction developed) on a Microplate Reader 450 (Biorad Laboratories,
Hemel Hempstead, UK).
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Pharmingen, San Diego, CA, USA
R&D Systems, Abingdon, Oxford
Later experiments used the Duoset ELISA Development System because of
increased sensitivity. The assay was developed according to the manufacturer's







2.6.3Antibody Detection From Mouse Sera
2.6.3.1 Der p 1-Specific IgGl and IgG2a
The ELISA methodology outlined above was undertaken for detection ofDer p 1 -
specific IgGl and IgG2a but plates were initially coated with Der p 1 (in place of the
capture antibody) at 5 pg/ml. Sera was added to the plates at concentrations of 1:10,
1:100 and 1:1000, in duplicate (50 pl/well). A standard curve was included using
either purified mouse IgGl (Pharmingen, 03001D) or IgG2a (Pharmingen, 03021D).
Standards were diluted in blocking buffer from 500 ng/ml to 0.5 ng/ml. Biotinylated
IgGl (MCA336B, Serotec Ltd, Oxford, UK) or biotinylated IgG2a (MCA421B,
Serotec) were used at 1 pg/ml.
2.6.3.2 Der p 1-Specific IgE
ELISA plates were coated with purified anti-mouse IgE (Pharmingen #0211 ID) at
2 pg/ml in binding buffer (50 pl/well) and were left o/n at 4°C. The plates were
washed 3 times with ELISA wash buffer and blotted dry on tissue. Blocking buffer
(3% BSA in PBS) was added to each well (200 pi) and left at room temperature for 3
hours. Plates were washed again as before, and sera was added (1:10,1:20, 1:40) in
1% BSA/PBS (50 pl/well), a positive control was included (from mice previously
immunised with Der p 1/alum and known to have high IgE levels) as well as a
commercial standard (Pharmingen #0313ID) diluted from 500 ng/ml to 1 ng/ml. The
plates were incubated overnight at 4°C. The plates were washed four times. Der p 1
was added to all wells with the exception of those containing commercial standard at
10 pg/ml (50 pl/well). Biotinylated anti-mouse IgE (Pharmingen #02112D) was
added to wells containing commercial standard at 1 pg/ml (50 pl/well). The plates
were incubated at 37°C for two hours. After four washes, biotinylated anti-Der p 1
(4C1 Indoor Biotechnologies Ltd, UK) was diluted 1:200 inl% BSA in PBS and
added (50 pl/well) to all wells except the commercial standard. PBS/1%BSA was
added to wells containing commercial standard to stop them from drying out. Plates
were incubated at 37°C for 1 hour. The plates were washed five times before the
addition of 100 pi/we11 ofAvidin-Horseradish Peroxidase (Pharmingen #554058)
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diluted 1:1500. Plates were incubated for 30 minutes at room temperature. The plates
were washed for a total of six times including two soaking steps of at least one
minute. Substrate solution (R&D systems, #DY999) (lOOpl/well) was added to the
plates. This involved mixing Substrate A (H2O2) and Substrate B
(tetramethylbenzidine) (1:1 ratio) before addition to plates which were then left in
the dark for up to 30 minutes for the reaction to proceed. The reaction was stopped
with 50 pi/well of 0.5M H2SO4. The optical density of each well was determined
using a microplate reader set to 450 nm.
2.6.3.3 Total IgE
The Der p 1-specific determination of IgE was only developed recently and so earlier
experiments measured total IgE determination.
The 'OptEIA™ Mouse IgE Set (2655K1, Pharmingen) was used to determine total
IgE. The assay was carried out according to the manufacturer's instructions but
briefly: plates were coated with 2 pg/ml of capture antibody (50 pl/well). The plates
were sealed and incubated overnight at 4°C. The plates were washed three times with
washing buffer. The plates were blocked with 200 pi of blocking buffer and left at
room temperature for 1 hour. The plates were washed as before. The standard was
added to the plates at 50 pi well from 200 ng/ml to 3.1 ng/ml. The sera samples were
diluted 1:10, 1:20 and 1:100 and added to the plates in duplicate (50 pl/well). The
plates were incubated for 2 hours at room temperature. The plates were washed five
times in total (three quick washes and two longer washes). The detection antibody
(at 1 pg/ml and 50 pl/well) was added to the plates along with the streptavidin-
horseradish peroxidase conjugate. The plates were incubated at room temperature for
a further hour. The plates were washed five times in total (three quick washes and
two longer washes). Substrate solution (Tetramethylbenzidine and hydrogen
peroxide) was added (100 pl/well). Plates were read at 450 nm after 30 minutes.
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2.7 Materials and Buffers
All chemicals were purchased from Sigma (Dorset, U.K.) unless otherwise stated.
Per p 1 Peptides
All of the Der pi peptides were manufactured by Ian Moss, Advanced Biotechnology
Centre, Charing Cross Hospital, London.









In H-2 mice, the immunodominant epitope ofDer p 1 is Der p 1 ;pl 10-131. This
sequence contains both the MHC class I (pi 11-119) and MHC class Il-binding
(pi 13-127) regions.
MEA Particles
These particles were provided by ALK (Horsholm, Denmark).
Der p 1 or Der p 1 ;pl 11-139 were encapsulated within the particles which consisted
of a polymer - poly-lactide-co-glycolide (PLG). The ratio of lactide to glycolide was




2.5 g 2,2,2-tribromomethanol (T4840-2)




1. The tribromoethanol was mixed with the alcohol on a heated stirrer until all the
crystals had dissolved.
2. Distilled H2O was added until completely dispersed.
3. The avertin was aliquoted and stored in the dark at 4°C for up to a year.
Use:
The avertin was warmed to 37°C for half an hour before use.
Complete Mouse RPMI culture media
Complete culture medium (500 ml), made from RPMI-1640 (R-0883, Gibco, Paisley,
UK) supplemented with 2 mM L-glutamine (Gibco, Paisley, U.K., 25033-010),
100 pg/ml penicillin/streptomycin (Gibco, Paisley, U.K. 15070-071), 5 x 10~5 M (3-
mercaptoethanol (M-7522) and 5% foetal calf serum (#4-101-500, Labtech
International, www.labtech-international.com). Kept at 4°C.
Coomassie Destain
10% glacial acetic acid (A-6283)
40% methanol (M-1770).
Coomassie Stain (1 L)
10% glacial acetic acid (A-6283)
40% methanol (M-1770)
1 g Coomassie brilliant blue (B-5133).
ELISA Binding Buffer
Carbonate-Bicarbonate buffer (C-3041). 1 capsule dissolved in 100 ml of dH^O
yields a 50 mM Carbonate-Bicarbonate buffer, pH 9.6.
ELISA Blocking Buffer




in Dulbecco's PBS (D-8537)
ELISA Wash Buffer
PBS (Oxoid, Ltd, Basingstoke, UK) containing 0.05% Tween 20 (P-1379).
ELISA Substrate Solution C (for non-Duoset ELISA kits)
ELISA ethanolamine buffer (Don Whitley Scientific, Shipton, U.K. E-016)
containing 1 mg/ml pNPP (N-2770). Made fresh.
PLL-Coated Glass Slides
Poly-L-lysine solution (P-8920) was dissolved 1:10 in dLLO. Slides were incubated
in the solution for five minutes at room temperature before drying o/n.
Reducing Loading Buffer
50 mM Tris-HCl (pH6.8) (T-3253)
2% SDS (L-4509)
0.1% bromophenol blue (B-5525)
5% P-mercaptoethanol (M-7522)
10% glycerol (BDH #110184K)
Red Blood Cell Lysis Buffer (Gey's Lysis Buffer)
8.29 g NH4Cl(A-5666)
1 g KHC03 (P-9144)
200 pi 0.5M EDTA
in 1 litre dH20.
Sterile filter and keep at 4°C.
Resolving SDS-PAGE Gel
1.7 ml 40% Bis-acrylamide (A-3699)
1.9 ml 1 M Trizma Base pH 8.8 (T-1503)
1.4 ml ddfLO 1 ml
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50 pU 10% SDS (L-4509)
Polymerisation of 5mls gel mixture catalysed by addition of 5 pi TEMED (T-9281)
and 50 pi 10% ammonium persulphate (A-3678).
Stacking Gel
402 pi 40% Bis-acrylamide (A-3699)
375 pi 1M Trizma Base pH 8.8 (T-1503).
2.2 ml ddH20
30 pi 10% SDS (L-4509)
Polymerisation of gel mixture was catalysed by the addition of 3 pi TEMED (T-
9281) and 30 pi 10% ammonium persulphate (A-3678).
SDS-Tris Glycine Electrophoresis Buffer
30 ml 1M Trizma Base (T-1503)
20 ml 1M Tris-HCl (T-3253)
28.8 g Glycine (G-7403)
20 ml 10% SDS (L-4509)
Made up to 2000 ml with ddH20
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Chapter 3
Induction of a Th2 response in mice
without the use of adjuvant.
3.1 Introduction
The aim of this study was to use an animal model for investigating potential
therapeutical approaches for modulating established Th2 responses. Alum is the
adjuvant of choice in therapy currently in use but we wanted to develop an alum-free
model. The reasons for this were threefold. Firstly we wished to adopt a more
physiologically relevant approach for inducing Th2 responses, secondly, we were
concerned that subtle differences in immune modulation might be difficult to detect
because alum induces such strong responses, finally, adjuvants by themselves induce
a nonspecific T cell activation as well as inflammatory responses and affect several
cellular functions [439, 440]. Hence the use of adjuvants may not be ideal for the
study of allergic disorders.
Protocols for the induction of systemic IgE responses to various allergens
with accompanying airway hyperresponsiveness have previously been devised by
other groups. These methods of sensitisation usually involve systemic immunisation
followed by local challenge of the airways using nebulised allergen. This protocol
was pioneered by Renz et al and subsequent studies have usually utilised part of this
nebulisation procedure [441], For example, painting the skin of Balb/C mice with an
ovalbumin solution followed by one period of nebulisation, induced systemic IgE,
IgGl antibody responses, immediate cutaneous hypersensitivity and increased airway
responsiveness [442], Earlier work by Holt et al, showed that priming mice with
ovalbumin intraperitoneally on a number of occasions without the use of adjuvant,
induced specific IgE responses [443],
In this study, nai've female H-2b (C57BL/6) mice were immunised using the
protocol described on page 101 which was adapted from a study by Gavett and
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colleagues [584]. Briefly, mice were immunised systemically on repeated occasions
with Der p 1 in saline and later rechallenged with Der p 1/saline intratracheally.
Results were compared with mice that were immunised with Der p 1 in alum
adjuvant using a conventional protocol (see protocol for specific details). The mice
were sacrificed 24 hours after the last intratracheal challenge (for adjuvant-free) or
48 hours after intranasal challenge (Der p 1/alum). The draining lymph nodes
(tracheal and cervical respectively), lungs and sera were removed from all animals.







Day 0 - 10 pg Der p 1 s.c. 20 pg Der p 1 i.t.
Days 2-14 - 10 pg Der p 1 i.p.
Per p 1/Alum Protocol
Day
0 14 28 35 37
2 pg Der p 1 in 4mg alum i.p.
2 pg Der p 1 in 4mg alum s.c.
20 pg Der p 1 i.n.
3.3 Results
Lymphocytes (2 x 105/well) were cultured in complete media either alone or
supplemented with 1, 5 or 20 pg/ml Der p 1. Due to insufficient cell numbers for
individual mice, lymph nodes were pooled within groups. Figure 3.1 shows
lymphocyte proliferation from the adjuvant-free and Der p 1/alum mice. There is a
dose-dependent increase in antigen-specific proliferation in the adjuvant-free mice
compared to the Der p 1/alum treated mice. At maximal proliferation the difference
between these groups is a six-fold increase.
There was no detectable IFN-y in any of the culture supernatants apart from
those restimulated with a-CD3/a-CD28 (results not shown), however, marked
amounts of IL-5 were detected in lymphocyte cultures from the adjuvant-free mice
and the levels paralleled proliferation (figure 3.2). Surprisingly, there was no
detectable IL-5 in the mice that were injected with Der p 1 in alum.
The presence of IL-13 in lymphocyte culture supernatants was also measured
as a second indicator of a Th2 phenotype. Only the adjuvant-free mice exhibited
detectable levels of this cytokine which closely paralleled IL-5 levels (figure 3.3).
Like IL-5, the Der pi in alum treated mice exhibited no detectable IL-13 which was
unexpected and cannot easily be explained.
Figure 3.4 shows the levels of IL-5 in BAL fluid taken from the mice. There
was no detectable level of either cytokine for the saline treated mice in both groups
but marked amounts were detected in the Der p 1 -treated mice with and without the
use of adjuvant. A similar trend in IL-4 production was also observed (fig. 3.5).
Extensive lung eosinophil infiltration was observed in both groups ofDer p 1
treated mice. Despite some individual variations, there was little difference overall in
eosinophilia between Der p 1/alum and the adjuvant-free mice (figure. 3.6).
Figure 3.7 shows photographs of cytospins ofBAL fluid from the adjuvant-
free mice. Eosinophils were presented as the dominant cell type (multi-lobed nuclei
with red intracellular granules; Figure 3.7a). Figure 3.7b was a control cytospin using
the BAL fluid from a mouse that had received saline alone intratracheally instead of
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Der p 1/saline. Very few eosinophils were found to be present with the population
consisting predominantly ofmacrophages (large mono-nuclear cells). No cytospins
were prepared from the alum treated mice.
The presence of different isotypes ofDer p 1-specific antibodies present in
the sera is shown in figure 3.8. The predominant isotype in both groups is IgGl.
Overall, the Der p 1/alum mice have more IgGl but there are still marked levels of
this isotype present in the sera of the adjuvant-free mice. Only small levels of IgG2a
were observed in the Der p 1/alum mice with hardly any detectable IgG2a in the
adjuvant-free mice. We were unable to detect any Der p 1-specific IgE in both the
Der p 1/alum treated mice or the adjuvant free mice.
This experiment was carried out once due to time constraints and limited
availability ofDer p 1. The results achieved for the Der p 1 mice without adjuvant
were thought to be good enough to use the same (or slight variations of the adjuvant
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Figure 3.1. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
Proliferation of draining lymph node cells.
Lymphocytes (2 x 105 per well) were restimulated in vitro with media alone or media
supplemented with 1, 5 or 20 pg/ml Der p 1. Proliferation was measured at 72 hours
after pulsing with thymidine at 66 hours. Lymph nodes were pooled within each
group ofmice: saline/alum (n = 5), Der p 1/alum (n =5), saline/adjuvant-free (n =3),
Der p 1/adjuvant-free (n = 4).
Mean +/- SE is shown.
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Adjuvant-Free Immunisation with Der p 1
IL-5 Production by TLN Cells
1 20
in vitro restimulation with Der p 1
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□ Der p 1 -treated
Figure. 3.2. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
IL-5 levels in the draining lymph node cultures.
Lymphocytes (2 x 10? per well) were restimulated in vitro with media alone or media
supplemented with 1, 5 or 20 pg/ml Der p 1. Supernatants were removed at 72 hours
for the measurement of IL-5 by ELISA. Lymph nodes were pooled within each
group ofmice: saline/alum (n = 5), Der p 1/alum (n =5), saline/adjuvant-free (n =3),
Der p 1/adjuvant-free (n = 4).
Mean +/- SE is shown.
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Figure 3.3. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
IL-13 levels in the draining lymph node cultures.
Lymphocytes (2 x 105 per well) were restimulated in vitro with media alone or media
supplemented with 1, 5 or 20 pg/ml Der p 1. Supernatants were removed at 72 hours
for the measurement of IL-13 by ELISA. Lymph nodes were pooled within each
group ofmice: saline/alum (n = 5), Der p 1/alum (n =5), saline/adjuvant-free (n =3),
Der p 1/adjuvant-free (n = 4).
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IL-5 Levels in BAL Fluid
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(Sal = saline-treated, Der= Der p 1-treated)
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Figure. 3.4. - Comparison ofDer p 1 immunisations with and without the use of
alum adjuvant.
IL-5 Levels in BAL fluid.
Mouse lungs were lavaged in situ after death with PBS. The lavage was centrifuged
to remove the cellular infiltrate (used for cytospins). The supernatant was frozen at
-70° until analysis by ELISA.
The presence of IL-13 in BAL fluid was also examined but levels were beyond the
threshold of detection.
Mean +/- SE is shown.
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Figure, 3.5. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
IL-4 Levels in BAL fluid.
Mouse lungs were lavaged in situ after death with PBS. The lavage was centrifuged
to remove the cellular infiltrate (used for cytospins). The supernatant was frozen at
-70° until analysis by ELISA.
The presence of IL-13 in BAL fluid was also examined but levels were beyond the
threshold of detection.
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Figure 3.6. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
Eosinophil infiltration into the lungs.
Eosinophils were detected by the eosinophil peroxidase assay.
Mean +/- SE is shown.
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Figure 3.7b
Figure. 3.7. - Eosinophil infiltration into the lungs of adjuvant-free mice -
cytospins.
Cytospins were prepared from the BAL fluid and stained with Diff-Quick solutions
(Eosin G (red) and Thiazine dye (blue)). Fig. 3.7a shows the cellular infiltrate from
the lungs ofmice immunised with Der p 1 intratracheally.
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Alum/Der p 1 Adjuvant-free
Figure 3.8. - Comparison of Der p 1 immunisations with and without the use of
alum adjuvant.
Der p 1-specific IgGl and IgG2a levels in sera.
Der p 1-specific IgGl and IgG2a antibodies were detected by ELISA.
Mean +/- SE is shown.
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3.4 Discussion
The aim of these experiments were to induce allergic Th2 inflammatory
responses without the use of adjuvant. Traditionally, alum (aluminium hydroxide)
has been used to enhance the immunogenicity of a protein and specifically promotes
Th2-cytokine mediated immunity that is usually indicated by the presence of IgGl
and/or IgE in the sera of animals [444-446]. In another study, it was reported that
eosinophilia was related to the dose of alum rather than the antigen adsorbed to it,
and the authors proposed that alum had a direct effect on T cells, causing them to
secrete chemotactic factors for eosinophils [447]. Alum enhances the
immunogenicity by converting the soluble protein antigen into particulate material,
which is more readily ingested by antigen-presenting cells such as macrophages. It
also creates a depot effect by slowly releasing the protein or peptide over a period of
time.
However, we were concerned that using alum to induce Th2 immunity to
Der p 1 was unphysiological and unrepresentative of natural exposure to allergen
which occurs in the absence of adjuvant. In addition, the strength of Th2 responses
induced by antigen delivered in alum might make it difficult to detect subtle changes
in phenotype mediated by potential therapeutic agents.
Adjuvant-free protocols are not a new concept. As discussed in the
introduction, Renz et al. sensitised mice to OVA by nebulisation. Whilst this
immunisation schedule was perfectly adequate, the amount of antigen required to
sensitise the mice was quite large. This was acceptable in a study utilising ovalbumin
(a fairly innocuous antigen) as the antigen of interest but our own antigen (Der pi)
was not as readily available and more importantly posed a safety hazard when
nebulised, thus, we adopted a protocol where antigen wastage and hazard to health
were minimal.
Thus, an immunisation protocol was established in house that could induce
allergen-specific Th2 responses both systemically and locally in the airways, by the
administration ofprotein in saline only. Mice that were immunised in this way
received 140 pg of Der p 1 in total, compared with 24 pg Der p 1 administered to the
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alum mice. Although seven times as much protein had to be administered, the results
were extremely encouraging.
It is difficult to directly compare local draining lymph node responses
between the two protocols, as the same lymph nodes were not examined. It was
thought that the lymph nodes closest to the site of intranasal (cervical)/intratracheal
(tracheal) immunisation should be examined. Consequently, local immune responses
from alum-treated mice were associated with the upper airways, whilst the adjuvant-
free mice were associated with the lower airways. A strong in vitro recall response
was also detected from tracheal lymphocytes but in contrast, there was minimal
response from the cervical lymphocytes of the Der p 1/alum treated mice (figure 3.1).
This may reflect differences in the amount of protein administered (60 pg:20 pg).
Also, intranasal administration of a single dose ofDer p 1 which was used in the
alum treated mice may have failed to provide sufficient antigen to recall responses in
the draining lymph nodes due to limited uptake. However, with intratracheal
instillation, which was the mode of delivery in the adjuvant-free protocol, all of the
antigen would remain within the lung and therefore, enter the immune system.
From the tracheal lymph node culture supernatants, we were able to detect the
presence of IL-5 (figure 3.2) and IL-13 (figure 3.3), which were both induced in an
antigen-dependent manner. No IFN-y was detected which suggests that the local
cytokine environment was predominantly of the Th2 phenotype. From these results
we can see that the cytokines tested from the cervical lymph node cultures, taken
from the Der p 1/alum treated mice were below the threshold for detection. This is
hardly surprising when proliferation levels were so low.
Despite receiving less protein intranasally, the Der p 1/alum mice still
exhibited high levels of eosinophilia that were certainly comparable to the adjuvant-
free mice (figure 3.6). This observation suggests that sufficient antigen enters the
lung to recruit eosinophils although is not capable of driving a recall response in the
draining lymph nodes. Cytospins prepared from the BAL fluid of the adjuvant-free
mice support the previous results, revealing visually the extent of lung eosinophilia.
Control mice that had been systemically immunised with Der p 1 in the same manner
but had received only saline intratracheally showed no eosinophilia with the
predominant cell type being macrophages (figure 3.7). Although we were unable to
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detect IL-5 or IL-13 in the cultures prepared from cervical lymph nodes, both 1L-5
and IL-4 were detected in BAL fluid taken from the Der p 1 in alum treated mice
(figures 3.4 and 3.5). It is difficult to explain why IL-5 and IL-13 could not be
detected in the Der p 1 in alum cervical lymph node cultures. The only explanation
that can be given is that the supernatants from these mice deteriorated before the
presence of these cytokines was established. If there had been more time available
and a more plentiful supply ofDer p 1, it would have been preferable to repeat the
experiment again in order to confirm and optimise the conditions.
Th2 responses were not investigated in the spleens from any mice because we
wished to focus on local responses in the airways, particularly pulmonary
eosinophilia. However, later experiments in which the adjuvant-free protocol has
been adopted, a dose dependent proliferative response of splenocytes in response to
Der p 1 is observed (counts usually in the range 15,000-20,000 CPM at 10 pg/ml Der
pi). This degree of responsiveness was comparable to that observed for the Der p
1/alum immunised mice (results not shown).
The results presented here suggest that Der p 1/alum induces the most marked
production of antigen-specific antibodies (figure 3.8). This is not unexpected due to
the depot effect of the alum on releasing the Der p 1, nevertheless moderate antibody
levels were still observed in the adjuvant-free immunised mice. The predominance of
Der p 1-specific IgGl further substantiates previous findings suggesting the presence
of a Th2 response.
In conclusion, we have shown that an allergic Th2 response with





New approaches to vaccine development include the synthesis of protein or
peptide sequences, which are homologous with epitopes capable of inducing
protective immunity against infectious organisms or innocuous allergens. This
'subunit approach' has a number of advantages over more traditional vaccines; they
are chemically well defined, and can be prepared reproducibly and inexpensively.
However, these subunit vaccines often display poor immunogenicity, resulting in the
need for repeated immunisations. One approach to overcome these problems
involves the use of controlled antigen delivery systems, which includes the
encapsulation of antigen [476].
Most microencapsulated vaccine systems consist of poly(lactide-co-
glycolide) (PLG) polymers containing the antigen [448, 449], virus [450] or peptide
[451] of interest. PLG microparticles are suitable vehicles for vaccine delivery
because they are biocompatible and biodegradable. PLG has had a history of safe use
in humans since the 1970s where the material has been used as resorbable sutures
[452]. Microparticles only induce a minimal inflammatory response after
immunisation and degrade to the normal metabolites - lactic acid and glycolic acid
by non-enzymic hydrolysis [453],
The particles have the ability to release entrapped antigen over extended
periods in a pulsatile manner depending on the ratios of lactic acid and glycolic acid.
The fastest degradation rates are observed with microparticles consisting of a 50:50
ratio. These are eliminated from the body in 50 - 60 days after subcutaneous or
intramuscular injection with a degradation half-life in the order of 14 days.
Increasing the lactic acid leads to extended retention in the circulation because it is
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more hydrophobic in nature than glycolic acid and therefore release rates can be
extended up to one year [454],
Another benefit for the use ofmicroparticles is that a single injection of
mixed ratio particles, can induce an immune response that mimics traditional
multiple dosing schedules [455], For example, a single immunisation with diphtheria
toxoid (DT) entrapped in controlled release microparticles can induce comparable
immune responses to three doses ofDT adsorbed to alum [456], In addition,
microparticles containing peptide or protein immunogens have been reported to
induce HIV neutralising antibodies for at least one year following a single
immunisation [457].
Particle size is an important parameter for determining immunogenicity. For
parenteral vaccination, the particles should be of a size that allows uptake by
macrophages and transport to the lymphatics. Only particles less than 10 pm are
taken up in this way [458].
The induction ofmucosal immune responses by oral delivery of
microparticles is highly desirable; advantages include the non-invasive protocol, cost
effectiveness and formulations for oral delivery could stabilise the vaccines making
them highly appropriate for use in third world countries. There are also important
immunological reasons for delivering vaccines by this route. Most human pathogens
gain access to their host across a mucosal surface. The gastrointestinal tract is largest
mucosal surface in man, so immune responses mounted at these surfaces would
provide a first line of defence, limiting or even preventing pathogens from attaching
to and crossing the mucosa [459].
PLG microparticles are particularly suitable for oral delivery because the
polymer is not broken down by enzymic degradation or acid hydrolysis in the gut
and thus the entrapped antigen remains protected. The first studies using PLG to
encapsulate proteins as subunit vaccines appeared in 1989 [460]. This work showed
successful elicitation of circulatory anti-toxin antibodies and also specific secretory
IgA antibodies in saliva, gut and broncho-alveolar washes, following oral
immunisation ofPLG encapsulated Staphylococcal enterotoxin B (SEB) toxoid. No
immune response was detected when non-encapsulated SEB was administered orally.
Thus microencapsulation had both a protective and immunopotentiating effect,
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probably resulting from a depot effect of antigen and also the direct delivery of
relatively high antigen concentrations into accessory and antigen-presenting cells
[461,462]
Again, uptake of particles was restricted by size, only those with a diameter
<10 pm were taken up into the Peyer's Patches. Those with diameters 5-10 pm,
were retained for extended periods whilst particles <5 pm were rapidly redistributed
to the spleen.
A priority area for future research would be to improve the uptake of
microparticles following oral administration. It is thought that only a tiny fraction
(<1%) of ingested microparticles are taken up by the gut-associated lymphoid tissue
(GALT) [463], Therefore, specific improvements in targeting vaccines to the
mucosae may result in the enhancement of an immune response.
The adsorption of antigen (tetanus toxoid) onto poly(L-lactic acid)
microparticles as opposed to encapsulation has also been shown to have an effect on
the immune response, when administered intranasally [464]. Higher antibody
responses were induced with adsorbed tetanus toxoid as opposed to free antigen.
Microparticles can also be used to induce cytotoxic T lymphocyte (CTL)
responses in a number of models. Early studies in mice show that oral or
intraperitoneal administration ofmicroparticles containing ovalbumin, induced CTL
responses in the spleen and draining lymph nodes in vitro [465, 466], Later studies
associated with disease models have also shown CTL induction. For example, the
CTL epitope of the measles virus was encapsulated and after a single i.p. injection,
CTL responses to the homologous peptide and measles virus were detected over a
period of four months. Responses peaked at 30 days after priming and were
maintained at high levels for 120 days. The responses were higher than those
observed when the CTL epitope was administered in saline or as an emulsion in
Incomplete Freund's Adjuvant [451, 467], A CTL response has also been observed
by encapsulating a synthetic malaria epitope and injecting the particles i.p. or s.c..
Mice that received two immunisations produced 6- to 8-fold higher activity and 5- to
40-fold higher antibody responses than those mice that only received one injection
[468]. This finding suggests that a memory immune response was induced with
microparticle formulations.
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Therefore, from the evidence above, it is clear that PLG microparticles are
capable of eliciting strong antibody, T cell proliferative and CTL responses.
However, the mechanisms of processing and presentation ofmicroencapsulated
antigens and their fate is still poorly understood. A recent study [469] has attempted
to investigate the capacity of human or murine macrophages and other APCs to
process and present microencapsulated antigens to MHC class I or class II-restricted
T cells in vitro. It was demonstrated that macrophages were able to present
exogenous microencapsulated antigen to both MHC class I- and class II-restricted T
cells in vitro and this was thought to occur principally by size dependent
phagocytosis. In addition, immature dendritic cells have also been shown to be
phagocytic [470], It is possible that the upregulation of dendritic cells in situ
(specifically the Langerhans cells), plays an important role in the uptake ofPLG
encapsulated antigen and subsequent migration to the draining lymph nodes, where
DCs can efficiently prime T cell responses.
In conclusion, microencapsulation of antigens might be of great importance
in developing subunit vaccines against bacterial, viral and parasital infections or
tumours where both humoral and cellular immunity are crucial.
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4.2 Visualisation ofMEA Particles
ALK, the sponsors of this study developed histological techniques for the
visualisation ofMEA particles. Figures 4.1- 4.3 represent studies undertaken in the
sponsor's laboratory in Denmark. The figures have been included in this thesis purely
to demonstrate how the MEA particles can be visualised in vitro and in vivo.
Figure 4.1 shows light microscopy ofPLG particles loaded with fluorescent
allergen in a water suspension. The allergen used in this study was an aqueous
allergen extract derived from the pollen of timothy grass, Phleum pratense. Freeze
dried extract ofPhleum pratense was conjugated with Fluorescein isothiocyanate
(FITC). PLG microparticles were then loaded with the FYTC-Phleum pratense
conjugate using the method described by Tice [471]. The microparticles were
suspended in water, spread on microscope slides, allowed to air dry and visualised at
the following magnifications: a: 40x, b: 63x and c: lOOx. The labelled allergen
appears green and is located within the PLG particles.
Figure 4.2 represents an immunohistochemical method for detecting allergen
within the particles. Lung tissue (figure 4.2b) from mice immunised intravenously
with MEA particles was treated and prepared for paraffin embedding, sectioned,
deparaffinated and immunohistochemistry performed by incubating sections with
monoclonal mouse antibodies to Phleum pratense. The particles were also visualised
in vitro by light microscopy (figure 4.2a).
Figures 4.3a to 4.3f show immunohistochemistry of Phleum pratense
microparticles in suspension (a and b), in lung tissue (c and d) and in kidney tissue (e
and f). Figures. 4.3a, c, and e represent positive controls of immunised mice,
whereas, figures. 4.3b, d, and f represent negative controls from unimmunised
animals. In the positive controls allergen was clearly visible in the centre and along
the periphery of the particles as visualised by reddish-brown dots. In the negative
microparticle suspension control (4.3b) only a very weak outline of particles was
seen. In the tissue sections the particles were spread evenly in both lung and kidney
tissues. A positive immune reaction was observed in the positive controls (c and e),
depicted by long arrows. Additionally a non-specific but distinct immunoreaction
was observed in some of the nuclei of the cells in the lung and kidney sections
(positive and negative controls), which is depicted by short arrows.
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Figure. 4.1. Visualisation ofMEA particles.
Mix of light- and fluorescence microscopy of the PLG particles loaded with
FITC labelled allergen.
The objectives used are a: 40x, b: 63x and c: lOOx. The labelled allergen appears




Figure 4.2a Visualisation of MEA particles.
Light microscopy of a particle using a 100X objective.
Immunohistochemistry has been performed on the particle suspension. A reaction
(red colour, white arrow) is clearly seen in the aggregate of allergens in the centre of
the particle. The black arrow shows the outline of the particle.
Figure 4.2b Visualisation ofMEA particles.
Lung tissue from a mouse given MEA particles intravenously (objective used
lOOx).
In the section, the allergens show a positive immune reaction (white arrow) within









Figure 4.3a Visualisation of MEA particles.
Positive immune reaction towards a Phleum pratense suspension of
microparticles.





Figure 4.3b Visualisation of MEA particles.
Negative immune reaction towards a Phleum pratense suspension of
microparticles.
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Figure 4.3c Visualisation of MEA particles.
Tissue sample from the lung of an intravenously-immunised mouse.
A clear immune reaction is present in the particles in the tissue (shown by long
arrows). Magnification 900x.
m
Figure 4.3d Visualisation of MEA particles.
Lung section from an unimmunised control mouse.
Secondary AEC staining (from the substrate 3-amino-9-ethylarbazole) of the nuclei
(short arrows) was observed in d as well as e. Magnification 900x.
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Figure 4.3e Visualisation of MEA particles.
Tissue sample from the kidney of an intravenously-immunised mouse.
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Figure 4.3f Visualisation of MEA particles.




Immunisation of unsensitised mice with MEA Der p 1
4.3 Induction of proliferative, cytokine and antibody responses after sub¬
cutaneous, intra-peritoneal and intra-venous immunisation with MEA Der p 1.
The objective of these experiments was to establish the kinetics and
determine the effect ofMEA Der p 1 when administered via different immunisation
routes, in the absence of adjuvant. Naive female H-2b (C57BL/6) mice were
immunised with 7 mg MEA Der p 1 microcapsules which contained approximately
50 pg Der p 1. The mice were immunised on day 0 either subcutaneously (s.c.)
(n=5), intraperitoneally (i.p.) (n=5) or intravenously (i.v.) (n=5). The spleens,
draining lymph nodes and sera were removed either 9, 21 or 42 days later. These
time points were chosen because antigen specific memory responses would be
present in the spleen by day 9 and the aim of this study was to investigate whether or
not a significant response would still be detectable 21 and 42 days after
immunisation. Splenocytes were cultured in complete media either alone or in the
presence of 0.2, 2 or 20 pg/ml Der p 1. Unless otherwise stated, the following graphs
represent mean values from pooled data obtained from individual mice.
Figure 4.4 shows splenocyte proliferation at days 9, 21 and 42. Each graph
represents the dose-responsive proliferation to Der p 1 in the three groups ofmice
following different routes of immunisation (s.c., i.p. and i.v.). Immunisation with
MEA Der p 1 by each of the chosen routes induces marked priming, however, there
is little difference between each group ofmice at the three time points.
For the draining lymph nodes (para-aortic for i.p., inguinal for s.c. and both
para-aortic and inguinal for i.v.) there were insufficient cells from the i.p. and the i.v.
groups ofmice to set up proliferation assays so only data from the s.c. group is
shown (figure 4.5). The lymphocytes were cultured in complete media alone or in the
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presence of 0.2, 2 and 20 pg/ml of the immunodominant peptide of Der p 1, residues
111-139. The highest level of proliferation was observed at day 9. By day 21, levels
had decreased and by day 42 there was no antigen-specific proliferation. IFN-y and
IL-5 were not detected in any of the lymphocyte culture supernatants. The threshold
of sensitivity of the ELISAs (IFN-y and IL-5) was in the region of
0.2 ng/ml.
In contrast, IFN-y could be detected in some of the splenocyte culture
supernatants. The highest levels of IFN-y were observed in the day 9 splenocyte
cultures (figure 4.6). Differences in the route of immunisation were evident, with the
1.p. route exhibiting the highest levels of IFN-y in response to restimulation with 2
and 20 pg/ml Der p 1. Levels of IFN-y were diminished by day 21 and were virtually
non-existent by day 42. There was no detectable IL-5 in any of the splenocyte
cultures (results not shown).
Figure 4.7 shows the levels ofDer p 1-specific IgGl, IgG2a and total IgE
from the sera of the mice at the three time points. The sera was titrated at three
concentrations (1:10, 1:100 and 1:1000) with results shown for the 1:100 dilution. As
expected, Der p 1-specific IgGl was barely detectable in any of the mice at day 9.
However, levels had markedly increased by day 21 and were higher still at day 42.
There was little to differentiate between the groups ofmice at day 21 and it was hard
to compare the different routes at day 42 because the i.v. sera was only diluted 1 in
10 as opposed to 1 in 100. This was due to experimental error. There was insufficient
sera to retest at limiting dilutions.
Levels ofDer p 1 -specific IgG2a and total IgE were observed but these were
below 5 ng/ml and were far reduced compared to IgGl.
At this time, we had not developed an ELISA for Der p 1 -specific IgE so only
total IgE was measured. There is barely any difference in total IgE levels when
comparing days 9 and 21, with only a slight increase at day 42 (figure 4.7). Overall,
total IgE levels were not elevated to the same extent as Der p 1 -specific IgGl but IgE
levels are always lower than IgG.
IL-2 (supernatants removed at 24 hours from splenocyte cultures) and IL-4
(supernatants removed at 48 hours from splenocyte cultures) levels were also
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measured using IL-2 and IL-4 dependent cell lines (HT-2 and CT.4S respectively).
Neither cytokine was detectable in any of the culture supernatants.
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Figure 4.4. Immunisation with MEA Der p 1 via different routes.
Days 9, 21 and 42 - Proliferation of splenocytes.
C57BL/6 mice were immunised with 7 mg MEA Der p 1 either s.c. (n=5), i.p. (n=5)
or i.v. (n=4). The spleens were removed either 9, 21 or 42 days later and cultured
with media alone or in the presence of 0.2, 2 or 20 pg/ml Der p 1. Proliferation was
measured at 72 hours after pulsing with thymidine at 66 hours.
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Figure 4.5. Immunisation with MEA Der p 1 via different routes.
Proliferation of lymphocytes from the inguinal lymph nodes of the sub-
cutaneously immunised mice.
C57BL/6 mice were immunised with 7mg MEA Der p 1 either s.c. (n=5), i.p. (n=5)
or i.v. (n=4). The draining lymph nodes were removed either 9, 21 or 42 days later
and cultured with media alone or in the presence of 0.2, 2 or 20pg/ml p(l 11-139).
Proliferation was measured at 72 hours after pulsing with thymidine at 66 hours.
There were insufficient cells to set up cultures for the i.p. and i.v. mice.
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Figure. 4.6. Immunisation with MEA Der p 1 via different routes.
Days 9, 21 and 42 - IFN-y production by splenocytes.
Splenocytes (4 x 105/well) were cultured in media alone or in the presence of 0.2, 2
or 20 pg/ml Der p 1. Supernatants were removed at 48 hours and frozen at -20°C
until analysis by ELISA.


















































Figure 4.7. Immunisation with MEA Der p 1 via different routes.
Derpi- specific IgGi, IgG2a and total IgE levels in sera of mice
sacrificed at 9, 21 and 42 days.
The presence of antibodies was detected by ELISA.
The sera was diluted 1:100.
* Sera diluted 1:10.
Mean +/- SE is shown.
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4.4 Sub-cutaneous immunisation with varying amounts ofDer p 1
After establishing the basic kinetics to induce maximum T cell and B cell
responses with subcutaneous, intraperitoneal and intravenous immunisation, it was
decided to investigate the subcutaneous and intraperitoneal (discussed later) routes of
immunisation in more depth because these routes had exhibited stronger immune
responses than the intravenous route. In these experiments, the effect of dosage on
the immune response was measured. Firstly, subcutaneous delivery was analysed. In
these experiments, the amount ofmicroencapsulated (MEA) Der p 1 was varied and
placebo microparticles (containing no Der pi) were included in the study along with
a positive control - Der p 1 in Complete Freunds' Adjuvant (CFA).
Naive female C57BL/6 mice were immunised with either 7 mg, 14 mg or 30
mg ofMEA Der p 1 microcapsules (containing 50 pg, 100 pg or 150 pg Der p 1
respectively) or 7 mg placebo microcapsules (n=5 for each group ofmice) or 50 pg
Der p 1 in CFA. The mice were immunised s.c. on day 0 and sacrificed 11 days later,
when spleens, inguinal lymph nodes and sera were removed for analysis. Unless
otherwise stated, the following graphs represent mean values from pooled data
obtained from individual mice (n=5). The experiment was repeated twice with the
strongest results being shown.
Figure 4.8 shows splenocyte proliferation. Mice immunised with MEA
Der p 1 all exhibited dose-responsive proliferation but there was no marked
difference between the groups. The levels ofproliferation were actually slightly
elevated to that induced with Der p lin CFA.
Figure 4.8 also shows lymphocyte proliferation from the inguinal lymph node
cultures. A small background response was observed in mice immunised with
placebo particles, suggesting that the PLG polymer of the microparticles induced a
small amount of non-specific proliferation. The 7 mg and 30 mg MEA Der p 1
groups showed maximal proliferation at the 2 pg dose ofDer p 1 ;pl 11-139, which
decreased at 20 pg/ml Der p l;pl 11-139. PI 11-139 has been shown to be an
immunodominant epitope ofDer p 1 in mice on a H-2b background [560]. Again
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proliferation levels for the MEA Der p 1 groups were higher than the Der p 1/CFA
group.
IFN-y levels in the supernatants obtained from placebo splenocyte cultures
were barely detectable (figure 4.9). IFN-y production was evident in all the MEA Der
p 1 mice. Maximal IFN-y levels were observed in the 14 mg group; and at a
restimulation concentration of 20 pg/ml. this was more than two-fold greater than
that produced by the splenocytes from the 7 mg MEA Der p 1 group. IFN-y
production declines by approximately 30% in the 30 mg MEA Der p 1 mice. The
7 mg group was comparable to that induced with Der p 1/CFA. No IFN-y was
detected in any of the lymph node cultures.
There was no detectable IL-5 in any of the splenocyte or lymph node cell
cultures.
The highest levels ofDer p 1-specific IgGl were found in the Der p 1/CFA
group which is somewhat surprising as the administration of CFA is usually
associated with Thl responses and thus production of IgG2a, however, there were
marked levels ofDer p 1-specific IgGl in the three groups ofmice immunised with
MEA Der p 1 (figure 4.10). The highest levels were observed in the 30 mg group.
Placebo-immunised mice had Der p 1-specific IgGl levels barely above background.
All groups exhibited small levels ofDer p 1-specific IgG2a (figure 4.10),
with the 14 mg group exhibiting slightly higher levels than the rest.
Der p 1 -specific IgE was determined for all mice with the exception of the
Der p 1/CFA group. Production of IgE was dose responsive with respect to MEA
dosage. Although a clear trend can be observed, this was not statistically significant.
In summary, maximum proliferation was observed in the 7 mg MEA Der p 1
immunised mice. Maximum cytokine production was observed in the 14 mg MEA
Der p 1 mice with maximum antibody responses being observed in the 30 mg MEA
Der p 1 mice. The reductions in proliferation and cytokine production in the 30 mg
MEA Der p 1 mice compared to the 7 mg MEA Der p 1 mice suggest that high doses
ofMEA may be detrimental. However, as the placebo particles were only tested at a
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Figure 4.8. Subcutaneous with varying amounts ofMEA Der p 1.
Proliferation of splenocytes and lymphocytes.
C57BL/6 mice were immunised with either 7 mg placebo, 7 mg, 14 mg or 30 mg of
MEA Der p 1. The spleens and inguinal lymph nodes were removed 11 days later.
Single cell suspensions (4 x 105/well splenocytes, 2 x 105/well inguinal LN cells)
were cultured with media alone or in the presence of 0.2, 2 or 20 pg/ml Der p 1 (for
splenocytes) or Der p 1 ;pl 11-139 (for inguinal LN cells).
Mean +/- SE is shown.
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Figure 4.9. Subcutaneous immunisation with varying amounts of MEA Der p 1.
IFN-y and IL-5 levels in splenocyte supernatants.
Splenocytes (4 x 10 /well) were cultured in media alone or in the presence of 0.2, 2
or 20 pg/ml Der p 1. Supernatants were removed at 48 hours and frozen at -20°C
until analysis by ELISA.
Mean +/- SE is shown.
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Figure 4.10. Sub-cutaneous immunisation with varying amounts of
MEA Der p 1.
Der p 1-specific IgGl, IgG2a and IgE levels in sera.
Antibody levels were detected by ELISA.
Sera was diluted 1:10 for IgGl and IgG2a. Sera was diluted 1:20 for IgE. There was
insufficient sera to test IgE levels in Der p 1/CFA mice.
Mean +/- SE is shown for upper chart.
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4.5 Intra-peritoneal immunisation with varying amounts of Der p 1
The aim of these experiments was to determine the optimal dosage ofMEA
Der p 1 given intraperitoneally to mice. A placebo group was not included in this
study due to a limited supply ofmice and materials. In addition, it was felt that the
effects of placebo microparticles had already been determined in previous
experiments.
Naive female C57BL/6 mice were immunised with either 3.5 mg, 7 mg,
14 mg or 30 mg ofMEA Der p 1 microcapsules (containing approximately 25 pg,
50 pg, 100 pg or 150 pg Der p 1). The mice were immunised i.p. on day 0 and
sacrificed 21 days later, when spleens, para-aortic lymph nodes (PALN) and sera
were removed for analysis.
Figure 4.11 shows the levels of splenocyte and lymphocyte proliferation in
response to restimulation with Der p 1 and Der pi ;pl 11-139 respectively. Control
polyclonal stimuli of a-CD3 and a-CD28 were also set up but results have not been
shown. All groups ofmice show dose-dependent proliferation but there is little to
distinguish between the groups. Proliferation of the para-aortic lymph nodes barely
rises above background levels.
IFN-y was detectable in all of the splenocyte culture supernatants and was
dose-dependent with regards to MEA Der p 1 dosage; however, no IL-5 was detected
in these culture supernatants (figure 4.12). The level of IFN-y produced was
approximately 20 % of that produced by the subcutaneous route of administration.
However, this may be explained by kinetics. Intraperitoneally immunised mice were
sacrificed at day 21, whereas, subcutaneously immunised mice were sacrificed at day
11.
The lymph node culture supernatants produced no detectable IFN-y or IL-5
which can probably be attributed to cell numbers (2 x 105/well).
Der p 1 -specific IgGl was only detectable in the 30 mg MEA Der p 1 group
(figure 4.13). This was comparable to the levels observed for the 30 mg MEA Der p
1 s.c.- immunised mice (figure 4.10). There was no detectable Der p 1-specific IgG2a
in any of the groups. Der p 1-specific IgE was detected in all three groups but there
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was no significant difference between experimental groups. Levels of IgE observed
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Figure 4.11. Intra-peritoneal immunisation with varying amounts of
MEA Der p 1.
Proliferation of splenocytes and para-aortic lymph node cells.
C57BL/6 mice were immunised with either 3.5 mg, 7 mg, 14 mg or 30 mg ofMEA
Der p 1. The spleens and para-aortic lymph nodes were removed 21 days later.
Single cell suspensions (4 x 105/well splenocytes, 2 x 105/well para-aortic lymph
node cells) were cultured with media alone or in the presence of 0.2, 2 or 20 pg/ml
Der p 1 (for splenocytes) or Der p l;pl 11-139 (for PALN cells).
Mean +/- SE is shown.
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Figure 4.12. Intra-peritoneal immunisation with varying amounts of
MEA Der p 1.
IFN-y and IL-5 levels production by splenocyte supernatants.
Splenocytes (4 x 105/well) were cultured in media alone or in the presence of 0.2, 2
or 20 pg/ml Der p 1. Supernatants were removed at 48 hours and frozen at -20°C
until analysis by ELISA.
Mean +/- SE is shown.
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Figure 4.13. Intra-peritoneal immunisation with varying amounts of
MEA Der p 1.
Der p 1-specific IgGl, IgG2a and IgE levels in sera.
Antibody levels were detected by ELISA.
Sera was diluted 1:10 for IgGl and IgG2a. Sera was diluted 1:20 for IgE.
Mean +/- SE is shown.
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4.6 Oral Administration ofMEA Der p 1
A number of studies have shown that the oral administration ofmicroparticles
containing antigen induces systemic responses [466, 472], We decided to investigate
whether the oral administration ofMEA Der p 1 could also prime antigen-specific
responses. Previous studies using three consecutive oral doses ofMEA Der p 1 (126
mg MEA Der p 1 containing 900 pg Der p 1 in total) hardly induced an immune
response (results not shown), combined with a study by Lavelle, suggesting that only
a tiny fraction (<1%) of ingested microparticles were actually taken up by the gut-
associated lymphoid tissue [463], a multiple-dosing schedule was adopted, in an
attempt to ensure that sufficient protein was administered.
Five C57BL/6 female mice were fed by oral gavage with 30 mg ofMEA
Der p 1 in 200pl 0.87% NaCl. Before the gavage, the mice were lightly anaesthetised
with halothane gas. The mice were gavaged on five consecutive days and then rested
for two days. This procedure was repeated twice more so that the mice received a
total of 450 mg MEA Der p 1, which contained approximately 3.2 mg
Der p 1. Another five mice received the same amount of placebo particles. Although
this seems a very large dose of antigen to administer, previous studies using
ovalbumin as the model antigen use a similar amount (3 mg) in their immunisation
protocols [465, 472].
Unfortunately, a control group ofDer p 1 in saline was not included in this
study because of difficulties in obtaining sufficient quantities of antigen. All mice
were sacrificed eleven days after the final immunisation when the spleen, mesenteric
lymph nodes, Peyer's patches and sera were removed.
Figure 4.14 shows splenocyte, lymph node and Peyer's patch proliferation
respectively from both the MEA Der p 1 and placebo mice. There was a small
amount of splenocyte proliferation in bothMEA Der p 1 and placebo treated mice at
a restimulation concentration of 20 pg/ml Der p 1. This suggests that there may have
been traces of endotoxin present in the purified Der p 1. Splenocytes and mesenteric
lymph node cells from both groups ofmice proliferated well in response to
concanavalin A (used as a positive control), proving that MEA Der pi was not toxic
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to these cells (figure 4.15). However, there was a marked decrease in proliferation of
the Peyer's patch cell cultures from the MEA Der p 1 mice compared with placebo,
suggesting that there the Peyer's patch cells were more sensitive to any potential
toxic effects ofMEA Der p 1.
IFN-y and IL-5 levels were not detected in either the spleen, mesenteric
lymph node or Peyer's patch cell cultures.
Figure 4.16 shows the Der p 1-specific IgGl and IgG2a levels in sera. A very
small amount (<0.5 ng/ml) of IgGl was detected in both groups ofmice but this is on
the threshold of the ELISA's sensitivity. No Der p 1-specific IgG2a was detected in
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Figure 4.14. Oral administration with placebo or MEA Der p 1.
Proliferation of splenocytes, MLN cells and Peyer's patch cells.
C57BL/6 mice were given placebo or MEA Der p 1 by oral gavage. The spleens,
mesenteric lymph nodes and Peyer's patches were removed 11 days after the final
administration. Single cell suspensions (4 x 105/well splenocytes, 2 x 105/well
lymphocytes and Peyer's patch cells) were cultured with media alone or in the
presence of 0.2, 2 or 20 pg/ml Der p 1 (splenocytes) or Der p 1; 111-139
(lymphocytes and Peyer's patch cells). Proliferation was measured at 72 hours after
pulsing with thymidine at 66 hours.
Mean +/- SE is shown.
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Figure 4.15. Oral administration with placebo or MEA Der p 1.
Proliferation of splenocytes, MLN and Peyer's patch cells in response to
concanavalin A.
C57BL/6 mice were given placebo or MEA Der p 1 by oral gavage. The spleens,
mesenteric lymph nodes and Peyer's patches were removed 11 days after the final
administration. Single cell suspensions (4 x 105/well splenocytes, 2 x 1 05/well MLN
and Peyer's patch cells) were cultured with 1 pg/ml concanavalin A. Proliferation
was measured at 72 hours after pulsing with thymidine at 66 hours.
Mean +/- SE is shown.
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Figure 4.16. Oral administration with placebo or MEA Der p 1.
Der p 1-specific IgGl and IgG2a levels in sera.
Antibody levels were detected by EEISA.
Sera was diluted 1:10.
Mean +/- SE is shown.
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4.7 Assessment of Tolerance Induction by Oral Feeding in the Mouse
The objective of this study was to assess whether oral administration ofMEA
Der p 1 induced tolerance. The findings of the previous experiment discussed in this
chapter suggested that the lack of an immune response could be attributed to
tolerance induction but from the immunisation protocol used it was impossible to
determine this. Two groups ofmice were included in this study, one group was fed
with 42 mg MEA Der p 1 comprising 300 pg Der pi, on three consecutive days with
a control group receiving the same amount of placebo microparticles. Thirty three
days after the last oral administration, all mice received 50 pg Der p 1 in CFA. After
a further ten days the mice were sacrificed and spleen, inguinal lymph nodes and sera
were removed. This protocol is different to the one adopted in the previous
experiment because the amount ofMEA Der p 1 available was a limiting factor.
However, preliminary experiments had shown that a weak immune response could
be induced with three oral immunisations of 42 mg ofMEA Der p 1 (results not
shown). Therefore, due to material constraints, it was decided to apply this
knowledge to determine whether oral administration ofMEA Der p 1 resulted in
tolerance induction.
Figure 4.17 shows the splenocyte and inguinal lymph node proliferation
levels in response to Der p 1 and Der p l;pl 11-139 respectively. Both groups ofmice
exhibited equal levels of splenocyte proliferation at the highest dose ofDer p 1
(20 pg/ml). The proliferation of inguinal lymph node cells peaked at 2 pg/ml Der p
l;pl 11-139 and was three times higher in the MEA Der p 1 mice (although SE
values are large).
IFN-y was detected in the splenocyte culture supernatants from the MEA
Der p 1 mice only (figure 4.18). The highest level observed was with the 20 pg/ml of
Der p 1. It was a little strange that no detectable IFN-y was observed in splenocyte
cultures from the placebo mice after having received an immunisation ofDer pi in
CFA. This may be attributed to the sensitivity of the ELISA which had a sensitivity
threshold in the region of < 500 pg/ml. IL-5 was not detected in any of the culture
supernatants.
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Der p 1-specific IgGl and IgG2a were not detected in any of the mice but
total IgE and small amounts of antigen-specific IgE were detected (figure 4.19).
However, there were no significant differences between the two groups ofmice.
Levels ofDer p 1-specific IgE were just above the sensitivity of the ELISA (20 U)
but the fact that the placebo particles induce Der p 1 -specific IgE suggests that the
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Figure 4.17. Assessment of tolerance induction after oral administration with
MEA Der p 1.
Proliferation of splenocytes and inguinal lymph node cells.
C57BL/6 mice were given placebo or MEA Der p 1 by oral gavage on 3 consecutive
days. 33 days after the last oral administration, the mice received a 50 pg dose of
Der p 1 in CFA. The spleens and inguinal lymph nodes were removed 10 days after
Der p 1/CFA administration. Single cell suspensions (4 x lOVwell splenocytes and 2
x 10 /well inguinal lymph node cells) were cultured with media alone or in the
presence of 0.2, 2 or 20 pg/ml Der p 1. Proliferation was measured at 72 hours after
pulsing with thymidine at 66 hours.
Mean +/- SE is shown.
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Figure 4.18. Assessment of tolerance induction after oral administration with
MEA Der p 1.
IFN-y and IL-5 production by splenocytes.
Splenocytes (4 x 105/well) were cultured in media alone or in the presence of 0.2, 2
or 20 (tg/ml Der p 1. Supernatants were removed at 48 hours and frozen at -20°C
until analysis by ELISA.
Mean +/- SE is shown.
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Figure 4.19. Assessment of tolerance induction after oral administration with
MEA Der p 1.
Derpi- specific IgGl, IgG2a, IgE and total IgE levels in sera ofmice.
The presence of antibodies was detected by ELISA.
The sera was diluted 1:1000 for upper chart and 1:20 for lower chart.
Mean +/- SE is shown.
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4.8 Investigating whether the intranasal instillation of MEA Der p l;plll-
139 before sensitisation protect against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen
The intranasal route is an attractive route for the mucosal delivery of
vaccines. The nasal epithelium is accessible, is less exclusive to high molecular
molecules than in other mucosa, and its mucus covering contains considerably lower
levels of proteolytic enzymes compared with the gut. Furthermore it is now proven
that nasal associated lymphoid tissues (NALT) have a lymphoepithelium, which
contain M-cells for selective antigen uptake [473]. Intranasal administration of
encapsulated Yersinia pestis subunits protected mice from an aerosol challenge with
a virulent strain of pneumonic plague [474], The predominance of IgGl in sera
suggested that the response was Th2-skewed. An early study by Yan et al
demonstrated high systemic and long-persisting IgG2a and local mucosal (slgA)
immunity against aerosol challenge with ricin toxoid vaccine encapsulated in
polymeric microspheres after intranasal administration [475].
In this study, intranasal immunisation with microencapsulated Der p 1
peptide, p(l 11-139) was performed with the aim of protecting mice from subsequent
allergic challenge with Der p 1 via the airways. There were four groups ofmice in
the study: saline alone (n =5), peptide p(l 11-139) alone (n = 5), microencapsulated
peptide (MEA Der p 1 ;pl 11-139) (n = 7) and placebo microparticles (n = 4). The
protocol is shown in detail on the page 157 but briefly, mice were given the
appropriate intranasal treatment for five consecutive days. Mice were lightly
anaesthetised with halothane gas and a micro-pipette was used to instil 30 pi liquid
into the nostrils. At days 16 and 28 the mice received an i.p. immunisation of 10 pg
Der p 1 in alum. At days 13 and 16 after the last i.p. immunisation, the airways of the
mice were challenged with 50 pg Der p 1 by intratracheal immunisation. The mice
were sacrificed 24 hours after the last i.t. challenge. Lung lavage was immediately
performed in situ after death in order to obtain BAL fluid for cytospins and cytokine
determination. Whole lungs were removed to determine the extent of eosinophil
infiltration, and sera was taken to determine the presence ofDer p 1-specific IgGl,
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IgG2a and IgE antibodies. Tracheal lymph nodes were removed and pooled within
groups along with individual spleens. Single cell suspensions were prepared from
each mouse for in vitro restimulation with media alone or media containing 20 pg/ml
Der p 1, Der p l;pl 11-139, Der p l;pl 11-119 (CD8+ T cell epitope), Der p l;pl 13-
127 (CD4+ epitope), OVA peptide (an unrelated antigen) and a-CD3/CD28
antibodies (as a positive control, 5 pg/ml:2.5 pg/ml respectively).
Cytokine production by allergen reactive T cells isolated from mice treated
prophylacticaly by intranasal peptide administration.
Figure 4.20 shows IL-5 production by splenocytes after in vitro restimulation
with Der p 1, Der p l;pl 11-139 and Der p l;pl 13-127. The other in vitro stimuli are
not included in this figure (and in figs. 4.21-4.23) as cytokine production by these
splenocytes was not higher than background levels. IL-5 was produced by
splenocytes restimulated with a-CD3/CD28 antibodies (data are not shown). Mice
treated with MEA peptide showed a 69% reduction in IL-5 levels as compared with
the saline control group and a 62% reduction as compared to mice receiving peptide
alone after restimulation in vitro with Der p 1. When splenocytes were restimulated
in vitro with Der p 1 ;pl 11-139 and Der p l;pl 13-127, mice receiving MEA peptide
showed a reduction in IL-5 of 51% and 75% respectively compared to saline
controls. The threshold of sensitivity for the IL-5 ELISA was around 50pg/ml.
Figure 4.21 shows IL-13 production by splenocytes after in vitro
restimulation with Der p 1, Der p l;p(l 11-139) and Der p l;p(l 13-127). With the
exception of the placebo group, most mice fall within a tight range. IL-13 production
by MEA peptide mice was comparable to the saline controls. The threshold of
sensitivity for the IL-13 ELISA was around 20 pg/ml.
Results observed for the placebo mice in figures 4.20 (IL-5) and 4.21 (IL-13)
are quite intriguing. The level of IL-5 and IL-13 production suggested that a Th2
response was being induced. However, the experiment was only undertaken once and
only four mice were tested. Also, the largest inter-group variation was observed in
the placebo mice, therefore, it would be preferable to repeat the experiment before
any firm conclusions can be drawn on the effect of placebo microparticles on Th2
induction.
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Figure 4.22 shows IFN-y production by splenocytes after in vitro
restimulation with Der p 1, Der p 1 ;pl 11-139 and Der p 1 ;pl 13-127. Mice treated
with MEA peptide showed an 82% reduction in IFN-y compared with the saline
control group, and a 75% reduction in IFN-y was observed compared to the peptide
treated group. The threshold of sensitivity for the IFN-y ELISA was around
20 pg/ml.
Figure 4.23 shows IL-10 production by splenocytes after in vitro
restimulation with Der p 1, Der p l;p(l 11-139) and Der p l;p(l 13-127). Production
of IL-10 followed a similar trend to IL-5 and IL-13 production. Placebo mice showed
the highest levels of IL-10, whereas MEA peptide mice showed the least but this was
only marginally less than the saline controls. The threshold of sensitivity for the
IL-10 ELISA was around 20 pg/ml.
IL-5 and IL-13 production by TLN cells is shown in figure 4.24. The highest
levels of each cytokine are produced by the placebo-immunised mice. MEA peptide-
immunised mice show a marked reduction in the production of these cytokines
compared to the peptide-immunised mice (66% - IL-5, 55% - IL-13), however levels
are still higher than the saline-immunised mice.
TLN cells from the saline- and peptide-immunised mice produce the highest
amounts of IFN-y (figure 4.25). This suggests that the decreased production of IL-5
observed in the MEA peptide-immunised mice compared with peptide alone, is not
due to a Th2/Th0 —*■ Thl/ThO shift. IFN-y production by splenocytes shows a similar
pattern and thus supports this fact. There was an increase in levels of IL-10 produced
by antigen specific T cells obtained from the draining lymph nodes ofmice treated
intranasally with MEA Der p 1 ;pl 11 -139 or Der p 1 ;pl 11 -139 peptide alone, as
compared with cells obtained from saline controls. Comparisons of the ratio of IL-5
to IL-10, revealed a significant increase in the ratio of IL-10 (3.3:1 for MEA peptide
mice compared to 7.7:1 for saline mice).
Again, there is evidence of a considerable placebo effect. As mentioned
earlier, the experiment was only undertaken once and only four mice were contained
within the placebo group. The lymph nodes were pooled before culturing with
Der p 1, so the observed effect may be due to one or two of the mice producing large
amounts of IL-10 thus impacting on the group as a whole.
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Effect ofintra-nasal peptide administration on eosinophil levels in Der p 1 allergen
challenged airways.
Figure 4.26 shows the extent of eosinophil infiltration into the lungs ofmice.
Immediately, it is apparent that the number of eosinophils present in individual mice
vary widely within each group. The eosinophil peroxidase assay is quite a crude
method to measure the extent of eosinophilia and large inter-group variation can
often be attributed to: lavage technique, weight of lungs (varies due to dryness of
lungs) and loss of material to the homogenisation process. One mouse from the
saline group was not included as removal of lavage fluid had been unsuccessful. We
have found previously that this can lead to large differences when compared to
successfully lavaged mice. Despite large variations within groups, a clear trend can
be observed in that MEA peptide-immunised mice have a significant reduction in
eosinophilia (54% compared to saline controls (P <0.01) and 57% compared to
peptide). This correlates well with TLN IL-5 and IL-13 production.
The presence of IL-5 and IL-4 was also determined from BAL fluid (figure
4.27). There was little difference between the groups for IL-4 production but IL-5
production by MEA peptide mice was reduced by 62% compared to saline controls,
which supports the trend observed in eosinophilia levels.
The reduction in eosinophilia coupled with the trend in cytokine production
was therefore due to a loss of antigen specific T cell responsiveness and eosinophil
recruitment, rather than a Thl shift in cytokine production. The loss ofT cell
responsiveness to intact Der p 1, following mucosal tolerance induction with an
immunodominant T cell epitope (Der p 1 ;pl 11-139) , may be due to linked
suppression resulting in a loss of responsiveness to minor T cell epitopes within
Der p 1. Peptide alone failed to tolerise Der p 1 reactive T cells, suggesting that
MEA particles enhanced the tolerogenicity of the peptide.
Effect ofintranasal peptide treatment on antigen specific immunoglobulin levels
inducedfollowing systemic immunisation.
To determine whether the i.n. administration of a single T cell epitope peptide
could influence B cell responses, Der p 1 specific antibody levels in sera were
measured by ELISA. Der p 1 -specific IgGl, IgG2a and IgE levels in sera are shown
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in figure 4.28. Der p 1-specific IgE, IgGl and IgG2a levels were not reduced in mice
receiving MEA peptide compared with saline controls, although there was a 74%
reduction in Der p 1-specific IgGl levels, in sera obtained from Der p l;pl 11-139
treated mice. Small amounts of IgG2a (100-fold less than IgGl) were detected in all
mice but there were no significant differences between groups. Der p 1-specific IgE
was also determined using standard sera from mice immunised systemically with
Der p 1 in alum, to assign arbitrary values to the levels of IgE observed. The
placebo-immunised mice produced the greatest amount of IgE, although variation
within this group was quite large. This may be linked to the non-specific reduction in
IFN-y production. There was no significant difference between the other groups of
mice.
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Investigating whether the intranasal instillation ofMEA Der p l;plll-139
before sensitisation protects against the induction of Th2 mediated pulmonary
inflammation on sensitisation and challenge with antigen.
Protocol
Day
0,1,2,3,4 16 28 41 44 45
~Y~~
1) saline i.n. (n=5)
2) 100 pg Der p 1; pi 11-139 i.n. (n=5)
3) 14 mg MEA peptide containing
100 pg Der p 1 ;pl 11-139 i.n. (n=7)
4) 14 mg placebo i.n. (n=4)
10 pg Der p 1 in 4mg alum i.p.
50 pg Der p 1 i.t.
sacrifice
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Figure. 4.20. IL-5 production by splenocytes.
C57BL/6 mice were given saline alone, Der p 1 ;pl 11-139 peptide alone, MEA Der p
1 ;pl 11-139 or placebo microparticles by intranasal instillation. Single cell
suspensions (5 x 105/well splenocytes) were cultured with media alone or in the
presence of 20 pg/ml Der p 1, Der p 1 ;pl 11-139, Der p l;pl 11-119, Der p l;pl 13-
127, OVA peptide and a-CD3/CD28 antibodies. Supernatants were removed at 72
hours for cytokine determination. The graphs represent individual mice (diamonds)
as well as mean values within each experimental group (lines).
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Figure 4.21. IL-13 production by splenocytes.
C57BL/6 mice were given saline alone, Der p l;pl 11-139 alone, MEA Der p l;pl 11-
139 or placebo microparticles by intranasal instillation. Single cell suspensions (5 x
105/well splenocytes) were cultured with media alone or media supplemented with
20 pg/ml Der p 1, Der p l;pl 11-139, Der p l;pl 11-119, Der p l;pl 13-127, OVA
peptide and a-CD3/CD28 antibodies. Supernatants were removed at 72 hours for
cytokine determination. The graphs represent individual mice (diamonds) as well as
mean values within each experimental group (lines).
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Figure 4.22. IFN-y production by splenocytes.
C57BL/6 mice were given saline alone, Der p 1 ;pl 11-139 alone, MEA Der p 1 ;p 111 -
139 or placebo microparticles by intranasal instillation. Single cell suspensions (5 x
105/well splenocytes) were cultured with media alone or in the presence of 20 pg/ml
Derp 1, Derp 1 ;pl 11-139, Derp l;plll-119, Der p l;pl 13-127, OVA peptide and
a-CD3/CD28 antibodies. Supernatants were removed at 72 hours for cytokine
determination. The graphs represent individual mice (diamonds) as well as mean
values within each experimental group (lines).
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Figure 4.23. IL-10 production by splenocytes.
C57BL/6 mice were given saline alone, Der p l;pl 11-139 alone, MEA Der p 1 ;p 111 -
139 or placebo microparticles by intranasal instillation. Single cell suspensions (5 x
lOVwell splenocytes) were cultured with media alone or in the presence of 20 pg/ml
Der p 1, Der p 1 ;pl 11-139, Der p l;pl 11-119, Der p l;pl 13-127, OVA peptide and
a-CD3/CD28 antibodies. Supernatants were removed at 72 hours for cytokine
determination. The graphs represent individual mice (diamonds) as well as mean
values within each experimental group (lines).
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Figure 4.24. Investigating whether the intranasal instillation ofMEA Der p
l;pl 11-139 before sensitisation protects against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen.
IL-5 and IL-13 production by TLN cells.
C57BL/6 mice were given saline alone, Der p 1 ;pl 11-139 alone, MEA Der p 1;
pi 11-139 or placebo microparticles by intranasal instillation. Single cell suspensions
from pooled tracheal lymph nodes (5 x 1 07well TLN cells) were cultured with media
alone or in the presence of 20 pg/ml Derp 1, Derp 1 ;pl 11-139, Derp l;plll-119,
Der p l;pl 13-127, OVA peptide and a-CD3/CD28 antibodies. Supernatants were
removed at 72 hours for cytokine determination. Each sample is shown in duplicate.
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Figure 4.25. Investigating whether the intranasal instillation of MEA Der p
1 ;pl 11-139 before sensitisation protects against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen.
IFN-y and IL-10 production by TLN cells.
C57BL/6 mice were given saline alone, Der p l;pl 11-139 alone, MEA Der p 1 ;pl 11 -
139 or placebo microparticles by intranasal instillation. Single cell suspensions from
pooled tracheal lymph nodes (5 x lOVwell TLN cells) were cultured with media
alone or in the presence of 20 pg/ml Der p 1, Der p 1 ;pl 11-139, Der p 1 ;p 111-119,
Der p 1 ;pl 13-127, OVA peptide and a-CD3/CD28 antibodies. Supernatants were
removed at 72 hours for cytokine determination.
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Figure 4.26. Investigating whether the intranasal instillation of MEA Der p
l;pl 11-139 before sensitisation protects against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen.
Eosinophil Infiltration into Lungs
Eosinophils were detected by an eosinophil peroxidase assay.
Individual mice are represented by diamonds, mean values within each group are
represented by bars. Differences in means were significant (* P < 0.01).
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Figure 4.27. Investigating whether the intranasal instillation of MEA Der p
1;pi 11-139 before sensitisation protects against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen.
IL-5 and IL-4 levels in BAL fluid.
Mouse lungs were lavaged in situ after death with PBS. The lavage was centrifuged
to remove the cellular infiltrate (used for cytospins). The supernatant was frozen at
-70° until analysis by ELISA. The charts represent individual mice (diamonds) as
well as mean values within each experimental group (lines).
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Figure 4.28. Investigating whether the intranasal instillation of MEA Der p
l;plll-139 before sensitisation protects against the induction of Th2 mediated
pulmonary inflammation on sensitisation and challenge with antigen?
Der p 1-Specific IgGl, IgG2a and IgE levels in sera.
The graphs represent individual mice (diamonds) as well as mean values within each
experimental group (lines).
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Immunisation with MEA Der p 1 on sensitised mice.
4.9 Investigating whether the intranasal instillation ofMEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
The purpose of the experiments described here was to investigate whether the
intranasal administration ofMEA Der p 1 microparticles could down-regulate
established Th2 cytokine mediated allergic responses.
The immunisation protocol was chosen because we wanted to investigate a
therapeutic (treatment) regimen which involves sensitising mice to Der p 1 using an
adjuvant free protocol over the prophylactic regimen where mice are immunised with
Der p 1 in alum. The protocol is shown in detail on page 169. Mice were immunised
systemically by i.p. injection of 10 pg concentrations ofDer p 1 in saline. Sixteen
days after the last immunisation, groups ofmice received either saline alone (Group
A, n - 4), placebo particles (Group B, n = 4), Der p 1 alone (Group C, n = 4) or MEA
Der p 1 (Group D, n = 4) particles by intranasal instillation on 5 consecutive days.
After a further seven days, the mice were challenged by intra-tracheal instillation of
Der p 1 allergen into the airways (see protocol) and were then sacrificed 24 hours
after the final intra-tracheal challenge.
Figure 4.29 shows the splenocyte proliferative recall responses to a number
of in vitro stimuli. Single cell suspensions were restimulated with either Der p 1,
defined immunodominant epitopes ofDer p 1 - p( 111-139) (this peptide contains
both the CD4 and CD8 T cell epitopes), p(l 11-119) (the CD8 epitope), p(l 13-127)
(the CD4 epitope) or with ovalbumin (an irrelevant protein). All protein and peptide
concentrations were used at lOpg/ml. Each of the four groups ofmice showed a
small degree ofpriming in response to Der p 1, with the strongest proliferative
responses exhibited by the mice immunised with MEA Der p 1 (S.I. 2.8) and Der p 1
(S.I. 3.4). The degree of priming in the saline- and placebo-immunised groups were
similar (S.I. 1.9, 1.4 respectively). In all groups ofmice response to Der p 1 was the
strongest of the different stimuli. Proliferative responses to the three peptides were
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similar in magnitude, with no statistically significant differences between the four
groups (S.I. in the range 1 - 2).
Proliferation in tracheal lymph node cell cultures was certainly more marked
than splenocyte cultures (figures 4.30-4.31). The highest levels by far were exhibited
by the Der p 1 group ofmice (note scale). Restimulation with Der p 1 resulted in
memory responses five times higher than the saline group. Again it was difficult to
differentiate between which epitope (CD4 or CD8) induced the greatest response in
all groups of mice.
IFN-y and IL-5 levels were measured in the culture supernatants which were
removed at 72 hours. Neither cytokine was detectable in either splenocyte or lymph
node cultures which was strange as we would have expected to see some existence of
cytokines.
Marked levels ofDer p 1-specific IgGl were detected in all groups ofmice
but were highest in the Der p 1 and MEA Der p 1 groups (figure 4.32). Der p 1-
specific IgG2a was also detected in all groups but this was considerably reduced
when compared to IgGl levels (four-fold less for saline and placebo groups, ten-fold
less for Der p 1 and MEA Der pi). Der p 1-specific IgE was also tested but due to
diminishing quantities of sera it was not possible to test every mouse; saline (n = 2),
placebo (n = 2), Der p 1 (n = 4) and MEA Der p 1 (n = 3). IgE levels were highest in
the placebo group but with a mean of only two mice this may not reflect an accurate
result. There was little difference between Der p 1 and MEA Der p 1 but IgE levels
in both groups were considerably elevated compared to saline controls.
The highest levels of lung eosinophilia were detected in the MEA Der p 1 and
the Der p 1 groups ofmice (figure 4.33). These levels were approximately 3 times
higher than those detected in the saline and placebo groups.
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Figure 4.29. Investigating whether the intranasal instillation of MEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
Proliferation of splenocytes (5x10 cells/well) after in-vitro stimulation with media
alone or media supplemented with 10 pg/ml Der p 1, p(l 11-139), p(l 11-119), p( 113-
127) and OVA. Cells were cultured for 72 hours with the antigenic stimuli, pulsed
with thymidine for 18 hours and then harvested.
Mean +/- SE is shown.
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Figure 4.30. Investigating whether the intranasal instillation of MEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
Proliferation of lymphocytes (4 x 105 cells/well) after in-vitro stimulation with media
alone or media supplemented with 10 pg/ml Der p 1, p(l 11-139), p(l 11-119) or
p(l 13-127). Cells were cultured for 72 hours with the antigenic stimulus, pulsed with
thymidine for 18 hours and then harvested.
Mean +/- SE is shown.
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Figure 4.31. Investigating whether the intranasal instillation ofMEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
Proliferation of lymphocytes (4 x 10s cells/well) after in-vitro stimulation with media
alone or in the presence of 10 pg/ml Der p 1, Der p l;pl 11-139, Der p l;pl 11-119 or
Der p l;pl 13-127. Cells were cultured for 72 hours with the antigenic stimulus,
pulsed with thymidine for 18 hours and then harvested.
(Note: there were insufficient cells from the Der p 1 group ofmice to restimulate
with Der p l;pl 13-127.)
Mean +/- SE is shown.
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Figure 4.32. Investigating whether the intranasal instillation of MEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
Der p 1-specific IgGl, IgG2a and IgE levels in sera.
Antibody levels were detected by ELISA.
Sera was diluted 1:1000 for IgGl and IgG2a. Sera was diluted 1:5 for IgE.
Mean +/- SE is shown.
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Figure 4.33. Investigating whether the intranasal instillation of MEA Der p 1
prevents the induction of airway inflammatory responses in mice sensitised by
systemic immunisation with Der p 1.
Eosinophil Infiltration into Lungs
Eosinophils were detected by an eosinophil peroxidase assay.
Mean +/- SE is shown.
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4.10 Discussion
The purpose of this study was to investigate the ability ofMEA Der p 1
microparticles to induce an immune response, with the hope that these particles could
eventually be utilised as a potential therapy for the alleviation of allergic disease,
either by tolerance induction or immune deviation. These responses were generated
in vivo by a number of immunisation protocols and then measured using established
in vitro protocols. This involved restimulation with antigen after which proliferative
responses and cytokine production were determined. The B cell response was also
measured by determining the levels of antigen-specific antibody isotypes present in
sera. Initially a number of experiments were undertaken in order to determine the
most effective route of immunisation (sub-cutaneous, intra-peritoneal, intravenous,
oral or intra-nasal). The routes of immunisation (i.p. and s.c.) that induced the
greatest immune response were investigated further to determine optimum dosage
and kinetics but these routes of administration were not used for subsequent
experiments. The possibility of tolerance induction after oral administration ofMEA
particles was investigated, along with the effect ofMEA Der p 1 on an established
allergic response in a mouse model.
PLG microparticles are very stable if kept at 4°C in a moisture-deficient
environment. After injection, microparticles induce only a minimal inflammatory
response and degrade by non-enzymic hydrolysis to the normal metabolites, lactic
and glycolic acids [453]. One mechanism of immune stimulation by PLG
microparticles is thought to operate via a depot effect resulting from slow antigen
release at the site of delivery. A second mechanism involves a more vigorous
stimulation resulting from efficient intracellular delivery of high concentrations of
antigen to APCs and subsequent presentation to T cells [462].
A study by O'Hagan et al demonstrated that the entrapment of the soluble
protein OVA, normally a poor immunogen, in PLG microparticles resulted in the
induction of potent serum IgG following i.p. or s.c. immunisation [476], These IgG
responses were significantly greater than or comparable to those induced with OVA
and Freunds' adjuvant. The data in this study was in agreement with these findings,
with high levels of antigen-specific IgGl being detected 21 and 42 days after a single
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s.c. or i.p. immunisation (figure 4.7) which was comparable to the response induced
with Der p 1 in Freunds' adjuvant.
The induction ofCD4+ T-cell responses with MEA Der p 1 was demonstrated
by proliferation and cytokine production by immune splenocytes restimulated in
vitro with Der p 1. Immunisation with MEA Der p 1 by the i.p. route induced CD4+
T cells that secreted high levels of IFN-y in response to specific antigen stimulation
in vitro (figure 4.12). This was in agreement with the findings ofMoore et al who
immunised mice with recombinant HIV protein entrapped in PLG microparticles
[477], The IFN-y response was most predominant at day 9 of our study. By day 21
levels of IFN-y were diminished and were virtually abolished by day 42 (figure 4.6).
This was supported by the antigen-specific IgGl/IgG2a data with levels of IgGl (an
indicator of the presence of Th2 cytokines) increasing steadily as the time increased
(figure 4.7). Unfortunately we were not able to support this further with IL-5 data.
IL-5 production in the splenocyte culture supernatants was undetectable following
each route (i.p. s.c. i.v.) of immunisation. From other unrelated experiments, I have
found that proliferation levels must be significantly higher than those exhibited in
this experiment for IL-5 to be detected. Therefore, it is suggested that IL-5 was
produced by this population ofCD4+ T cells, especially at the later time-points but
was beyond the threshold of detection by ELISA used in this study. This observation
seemed to be supported by other PLG studies when only small amounts of IL-5 were
detected after s.c. and i.p. immunisation with microparticles entrapping HIV proteins,
however, the use of viral proteins in these studies would preferentially induce CD8+
IFN-y responses [477, 478]. Therefore, it is proposed that ThO/Thl cells were
induced at the early time-points after immunisation but a mixed Thl/Th2 population
ofCD4+ T cells was induced at later time-points with Th2 CD4+ T cells becoming
more predominant by day 42.
Intra-peritoneal immunisation is thought to favour Thl induction because this
site is rich in macrophages which have been shown to act as APCs for Thl cells
[479]. It seems likely that phagocytosis by macrophages probably accounts for the
ability of PLG microparticles to function as a potent antigen delivery systems, since
macrophages process and present antigens together with class II molecules to T-
helper cells to induce T-cell dependent immune responses [480]. Sub-cutaneous
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administration ofMEA particles delivers them to the extensive network of
Langerhans cells that are situated under the skin. The Langerhans cells capture the
antigen and then migrate to the draining lymph nodes where they mature and present
the antigen to T helper cells in association with MHC class II. Therefore,
phagocytosis ofMEA Der p 1 particles probably resulted in the delivery of relatively
large amounts of undegraded antigen intracellularly to APCs resulting in more
effective antigen presentation.
A recent study by Ricciardi-Castagnoli and colleagues suggests an alternative
mechanism for bacterial uptake in the gut mucosa other than by M cells [481]. They
demonstrated that DCs could open the tight junctions between epithelial cells, send
their dendrites outside the epithelium and directly sample bacteria. Although not at
all proven, it may be possible that DCs could sample MEA Der p 1 microparticles in
a similar manner. However, this mechanism is dependent on DCs expressing tight
junction proteins, whose expression is regulated during the maturation process,
which in turn, is induced by bacteria or bacterial LPS. For MEA particles to be taken
up in this manner would suggest that the particles induced inflammation which is
unlikely considering the dearth of evidence regarding there safe use in vivo.
After establishing the basic kinetics and identifying that the intra-peritoneal
and sub-cutaneous routes induced the greatest immune response, further
investigation concentrating on these routes was undertaken. These studies
specifically concentrated on the dose ofMEA Der p 1 with comparisons being made
to the induction of immune responses with Der p 1 in CFA as a positive control.
Altering the dose ofMEA Der p 1 within the range of 7-30 mg, did not have
a marked effect on the immune response. However, good proliferative responses (2-3
times higher c.f. media control) were induced in all groups which were stronger than
that induced with Der p 1 in CFA. When immunising subcutaneously, 14 mg MEA
Der p 1 (containing approximately 100 pg Der p 1) induced the greatest level of
IFN-y production in the splenocyte cultures (figure 4.9). The same dose ofMEA Der
p 1 also induced IFN-y production by splenocytes from intra-peritoneal immunised
mice (figure 4.12). However, these levels were markedly reduced compared to sub¬
cutaneous immunisation. This may be attributable to the route of administration and
also kinetics. The Langerhans cells in skin could prime T cell responses more
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efficiently than DCs or macrophages in the peritoneal cavity. The subcutaneously-
injected mice were sacrificed 11 days after immunisation whereas the intra¬
peritoneal mice were killed 21 days after immunisation. However, these finding do
support the results from the previous experiment. IgGl levels were highest in s.c.
mice that had received 30 mg MEA Der p 1 (figure 4.10) and were evident in the
30 mg i.p. group only (figure 4.13). This could be explained by the ratio of the PLG
polymer which was 60:40 lactide:glycolide. This ratio degrades relatively rapidly and
releases the entrapped antigen over a few weeks. As more antigen became available
for presentation and processing, in turn the memory B cell population became
expanded and secreted more antigen-specific IgGl antibodies. A large amount of
evidence suggests that antibody class switching is induced by B cell activators in the
presence of specific cytokines. IL-4, TGF-P and IFN-y regulate isotype specificity of
switching by regulating transcription of unrearranged or germline Ig Ch genes before
class switching [482, 483], IL-4 induces germline yi and 8 transcripts in mouse B
cells and subsequent switching to these same isotypes [266, 484, 485]. Addition of
IFN-y to LPS-activated B cells induces germline y2a transcripts and subsequent
switching to IgG2a in mouse B cells [486, 487]. In our system the predominance of
IgGl over IgG2a suggests that IL-4 would have been present in our cultures even
though we failed to detect any. However, IL-4 is notoriously difficult to detect.
Although only relatively short kinetics were employed in this experiment, other
studies have shown that neutralising antibodies can be detected for at least a year
following a single immunisation of microencapsulated peptide or protein [457],
Protein antigens cannot be used for in vitro restimulation of certain lymph
node cultures unless exogenous feeders are added, so most lymph node cultures were
restimulated with the immunodominant Der p 1 epitope Der p 1 ;pl 11-139 instead of
the whole protein. The lack of a proliferative response in most lymph node cultures
may be attributed to kinetics. Most draining lymph nodes were removed at least a
week after immunisation, by which time the antigen-specific lymphocytes may have
left the site of immunisation and migrated to other lymphoid organs such as the
spleen.
As described previously the oral delivery ofPLG microparticles confers a
number of advantages over systemic immunisation. PLG microspheres protect the
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antigen from degradation [488] and are designed to increase antigen uptake by M
cells [488, 561], Certain parallels between the functions ofM cells and macrophages
have been drawn with respect to the uptake of particulate antigens [462].
In this study, the oral administration ofmicroencapsulated Der p 1 particles
did not elicit an immune response. This could be due to a number of reasons but can
probably be attributed to insufficient priming. Although an intensive dosing schedule
was employed this does not seem to have had an effect. One study suggests that only
a tiny fraction (<1%) of ingested microparticles is actually taken up by the gut-
associated lymphoid tissue [463], on the other hand, PLG microencapsulation is
thought to enhance the particles' uptake by M cells [489, 490] because of strong
adhesive interactions with gastrointestinal mucus and the brush-border glycocalyx
[388]. This layer contains absorbed pancreatic enzymes and stalked intramembrane
glycoprotein enzymes responsible for digestion [390]. The PLG microparticles
maintain contact with the intestinal epithelium for extended periods of time and
actually penetrate through and between cells. Strong biologically adhesive
interactions delay the passage ofmicroparticles through the gastrointestinal system.
A study by Mathiowitz et al. suggested that some of the best materials for the
construction ofbiologically erodable microparticles were polyanhydride copolymers
of fumaric and sebacic acid which demonstrated higher biological adhesive
properties than PLG [491],
There are plenty of studies to suggest that immune responses (mucosal and
systemic), can be induced by utilising the oral route of immunisation [448, 466, 472,
492], although the dosing regimens vary greatly with multiple doses or combinations
of oral and parenteral administrations. One study showed that an immune response
could be detected after only one oral dose [492], Repeated oral feeding ofMEA Der
p 1 in our study did not prime mice for a detectable immune response. In fact in
order to induce antibody responses in orally fed mice, a subcutaneous boost with
MEA Der p 1 was required in addition to the oral immunisation protocol. A
combination of oral and subcutaneous immunisations ofMEA Der p 1 did not
enhance antibody responses above the levels observed for subcutaneous
administration alone (results not shown).
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There was however, the possibility that oral priming was inducing a tolerant
state in the mice, and that this rendered them non-responsive rather than unprimed.
To answer this question, mice were fed on three consecutive days with 42 mg MEA
Der p 1 (containing approximately 300 pg Der p 1) or placebo and then challenged
subcutaneously 28 days later with 50 pg Der p 1 in CFA. The mice were sacrificed
10 days later with no difference in proliferative responses being detected between
control and experimental animals (figure 4.17). Therefore, this experiment suggested
that oral administration ofMEA Der p 1 did not induce a state of tolerance in the
mice.
Serological data indicated that subcutaneous treatment with MEA Der p 1
was necessary to prime antibody responses. In agreement with other studies by this
group, the predominant antibody isotype was IgGl. Many investigators have
confirmed that for certain infectious diseases, the mucosal route is the most
appropriate route of immunisation [474, 475, 488, 493], It has been shown that
several anatomically separate mucosal surfaces can be protected through the mucosal
administration of a vaccine at a single site [494, 495]. Mucosal vaccination offers the
added advantage that some degree of systemic immunity can be induced along with
local responses, due to translocation of antigenic material from sub-epithelial
compartments to systemic lymphoid organs such as the spleen. As sensitisation to
Der p 1 occurs through the mucosa, it makes sense to adopt a vaccination protocol
via the same route, which was why the intra-nasal route of administration was
chosen. In addition, the nasal epithelium is more accessible to high molecular weight
molecules than in other mucosa [496], and its mucus coating contains lower levels of
proteolytic enzymes than in the gut [497]. Furthermore, it has been proposed that the
nasal-associated lymphoid tissues (NALT) have a lymphoepithelium, which, like that
in the intestinal mucosa, contains M-cells for selective antigen uptake [473, 498],
A previous study by Almeida et al in rats and rabbits showed that particles of
average size 0.51 pm and 0.83 pm when administered intra-nasally could penetrate
into the blood circulation [464], Our particles ranged in size mostly from 1-10 pm
but a small proportion of particles were <1 pm and a second study by Yan et al
found that microparticles between 2.6 - 5.8 pm were very effective carriers of their
chosen immunogen (ricin toxoid) [475].
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With this in mind we decided to investigate whether intranasal administration
ofMEA Der p 1 ;pl 11-139 peptide before sensitisation could protect against the
induction of allergic response. The hypothesis was that intranasal administration of
MEA peptide would induce tolerance more readily and thus protect against a local
challenge with Der p 1. Also, concerns about the potential for triggering IgE
mediated inflammatory responses by using whole Der p 1, have prompted
investigations on the use of T cell epitope peptides in therapy. Previous studies
demonstrated that residues pi 11-139 ofDer p 1 contained an immunodominant T
cell epitope. Stimulation with a peptide covering this region induced
lymphoproliferative responses in human T cell clones, and murine T cell lines
obtained from Der p 1 immunised mice expressing the H2-b haplotype [499, 500],
The intranasal administration of peptide Der p 1 ;pl 11 -139 to naive mice protected
against the induction ofThl mediated DTE1 responses, following immunisation with
Derp 1 in CFA [501],
From the cytokine and antibody data, there is a possibility that tolerance in
MEA peptide mice has been induced. The fact that Der p 1-specific IgE can still be
detected though casts some doubt over tolerance induction. A study by Hurst and
colleagues found that tolerance was established following the inhalation of small
amounts of aerosolised OVA [437]. The characteristics of this tolerance were the
absence of antigen-specific IgE in vivo, and both Thl and Th2 cytokines upon Ag
restimulation in vitro. Seymour et al found that the establishment of aerosol-induced
IgE tolerance did not involve immune Th2 —* Thl deviation [502]. In addition, Hurst
et al found that this form of tolerance was accompanied by high titres of antigen-
specific IgGl. This fact supports our own study where MEA peptide-treated mice
showed the highest levels ofDer p 1-specific IgGl (figure 4.28). Surprisingly, mice
treated with peptide alone had much lower levels of IgGl and cytokine levels were
markedly (but not statistically) higher than MEA peptide mice.
The eosinophil infiltration results were striking although again, were not
statistically significant (figure 4.26). Mice administered MEA encapsulated peptide
intranasally had a marked reduction in the number of lung eosinophils after
inhalation of the Der p 1 allergen. Mucosal tolerance is linked to the degree to which
the CD4+ T cell population is initially activated, since the intranasal administration of
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peptide alone, failed to protect against the induction of eosinophilia. As discussed
earlier, antigen concentration and TCR affinity are critical in determining the
strength of initial activation signals that precede T cell tolerance [136, 503], The data
suggests that by using MEA peptide, the concentration of peptide released
systemically was increased, thus strengthening the initial TCR mediated activation
signal. Studies involving the intranasal administration ofwhole antigen,
demonstrated that the induction of peripheral T cell tolerance was accompanied by
modified B cell responses, with reductions in specific IgE and changes in the ratio of
IgGl to IgG2a levels in sera [146, 504], In this study, the intranasal administration of
a microencapsulated T cell epitope peptide suppressed local Th2 dependent
inflammatory responses in the airways but did not greatly influence B cell dependent
responses such as antibody levels in sera. A number of studies in animal models of
asthma demonstrate that the typical processes of asthma such as eosinophil
infiltration of the bronchial mucosa and BHR are elicited independently of the
presence of B cells and IgE Ab's, but are dependent on the presence ofT cells [505-
507]. Failure to significantly downregulate allergen induced eosinophilia following
mucosal delivery of peptide to sensitised mice, suggests that it may be more difficult
to suppress established Th2 mediated responses, by tolerance induction. This view is
supported by a recent publication demonstrating that ongoing Th2 responses in the
lungs ofmice prevented induction of tolerance to aerosolised OVA [437].
Tolerance can be mediated by a number ofmechanisms. One mechanism is
that of linked suppression which is thought to account for the loss of responsiveness
to all epitopes within a protein, following the induction ofT cell tolerance using a
single immunodominant epitope. This form ofbystander suppression may be
mediated via an antigen non-specific cognate interaction with APCs [508], possibly
involving signalling through notch ligands and their receptors [342] and / or through
the production of immunosuppressive cytokines such as IL-10 and TGF-(3. IL-10 has
been shown to be critical in the induction ofmucosal tolerance to a Thl response to
autoantigen [509]. In addition, an increase in IL-10 production by peripheral CD4+ T
cells has been shown in clinical studies following allergen specific immunotherapy
(SIT) [510],
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In this study, an increase in IL-10 production was not observed by antigen
stimulated cells from the draining lymph nodes ofmice treated intranasally with
MEA peptide. However, there was a large decrease in eosinophilia (figure 4.26) in
the MEA peptide group which was paralleled by a reduction in IL-5 (figures 4.20 and
4.24) - critical to the differentiation and survival of eosinophils. Although we were
unable to detect an increase in IL-10, it is possible that IL-10 induced tolerance in the
antigen reactive CD4+ Th2 population, may have occurred during antigen
presentation in the draining lymph nodes, resulting in a loss of localised IL-5
production and consequently a fall in airway eosinophil levels.
Results from the placebo mice were quite intriguing. The level of IL-5
(figures 4.2 and 4.24) and IL-13 production (figures 4.21 and 4.24) suggested that a
Th2 response was being induced. However, the experiment was only able to be
undertaken once and only four mice were tested. The largest inter-group variation
was exhibited by the placebo mice therefore, it would be preferable to repeat the
experiment before any firm conclusions can be drawn on the effect of placebo
microparticles on Th2 induction.
Recent evidence suggests that the induction ofmucosal tolerance may be
dependent on IL-10 production by pulmonary dendritic cells [511], IL-10 is a critical
growth factor for a population of antigen specific CD4+ CD45RBlowCD25+ T
regulatory type 1 cells (Trl), which are thought to be central to the induction and
maintenance of peripheral tolerance [512, 513]. Cottrez et al showed that the transfer
ofTrl T cell clones but not Thl or Th2 clones, at the time ofOVA immunisation
inhibited antigen specific serum IgE responses [514], Although IL-10 was originally
described as a murine Th2 factor, it is now recognised that this cytokine inhibits Th2
mediated responses, including airway eosinophilia [515]. The ability of IL-10 to
suppress DC maturation may be central to the induction ofT cell tolerance and
immunoregulation by Trl cells [516, 517]. A recent study by Zuany-Amorim and
colleagues showed that the treatment ofmice with SRP299, a killed Mycobacterium
vaccae-suspension, gives rise to allergen-specific CD4+CD45RB|0 regulatory T cells,
which confer protection against airway inflammation [583]. This specific inhibition
was mediated through 1L-10 and TGF-fl, as antibodies against IL-10 and TGF-(3
completely reversed the inhibitory effect ofCD4+CD45RBl0 T cells.
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Even though preceding MEA Der p 1 experiments suggested that the induced
immune response was largely Th2-orientated, it was decided to give MEA Der p 1 to
mice with an established Th2 response, as this most closely mimicked the real life
situation where most immunotherapies are given to patients with established allergic
disease. Mice were primed for a Th2 response with a number of systemic
immunisations ofDer p 1 (without adjuvant), in order to establish more physiological
conditions, perhaps comparable to exposure in man. Mice then received five doses of
MEA Der p 1 intranasally before receiving three tracheal instillations ofDer p 1, to
determine whether intranasal administration of the antigen could tolerise an existing
Th2 response to subsequent airway challenge with Der p 1. It was found that the i.n.
administration ofMEA Der p 1 actually increased Th2 priming and in fact,
exacerbated the allergic response as exhibited by the lung eosinophil data. Similar
results were observed when Der p 1 alone was given intranasally. It seems that our
established Th2 response was far too strong to be down-regulated. This is supported
by the results ofHurst and colleagues who found that the establishment of normal
IgE tolerance to inhaled OVA Ag could be subverted by strong local Th2 responses
but not Thl responses, to unrelated antigens or pathogens in the lung, and that this
prevention was largely the consequence of local IL-4 production immediately before
inhalation ofOVA [437], An intranasal KLH challenge to sensitised KLH/alum
before the primary exposure ofmice to OVA by aerosol isation resulted in the
sensitisation, not tolerance ofmice to OVA. Likewise, infection of mice with
antigens such as Nippostrongylus brasiliensis or exposure to A. fumergatus extract,
both ofwhich produce vigorous Th2 responses, prevented the establishment of IgE
tolerance to aerosolised OVA. There is no evidence from other groups that the






Chitosan is a polysaccharide composed of two subunits, D-glucosamine and
N-acetyl-D-glucosamine linked together by (3(1,4) glycosidic bonds. It is obtained
industrially by hydrolysing the aminoacetyl groups of chitin. Chitin is one of the
most abundant polysaccharides in nature, second only to cellulose. It is a structural
component of the exoskeleton of crustacea and insects. After the deacetylation of
chitin, the resulting chitosan is dissolved in acid, filtered, washed and dried to give
amine free chitosan. The chemical formula of chitosan is (CeHuCftNV
Chitosan has already been used in a wide array of applications - personal care
products (hair treatment, skin care, moisturiser, wound healing), food products (wine
and juice clarification, protective fruit coating, hypercholosterolemic behaviour), for
clarification and waste management (treatment of sewage, sludge and brewers'
waste, chelation of toxic heavy metals and radioactive materials), in agriculture (seed
coating, as a flocculating agent, as a controlled release agent for pesticides and
herbicides), for biotechnology products (to separate and purify biologicals and to
immobilise enzymes and cells) and in pharmaceuticals [518].
Chitosan is soluble in acidic solutions but insoluble at pH > 6.5 and in most
organic solvents. This property of chitosan is disadvantageous for biomedical
applications because at physiological pH (7.4), most chitosans precipitate from
solution and consequently become ineffective. In recent years, chitosan has been
manipulated in order to increase its solubility over a wider pH range. Several
derivatives of chitosan have been synthesised among which is N-trimethyl chitosan
chloride (TMC). It was found that the greater the degree of trimethylation, the greater
the solubility of the polymer at neutral pH values [519].
Chitosan is considered to be a biocompatible, biodegradable and non-toxic
polymer [520]. It was found not to have a damaging effect on nasal membranes in
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rats [521] and also, is non-toxic in humans as studies have shown that when
administered intra-nasally, only transient decreases in mucociliary transport rates
were detected in vitro, leaving no permanent damage to this defence system [522],
However, one group studied the effects of chitosan on a murine melanoma cell line
(B16F10) and rat erythrocytes and found that cell viability was compromised and
haemoglobin release was increased in a concentration-dependent way [523].
The mechanism of action of chitosan is believed to be a combination of
bioadhesion and an ability to widen the tight junctions between epithelial cells in a
transient fashion. The fact that chitosan is a cationic macromolecule, means that it
can interact with anionic components (e.g. sialic acid) of the glycoproteins on the
surface of epithelial cells. In addition, the interior of tight junctions is highly
hydrated and contains fixed negative charges. A change in the relative concentration
of specific ion species within the tight junction could result in an alteration of tight
junction electrical resistance which, in turn, could lead to its opening [524],
As discussed previously in this thesis, the nasal mucosa is an attractive site
for the non-parenteral delivery of proteins and peptides for the induction of mucosal
immunity or tolerance. The benefits of nasal delivery include ease of administration
and patient acceptability however, this route of delivery has a number of drawbacks.
First, the nasal mucosa provides a substantial barrier to the free diffusion of
macromolecules [525]. Second, the enzymatic activity present in nasal secretions can
limit protein delivery [526]. Third, in humans, the surface area of the nasal mucosa is
9 •
only ~ 150 cm [527], limiting the amount of protein that can be absorbed from one
application. Finally, the typical residence time of a protein delivered to the nasal
mucosa in only 15-30 minutes due to rapid ciliary clearance [528]. A possible
strategy to circumvent this, is to prolong the contact between the protein/peptide and
the mucosa. Chitosan acts as a bioadhesive system by forming a gel-like structure at
the contact of the mucus. However, the use of chitosan in nasal formulations still
remains under investigation with relatively few studies published in the literature.
The first published study based on a chitosan nasal delivery system
containing a model drug (insulin) was by Ilium and colleagues [529]. Their main
goal was the enhancement of the systemic bioavailability of insulin after intranasal
instillation in rats and sheep. The authors showed that a concentration of 0.5%
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polymer was sufficient to vastly improve plasma insulin levels. More recently,
insulin-loaded chitosan nanoparticles were used in a rabbit model and were found to
enhance the nasal absorption of insulin to a greater extent than an aqueous solution
of chitosan and insulin [530].
Bacon et al investigated the ability of chitosan to augment the
immunogenicity of influenza vaccines given intranasally [531]. Groups of mice were
vaccinated three times intranasally with 10 pg of purified influenza B/Panama virus
surface antigens (PSAs) either alone or mixed with chitosan. Parenteral
immunisation with B/Panama PSA and Alhydrogel elicited high titres of anti-
B/Panama antibodies in serum but a very poor respiratory anti-B/Panama IgA
response. In contrast, intranasal immunisation with PSA plus chitosan stimulated
very strong local and systemic anti-B/Panama responses. The mean serum IgG titres
and the HAI (haemagglutinin inhibition) titres of the PSA-plus-chitosan-immunised
mice were significantly greater (P < 0.05) than those of the PSA intranasal
immunised mice.
Chitosan has also been investigated as a candidate vector for DNA delivery
[532-534]. In one study, low molecular mass chitosans were found to complex DNA
more effectively than poly (L-lysine) was able to and also provided protection
against nuclease degradation [533]. In another study, chitosan-DNA (encoding a
peanut allergen gene) nanoparticles were orally administered to mice. These mice
produced secretory IgA and serum IgG2a and showed a substantial reduction in
allergen-induced anaphylaxis associated with reduced levels of IgE, plasma
histamine and vascular leakage [534],
In conclusion, the majority of current studies into chitosan, seem to be
focussed on enhanced drug or DNA delivery, especially across mucosal surfaces
(e.g. nasal or gut).
As discussed earlier, Der p 1 is a major target allergen of the human immune
response to house dust mite in allergic asthmatics. The use of Der p 1 as an intact
molecule in immunotherapy via the airways has inherent limitations due to the
triggering ofmast cell degranulation and potentially life-threatening anaphylaxis. A
number of clinical studies have investigated the use of peptides in conventional
therapy using the systemic route of delivery, as a means of avoiding the risk of
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triggering inflammatory responses following the cross-linking of FcsR's on effector
cells by IgE-allergen complexes [535].
In this study, the intranasal administration of a peptide encoding an
immunodominant T cell epitope ofDer p 1 was investigated to see whether
peripheral CD4+ T cell responses and airway eosinophilia could be suppressed in a
murine model of pulmonary inflammation. Previous studies have shown that
intranasal administration ofDer pl;plll-139 protected against the induction of
systemic Thl-mediated DTH responses in mice immunised with Der p 1 in CFA.
Antigen-specific T cell tolerance correlated with loss of proliferation, IL-2
production and ability to provide cognate help for antibody production, following
stimulation in vitro [501].
The Der p 1 ;pl 11 -139 was adsorbed to chitosan prior to administration in
order to maximise the passive diffusion of peptide across the intercellular barriers,
formed by the tight junctions. This maximisation was critical in order to reach the
TCR activation threshold for tolerance induction. Thus, the delivery of peptide
adsorbed to chitosan could facilitate tolerance induction by increasing the level of
peptide released systemically [536, 537].
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5.2 Investigating whether Chitosan promotes the induction of tolerance.
Protocol
Mice (female, C57BL/6, 6-8 weeks old) were immunised on days 0, 1, 2 and 3 with
either:
1. 20 pi 0.25% w/v chitosan i.n. (n = 15)
2. 100 pg Der p l;pl 11-139 in 20 pi PBS i.n. (n = 15)
3. 100 pg Der p 1 ;pl 11-139 in 20 pi 0.25% w/v chitosan i.n. (n = 15)
For i.n. immunisations, mice were lightly anaesthetised with halothane, and 20 pi
of sample (10 pi per nostril) was applied to the external nares with a micropipette
(Gilson). Five mice from each group were sacrificed on days 2, 4 and 8 after the last
i.n. immunisation. Spleen and cervical lymph nodes were removed from each mouse.
Pooled cervical lymph node cells and splenocytes from individual mice were
restimulated in vitro with either media alone, or media supplemented with 5 and
20 pg/ml Der p l;pl 11-139. 20 pg/ml of haemagglutinin peptide (HA) - an unrelated
antigen was used as a specificity control, and a-CD3/CD28 (5 pg/ml:2.5 pg/ml) was
included as a positive control. Supernatants were removed at 72 hours for cytokine
determination. The cells were pulsed at 72 hrs with [ H]-thymidine for a further 18
hours when the cells were harvested to determine the extent of proliferation.
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Results
The aim of this study was to determine whether the intranasal administration
of an immunodominant T cell epitope ofDer p 1 ;pl 11-139 adsorbed to chitosan,
protected against the induction of Th2 mediated airway inflammatory responses to
the Der p 1 allergen in a murine model of pulmonary inflammation.
The first question to address, was whether Der p 1 ;pl 11 -139 adsorbed to
chitosan and delivered intranasally, was able to prime an immune response and to
determine the qualitative nature of that response. For this purpose, mice were
administered an equivalent of (3 x 100 pg) Der p l;pl 11-139 intranasally on 3
consecutive days. After 2 days, 4 days and 8 days, lymphocytes were isolated from
the cervical lymph nodes draining the nasal cavity and from the spleen, which were
then stimulated with increasing doses of peptide. The results shown are from one
experiment.
At 2 days, CD4+ lymphocytes from peptide and chitosan/peptide mice were
hyperresponsive to in vitro restimulation with Der pl;pl 11-139 peptide, with dose
dependent increases in proliferation and production of IL-5 and IFN-y (figures 5.1 -
5.8). Closer investigation of the cytokine recall response revealed that at equimolar
concentrations of peptide, T cells isolated from chitosan-peptide treated mice
exhibited a change in T cell effector function from a Th2/Th0 to a Thl/ThO
phenotype, compared to the peptide treated mice, which was accompanied by an
increase in the ratio of IFN-y to IL-5 production. This was consistent at 5 pg/ml and
20 pg/ml Der p l;pl 11-139, indicating that this was not due to differences in TCR
activation thresholds. By day 4 and certainly day 8, T cells obtained from all groups
of mice were hyporesponsive to in vitro restimulation with Der p l;pl 11-139
peptide, with a loss in both proliferative and cytokine responses. Mice treated with
chitosan alone did not show any T cell activation. There was no response to in vitro
restimulation with HA by any of the experimental groups, proving that the
proliferative responses observed after restimulation with Der p 1 or its related
peptides were antigen specific.
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Figure 5.1 - Investigating whether chitosan promotes tolerance induction.
Proliferation of splenocytes.
Single cell suspensions were prepared from individual spleens which were then
cultured (5xl07well) with media alone or media supplemented with 5 and 20 pg/ml
Der p 1 :pl 11-139. Proliferation was measured at 90 hours after pulsing with
thymidine at 72 hours.
Mean +/- SE is shown.
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Figure 5.2 - Investigating whether chitosan promotes tolerance induction.
Proliferation of CLN cells.
Single cell suspensions were prepared from pooled cervical lymph nodes which were
then cultured (5xl05/well) with media alone or media supplemented with 5 and
20 pg/ml Der p 1 ;p( 111-139). Proliferation was measured at 90 hours after pulsing
with thymidine at 72 hours.




































Figure 5.3 - Investigating whether chitosan promotes tolerance induction.
IFN-y production by splenocytes after restimulation with 5 pg/ml Der p 1
p(l 11-139).
Supernatants were removed at 72hours and frozen at -20°C until analysis by ELISA.






































Figure 5.4 - Investigating whether chitosan promotes tolerance induction.
IFN-y production by splenocytes after restimulation with 20 pg/ml Der p 1
p(lll-139).
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.






































Figure 5.5 - Investigating whether chitosan promotes tolerance induction.
IL-5 production by splenocytes after restimulation with 5 pg/ml Der p 1
p(lll-139).
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.












































Figure 5.6 - Investigating whether chitosan promotes tolerance induction.
IL-5 production by splenocytes after restimulation with 20pg/ml Der p 1
p(l 11-139).
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
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Figure 5.7 - Investigating whether chitosan promotes tolerance induction.
IFN-y production by CLN cells.
Single cell suspensions were prepared from pooled cervical lymph nodes and
restimulated in vitro with media alone or media supplemented with 5 and 20 pg/ml
Der p 1 ;p(l 11-139). Supernatants were removed at 72 hours and frozen at -20°C
until analysis by ELISA.
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Figure 5.8 - Investigating whether chitosan promotes tolerance induction.
IL-5 production by CLN cells.
Single cell suspensions were prepared from pooled cervical lymph nodes and
restimulated in vitro with media alone or media supplemented with 5 and 20 pg/ml
Der p l;p(l 11-139). Supernatants were removed at 72 hours and frozen at -20°C
until analysis by ELISA.
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5.3 Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2-mediated responses in a murine model of
pulmonary inflammation.
The previous study was extended by investigating whether the i.n.
administration Der p 1 ;pl 11-139 could prevent the induction of peripheral CD4+ T
cell responses and airway eosinophilia when adsorbed to chitosan, in a murine model
of pulmonary inflammation. As discussed earlier in this chapter, chitosan is thought
to enhance the passage of peptide across the mucosa through the tight junctions thus
leading to increased TCR activation and potentially enhance tolerance induction.
To address this hypothesis, mice were immunised i.n. on five consecutive
days with Der pi ;pl 11-139, adsorbed to chitosan or saline alone, chitosan alone, and
Der p 1 :pl 11-139 alone (protocol shown in detail on next page). After 12 days the
mice received two i.p. injections ofDer p 1/alum 12 days apart. The mice were
rested for 13 days before receiving two intra-tracheal instillations ofDer p 1 three
days apart. The mice were sacrificed 24 hours after the last i.t. challenge. Lung
lavage was immediately performed in situ after death in order to obtain BAL fluid
for cytospins and cytokine determination. Whole lungs were removed to determine
the extent of eosinophil infiltration, and sera was taken to determine the presence of
Der p 1-specific IgGl, IgG2a and IgE antibodies. Tracheal lymph nodes were
removed and pooled within groups along with individual spleens. Single cell
suspensions were prepared from each mouse for in vitro restimulation with media
alone or media supplemented with 20 pg/ml Der p 1, p(l 11-139), p(l 11-119), p(l 13-
127), OVA peptide (an unrelated antigen) and a-CD3/CD28 (as a positive control,
5 pg/ml:2.5 pg/ml respectively).
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Protocol
Day 0,1,2,3,4 16 28 41 44 45
l.n. l.p. l.p. i.t. i.t. sacrifice
v J
1) saline (20 pi) 10 pg Der p 1 /4 mg alum
2) 100 pg pi 11-139 (20 pi)
3) 0.25% (w/v) chitosan (20 pi) "
4) 100 pg pi 11-139 in
0.25% (w/v) chitosan (CPD)
5) 100 pg pi 11-139 in saline/alum
0.25% (w/v) chitosan (CPS)
20 pg Der p 1 (50 pi)
For each experimental group n=5 C57BL/6 female mice (6-8 weeks old).
CPD = Der p 1 adsorbed to chitosan followed by Der p 1 in alum
CPS = Der p 1 adsorbed to chitosan followed by Der p 1 in saline
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Results
This study investigated whether the i.n. administration of peptide adsorbed to
chitosan could lead to tolerance and a loss of cytokine production or alternatively,
facilitate the differentiation of an effector T cell population with a Thl/ThO
phenotype and thereby, prevent the induction of allergic inflammation.
Effect of intranasal peptide administration on proliferative responses.
Figure 5.9 shows the proliferation of splenocytes in response to various
stimuli. The major difference between groups was observed for Der p 1 and Der p
l;pl 11-139 in vitro restimulation. Proliferation of splenocytes from the chitosan-
treated mice was at similar levels to saline treated mice and higher than the other
groups. The stimulation indices in table 5.1a show little difference between the other
groups. For the other stimuli, proliferation was barely above background levels and
there were no clear differences between groups. As in the previous experiment there
was no response to the specificity control (OVA peptide), proving that the responses
observed were antigen-specific.
Cytokine production by allergen reactive T cells isolatedfrom mice treated
prophylacticaly by intranasal peptide administration.
Levels of the cytokines IL-5, IL-13, IL-10 and IFN-y in culture supernatants
were determined by ELISA. A summary of cytokine production in splenocytes after
restimulation with 20 pg/ml Der p 1 is shown in table 5.1b. IL-5 production by
splenocytes after restimulation with Der p 1; pi 11-139 and pi 13-127 is shown in
figure 5.10. The largest differences can be observed after Der p 1 restimulation.
There was a large amount of inter-group variation, thus, none of the data was
statistically significant. However, certain trends could be observed. There was a 35%
reduction in IL-5 production by splenocytes from the chitosan/peptide mice
compared to the saline control. However, IL-5 production from the peptide alone
mice was not suppressed (|50% on saline mice). Restimulation with Der p 1 ;pl 11 -
139 and Der p 1 ;pl 13-127 resulted in a similar pattern of IL-5 production from all
experimental groups. However, levels of production were decreased two-fold when
restimulated with Der p l;pl 11-139 and Der p 1 ;pl 13-127 compared to whole
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Der p 1.
IL-13 production by splenocytes mirrored IL-5 production and is shown in
figure 5.11. Although, IL-13 production by the peptide/chitosan mice was only 8%
less than the saline controls, the peptide mice had an elevated production of 103%.
IFN-y production by splenocytes was only evident with Der p 1 restimulation
(figure 5.12). Saline-treated mice produced the most IFN-y with chitosan-treated
mice producing the least. IFN-y production was also low in the chitosan/peptide mice
which was considerably less (>50%) than the peptide-treated mice.
IL-10 production by splenocytes is shown in figure 5.14. Again, it is
restimulation with Der p 1 that leads to the largest production of cytokine. The
results are similar to IL-5 and IL-13 production with the chitosan/peptide mice
producing 31% less IL-10 than the saline controls, and the peptide mice producing
23% more.
Figure 5.14 shows the IL-5 and IL-13 production from tracheal lymph node
cells after various in vitro stimuli. In contrast to systemic responses, the cytokine
response ofDer p 1 reactive T cells isolated from the draining lymph nodes of the
chitosan/peptide mice, 24 hours after challenge of the airways with Der p 1, were not
inhibited as compared to the saline control group. Although the cytokine response
from the chitosan/peptide mice was not inhibited, cytokine production by the
peptide-treated mice was markedly increased (5-fold for IL-5 and 7-fold for IL-13).
This increase in cytokine production observed in the draining lymph nodes rather
than the spleen indicated that the intranasal administration of soluble peptide to nai've
mice prior to sensitisation, primed localised Th2 responses. These differences were
not so apparent with the other in vitro stimuli.
Therefore, it appears that a dichotomy exists in the cytokine profiles of
allergen reactive T cells from local versus systemic sites in the chitosan/peptide
mice. To investigate whether localised tolerance in the lymph nodes draining the
sites of allergen exposure was maintained by active immunoregulation, levels of the
immunosuppressive cytokine IL-10 were determined (figure 5.15). An increase of
100% in the level of IL-10 production by Der p 1 reactive T cells isolated from the
tracheal lymph nodes of chitosan/peptide mice (compared to saline controls) was
observed compared to a decrease of 31% in systemic IL-10 production (table 5.1b). T
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cells isolated from the draining lymph nodes of peptide-treated mice showed an
increase in IL-10 production of 70% on control mice but this level of production was
insufficient to suppress eosinophilia (figure 5.16). This may be explained by the
larger IL-5:IL-10 ratio of the peptide mice (8) compared to the peptide/chitosan mice
(2) (table 5.1c).
Effect of intra-nasal peptide administration on eosinophil levels in Der p 1 allergen
challenged airways.
The infiltration of eosinophils into the lungs was investigated by using the
eosinophil peroxidase (EPO) assay and is shown in figure 5.16. This assay has
limitations for the quantitation of eosinophilia and large inter-group variation can
often be attributed to: lavage technique, weight of lungs (varies due to dryness of
lungs) and loss ofmaterial to the homogenisation process. Thus, there was little
difference in eosinophil infiltration between the four groups of mice. All groups have
a level of eosinophilia of approximately 10,000 eosinophils/gram lung. The
preparation of cytospins from the BAL fluid can also be used to assess the extent of
eosinophil infiltration. This assay is considered less prone to the variables affecting
the EPO assay. However, results mirrored that of the EPO assay with
chitosan/peptide mice exhibiting similar levels of eosinophilia to the saline controls
(figure 5.16).
The BAL fluid was also used to determine IL-5 and IL-4 levels. There was a
65% reduction in IL-5 and a 73% reduction in IL-4 from the chitosan/peptide mice
compared to the saline controls. However, mice treated with chitosan alone also
exhibited similar reductions in cytokine production (figure 5.17).
Effect ofintranasal peptide treatment on antigen specific immunoglobulin levels
inducedfollowing systemic immunisation.
To investigate whether the tolerisation of T cells reactive with an
immunodominant region ofDer p 1, by the intranasal administration of the peptide
Der p 1 ;pl 11-139 was sufficient to inhibit antibody production following
immunisation with the intact Der p 1 allergen, IgGl, IgE and IgG2a production was
measured. Figure 5.18 shows the Der p 1 -specific IgGl, IgG2a and IgE levels in
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sera. By far the most abundant antibody was IgGl. The chitosan/peptide mice
showed a decrease of 28% in IgGl production compared to saline controls, however,
the peptide treated mice showed a reduction of 74%. In contrast, IgE levels were not
reduced. Chitosan/peptide mice showed an increase of 170% compared to saline
controls (P < 0.05) with peptide treated mice showing an increase of 55% in IgE
production. Levels of IgG2a were almost identical in all experimental groups. The
increase in IgE production may be due to the non-specific inhibitory effect of
chitosan on IFN-y production, since IFN-y counterbalances the development of Th2
responses and production of IL-4, a cytokine critical for induction of IgE. The failure
to inhibit antibody production, in spite of significant reductions in Der p 1 reactive T
cell effector functions, may be due to the emergence ofT cells reactive with minor
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Fig. 5.9 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
Proliferation of splenocytes.
Single cell suspensions were prepared from whole spleens which were cultured with
media or media supplemented with 20 pg/ml Der p 1,10 pg/ml Der p l;pl 11-139, 10
pg/ml Der p l;plll-119, 10 pg/ml Derp 1 ;pl 13-127 or 10 pg/ml OVA.
Proliferation was measured at 90 hours after pulsing with thymidine at 72 hours.
CPD = chitosan/peptide-treated mice
Mean +/- SE is shown.
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Table 5.1a Proliferation of Splenocytes - Stimulation Indices
In vitro restimulation with:
Intranasaltreatment
media Der p 1 plll-139 plll-119 pll3-127 OVApep
Saline 1.0 9.3 3.8 1.5 1.8 1.1
Peptide 1.0 9.1 2.6 1.5 1.9 1.0
Chitosan 1.0 11.2 4.0 1.7 2.4 1.2
CPD 1.0 8.6 2.3 1.5 1.5 1.1
Table 5.1b Cytokine Production by Splenocytes After in vitro Restimulation
with 20ng/ml Per r> 1
IL-5 IL-13 IFN-y IL-10
Saline - - - -
Peptide 150% T103°/o 134% 123%
Chitosan 1103% T237% 187% 135%
CPD 4.35% 18% 178% 131%
The percentages show either an increase or decrease in cytokine production in
relation to the saline control.
Table 5.1c Ratio of IL-5:IL-10 production in tracheal lymph node cells after in
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Figure 5.10 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IL-5 production by splenocytes.
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
Results for Der p 1 ;pl 11-119 and OVA-restimulation are not shown as no detectable
IL-5 was produced.
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Figure 5.11 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IL-13 production by splenocytes.
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
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Figure 5.12 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IFN-y production by splenocytes.
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
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IL-10 Production by Splenocytes After in vitro
Restimulation with 20pg/ml p(111-139)
Saline Peptide Chitosan CPD
i.n. treatment
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Figure 5.13 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IL-10 production by splenocytes.
Supernatants were removed at 72 hours and frozen at -20°C until analysis by ELISA.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
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Figure 5.14 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IL-5 and IL-13 production by TLN cells.
Single cell suspensions from pooled tracheal lymph nodes (5 x 10"/well TLN cells)
were cultured with media alone or media supplemented with 20 pg/ml Der p 1;
p(l 11-139), p(l 11-119), p(l 13-127), OVA peptide and a-CD3/CD28. Supernatants
were removed at 72 hours for cytokine determination.
Results for a-CD3/CD28 are not shown.
Mean +/- SE is shown.
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Figure 5.15 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IFN-y and IL-10 production by TLN cells.
Single cell suspensions from pooled tracheal lymph nodes (5x105/well TLN cells)
were cultured with media alone or media supplemented with 20 pg/ml Der p 1;
p(l 11-139), p(l 11-119), p(l 13-127), OVA peptide and a-CD3/CD28. Supernatants
were removed at 72 hours for cytokine determination.
Results for a-CD3/CD28 are not shown.







































Figure 5.16 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
Eosinophil infiltration into lungs and BAL fluid.
Lung eosinophil infiltration was detected by an eosinophil peroxidase assay.
The upper chart shows eosinophil infiltration into the lungs levels of individual mice.
Individual mice are represented by diamonds, mean values within each group are
represented by bars.
The lower chart shows the analysis of cell infiltration into BAL fluid using cytospins.
Mean +/- SE is shown.
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Figure 5.17 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
IL-5 and IL-4 levels in BAL fluid.
Mouse lungs were lavaged in situ after death with PBS. The lavage was centrifuged
to remove the cellular infiltrate (used for cytospins). The supernatant was frozen at
-70° until analysis by ELISA. The charts represent individual mice (diamonds) as
well as mean values within each experimental group (lines).
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Figure 5.18 - Intranasal administration of peptide adsorbed to chitosan protects
against the induction of Th2 mediated responses in a murine model of
pulmonary inflammation.
Der p 1-Specific IgGl, IgG2a and IgE levels in sera.
Antibody levels were measured by ELISA. The charts represent individual mice
(diamonds) as well as mean values within each experimental group (lines).
Significant differences between treatment and control groups are indicated
(P < 0.05).
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5.4 Intranasal instillation of chitosan and Der p 1 ;pl 11-139 after systemic
Der p 1 sensitisation.
The purpose of this experiment was to investigate whether the intranasal
instillation ofDer p 1 ;pl 11-139 adsorbed to chitosan could down-regulate
established Th2 cytokine mediated allergic responses.
The immunisation protocol was chosen because we wanted to investigate a
therapeutic (treatment) regimen which involves sensitising mice to Der p 1 using an
adjuvant free protocol over the prophylactic regimen where mice are immunised with
Der p 1 in alum. The protocol is shown in detail on the following page. Mice were
immunised systemically by i.p. injection of 10 pg concentrations ofDer p 1 in saline.
Eleven days after the immunisation, groups ofmice received either saline alone,
chitosan alone, Der p l;pl 11-139 alone and Der p l;pl 11-139 adsorbed to chitosan.
The time period between initial sensitisation and 'treatment' was shortened slightly
(compared to previous protocols) due to time constraints. After 15 days the mice
were challenged by intratracheal instillation on 3 occasions at 3 day intervals. The
mice were sacrificed 24 hours after the final intratracheal challenge.
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Results
In this study we investigated whether the mucosal delivery of Der p 1 ;pl 11 -
139 to mice primed by systemic immunisation with Der p 1, would protect mice from
subsequent development of airway inflammatory responses after allergen challenge;
and, if so, whether tolerance was the underlying mechanism.
Clinically, patients are already sensitised to allergens when immunotherapy
begins. Thus, it would be more physiological if a protocol was adopted that measured
the effects of the administration of a candidate vaccine, in this case Der p 1 ;pl 11-139
adsorbed to chitosan after prior systemic sensitisation. The protocol is shown in
detail on page 217.
Proliferative responses ofallergen reactive T cells
Figure 5.19 shows the proliferation of splenocytes and tracheal lymph node
cells after in vitro restimulation with various stimuli. Splenocyte proliferation was
relatively low (counts < 15,000 cpm) and there was no difference between groups.
The most striking observation was the proliferation of tracheal lymph node cells
from peptide-treated mice. The intranasal instillation of peptide significantly
increased the in vitro proliferative response to Der p 1 and related peptides. Counts
were at least twice as high as any other group. This suggests that the intranasal
administration ofDer pi ;pl 11-139 primed localised responses in the draining lymph
nodes, leading to enhanced proliferative responses when the airways were later
challenged with whole Der p 1. Interestingly, when peptide was co-administered with
chitosan, proliferation was reduced to similar levels observed with the saline-treated
animals.
Cytokine production by allergen reactive T cells
IL-5 production by splenocyte and tracheal lymph node cells is shown in
figure 5.20. IL-5 production by splenocytes was below the threshold of detection of
the assay. However, IL-5 was detectable in the tracheal lymph node supernatants.
Like the proliferation results, the peptide-treated mice produced the largest amount
of IL-5 in response to in vitro restimulation with Der p 1 (mean = 7.4 ng/ml +/- 0.4),
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Der p l;pl 11-139 (mean = 9.4 ng/ml +/- 0.5) and Der p l;pl 11-127 (mean = 5.5
ng/ml +/- 2.4). Tracheal lymph node cells from the chitosan-treated mice produced
the most IL-5 after Der p 1 in vitro restimulation (mean = 3.3 ng/ml +/- 0.4). Neither
the saline- or chitosan/peptide mice produced detectable levels of IL-5.
IFN-y and IL-13 production by splenocytes and tracheal lymph node cells
was also tested. Neither of these cytokines were detected in the culture supernatants
as the levels were below the threshold of sensitivity of the ELISAs.
The presence of IL-5, IL-9 and eotaxin in BAL fluid was also investigated.
However, none of these cytokines/chemokines were detected.
Effect of intranasal peptide treatment on antigen specific immunoglobulin levels
inducedfollowing systemic immunisation.
Figure 5.21 shows the levels ofDer p 1-specific IgGl, IgG2a and IgE in sera.
With each antibody isotype, there was little difference between the groups. IgGl was
the most abundant antibody.
Effect of intranasal peptide administration on eosinophil levels in Der p 1 allergen
challenged airways.
Eosinophil infiltration into lungs was also determined and is shown in figure
5.22. There was a large amount of inter-group variation, however the
chitosan/peptide treated mice had levels of eosinophilia 43% less than the saline








































Figure 5.19 - Intranasal administration of chitosan and peptide after prior
systemic sensitisation to Der p 1.
Proliferation of splenocytes and tracheal lymph node cells.
C57BL/6 mice were immunised using the protocol outlined on page 217. Single cell
suspensions were prepared from pooled tracheal lymph nodes and individual spleens
(results pooled), which were then cultured (5xl05/well) with media alone or media
supplemented with 10 pg/ml Der p 1, p(l 11-139), p(l 11-119), p(l 11-137) and Bet v
1. A positive control of CD3/CD28 (5 pg/ml/2.5 pg/ml) was also included in the
study but results are not shown. Proliferation was measured at 90 hours after pulsing
with thymidine at 72 hours.
Mean +/- SE is shown.
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Figure 5.20 - Intranasal administration of chitosan and peptide after prior
systemic sensitisation to Der p 1.
IL-5 levels in splenocyte and tracheal lymph node culture supernatants.
The legend describes the intranasal treatment administered to the mice. Single cell
suspensions were prepared from pooled tracheal lymph nodes and individual spleens
(results pooled), which were then cultured (5 x 105/well) with media alone or media
supplemented with 10 pg/ml Der pi, p( 111-139), p(111-119), p( 111-137) and
Bet v 1. Supernatants were removed at 72 hours and frozen at -20°C until analysis by
ELISA.
Mean +/- SE is shown.
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Figure 5.21 - Intranasal administration of chitosan and peptide after prior
systemic sensitisation to Der p 1.
Der p 1-specific levels of IgGl, IgG2a and IgE in sera.
The presence of antibodies was detected by ELISA.
Individual mice are represented by diamonds. Mean values are represented by bars.
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Fig. 5.22 - Intranasal administration of chitosan and peptide after prior
systemic sensitisation to Der p 1.
Eosinophil infiltration into lungs.
Each diamond represents an individual mouse. The bars show the mean value for
each group.
The lower table shows the decrease in eosinophil production by the other groups of
mice in relation to saline controls.
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5.5 Discussion
The primary aim of this study was to establish whether chitosan could
prevent the induction of and/or reverse allergic inflammation; and secondly, if so,
whether the induction of tolerance or Thl immunity was the underlying mechanism.
An important factor in tolerance induction is the affinity of interactions between the
TCRs and their ligands which consequently affects the response generated [538-540].
As discussed in the main introduction to this thesis, in vitro studies have shown that
high affinity TCR-MHC class II peptide interactions prime Thl responses whereas
low avidity interactions prime Th2 responses [57], Effector T cell responses are also
differentially influenced when mice are immunised with altered peptide ligands [47].
Therefore, the selective priming of Th2 responses to inhalant allergens by pulmonary
DCs [541] may be partly attributable to low levels of antigen exposure and
consequently lower affinity TCR-MHC class II-peptide interactions. A number of
studies suggest that chitosan can be used to enhance immunological responses at the
nasal mucosa [529-531], Thus, the intranasal administration of an immunodominant
peptide ofDer pi- Der p 1 ;pl 11-139 adsorbed to chitosan was thought to increase
the uptake of antigen across the mucosa and thus increase the affinity of the TCR-
MHC class II interactions promoting tolerance induction or the priming ofThl
responses.
A previous study by Hoyne et al showed that intranasal administration ofDer
p l;pl 11-139 peptide protected against Thl mediated DTH responses [501],
however, we have consistently failed to induce Th2 cell tolerance to Der p 1 by the
intranasal administration of this peptide. In addition, Ebner et al found that
administration of increasing doses of Phi p 1 (a major allergen of timothy grass)
induced tolerance to the allergen associated with a shift in the cytokine profile of
allergen reactive T cells from a Th2 to a Thl like response [542]. In this study we
found that the intranasal administration ofDer pl;pl 11-139 peptide absorbed to
chitosan, lead to the hyperresponsiveness ofCD4+ lymphocytes at day 2, as a result
of in vitro restimulation with Der p l;pl 11-139 peptide (figure 5.2). Enhanced
proliferation and increases in IFN-y relative to IL-5 in the chitosan/peptide mice was
observed (figures 5.3-5.6), compared with T cells isolated from peptide treated mice.
This trend is observed in desensitization therapy which involves the administration of
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increasing doses of allergen to allergic patients, ie. there is a shift in the cytokine
profile of allergen reactive T cells from a Th2 to a Thl like response and in the
induction ofT cell tolerance [165, 166, 318, and 542], The transient increase in IFN-
y production by hyperreactive T cells was also observed in the chitosan/peptide mice
that were subsequently rechallenged via the airways with Der pi allergen. The
increase in IFN-y has been shown to play a protective role in the initial induction of
tolerance in nai've animals to inhalant antigen [146] [543].
Verhoef et al showed that the use of an altered TCR ligand derived from the
immunodominant T cell epitope of a group 2 allergen of house dust mite, lead to
elevated IFN-y levels compared to the native peptide under activating conditions but
under tolerising conditions, lead to the induction of T cell anergy and lower IL-10
production than the native peptide [544], It is conceivable that subtle changes in the
structure of the Der p 1 peptide, introduced by absorption to chitosan, may alter the
affinity of the peptide/MHC class interactions with the TCR.
To establish whether intranasal administration of peptide containing the
immunodominant T cell epitope of Der p 1 adsorbed to chitosan, protected against
subsequent induction of airway inflammatory responses, eosinophilia was measured
in the lungs and BAL fluid, following allergen provocation of the airways. Both
assays showed similar results with all groups ofmice exhibiting similar levels of
eosinophilia in the lungs as well as the BAL fluid (figure 5.16). This may be
explained by the higher ratio of IL-5:IL-10 in the tracheal lymph node cells of each
group ofmice (table 5.1c, page 206). As discussed earlier, IL-5 is directly
responsible for recruitment of eosinophil progenitor cells from the bone marrow,
their differentiation, maturation and survival in the airways [229, 545]. IL-13 is also
an important cytokine in the pathogenesis of asthma. When IL-13 production was
blocked in OVA-sensitised mice by the administration of a soluble IL-13a2-IgGFc
fusion protein, there was a complete reversal of allergen-induced AHR [201], In
addition, mice with a targeted deletion of IL-13 failed to develop allergen-induced
AHR, despite the presence of vigorous Th2-biased, eosinophilic pulmonary
inflammation [546]. Therefore, it is possible that the combined effects of IL-5 and
IL-13 have overridden the immunoregulatory effects of the IL-10.
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The investigation into the cytokine production by the Der p 1 specific T cells
in the spleen and the tracheal lymph nodes revealed the existence of a dichotomy.
Splenic production of IL-5, IL-13 and IFN-y was reduced in mice that had received
peptide adsorbed to chitosan (figures 5.10-5.12), indicating that protection against
allergen induced effector responses, was due to the induction of antigen specific T
cell tolerance and not a shift in cytokine production. In contrast, Der p 1 reactive T
cells from the tracheal lymph nodes draining the airways, did not show reduced
levels of IL-5 and IL-13 production (figure 5.14), nor was there an increase in levels
of IFN-y (figure 5.15). However, there was an antigen dependent increase in IL-10
production (figure 5.15) by cells isolated from the draining tracheal lymph nodes,
following allergen challenge. The fact that the production of IL-10 was antigen-
dependent, indicated that the Der p 1 reactive T cells were the principal source of this
immunoregulatory cytokine in the draining lymph nodes.
Previous studies have demonstrated that the intranasal administration of an
immunodominant epitope ofmyelin basic protein induced IL-10 production by
splenic T cells indicating that IL-10 producing regulatory T cells may also play a role
in the induction ofperipheral tolerance [509]. In addition, Stampfli and co-workers
demonstrated that administration of IL-10 into the lungs, using replication-deficient
adenovirus vectors in a murine model of airway hyperreactivity during the time of
mucosal sensitization, abrogated both the cellular and physiologic recall responses in
vivo. The prevention of airway eosinophilia by IL-10 was independent of IFN-yand
was associated with decreased production of IL-4, IL-5, andTNF-ct in the lungs
[547]. Thus, the evidence suggests that IL-10 is a critical regulatory molecule
involved in the prevention ofasthma.
It is possible to stimulate the generation ofT regulatory (Trl) cells in vitro by
stimulating CD4+ T cells with antigen in the presence of IL-10. These Trl cells
produce significant amounts of IL-10 as well as IFN-y, TGF-(3 and IL-5, but not IL-2
and IL-4 [512]. Also, when CD4+CD45RBlow Trl cells were co-transferred with
pathogenic CD4+CD45RBhlgh cells into SCID mice, there was protection against
inflammatory bowel disease, indicating that these cells were functionally active in
vivo [337, 512, 548]. Recently it has been demonstrated that in vitro generated Trl
cells can inhibit the priming of Th2 responses in vivo following transfer [514].
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Pulmonary DCs are thought to play a critical role in the induction of tolerance
to inhalant antigen and in the generation ofTrl cells. A recent study by Akbari et al
showed the migration of pulmonary DCs to the tracheal lymph nodes following
inhalation of antigen. The DCs expressed a mature phenotype and produced IL-10.
Furthermore, pulmonary DCs obtained from intranasal peptide treated wild type but
not IL-10 knock out mice, could adoptively transfer tolerance to naive mice and in
vitro, prime IL-10 and IL-4 producing CD4+ Trl cells [511].
Although a significant reduction in eosinophilia was not observed in
chitosan/peptide mice treated prior to systemic challenge with Der p 1 (figure 5.18),
there was a reduction in eosinophilia in mice that received chitosan/peptide after
systemic immunisation with Der p 1. This data suggests that these antigen specific
Trl cells may play an important role in maintaining tolerance through production of
IL-10 in lymph nodes draining the airways following antigen challenge.
In this study, an inhibition of antibody production following immunisation
with the intact Der p 1 antigen was not observed. Mice that received chitosan/peptide
showed no reduction in serum IgG levels and IgE production was actually increased.
A recent study by Hurst and colleagues found that the establishment of normal IgE
tolerance to inhaled OVA Ag could be subverted by strong local Th2 responses but
not Thl responses, to unrelated antigens or pathogens in the lung, and that this
prevention was largely the consequence of local IL-4 production immediately before
inhalation ofOVA [437]. An intranasal KLH challenge to mice sensitised with
KLH/alum before primary exposure to OVA by aerosolisation, resulted in the
sensitisation, not tolerance ofmice to OVA. Likewise, infection ofmice with
antigens such as Nippostrongylus brasiliensis or exposure to A. fumergatus extract,
both of which produce vigorous Th2 responses, prevented the establishment of IgE
tolerance to aerosolised OVA. Therefore, it may be possible that the mice in this
chitosan study have been exposed to some infectious agent or pathogen that has
enhanced the Th2 environment before the primary intranasal challenge with Der p 1
peptide. In addition, the increase in IgE production may have been due to the effect
of chitosan on IFN-y production, since IFN-y counterbalances the development of
Th2 responses and production of IL-4. The failure to inhibit antibody production, in
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spite of significant reductions in Der p 1 reactive T cell effector functions, may be
due to the emergence of T cells reactive with minor epitopes of Der p 1.
Finally, it seemed logical to examine the effects of peptide/chitosan treatment
on an established allergic response, as in the clinical situation subjects are already
sensitised to allergens. Peptide treatment alone greatly enhanced the established Th2
response which was most evident in the tracheal lymph nodes. However, when
peptide was co-administered with chitosan, proliferation and IL-5 production were at
levels comparable to the saline controls (figure 5.19). Although this is clearly not a
reduction in the allergic response below control levels, the comparison with the
peptide-treated mice is certainly intriguing. The eosinophil infiltration results suggest
that chitosan/peptide treatment may slightly alleviate lung inflammation but the
results were not statistically significant (figure 5.22).
As mentioned previously, the absorption of peptide to chitosan could alter its
structure thus affecting the affinity of binding to the TCR-MHC II complexes. Also,
the bioadhesive properties of chitosan coupled with its ability to form nanoparticles
complexes leading to better presentation of antigens to the immune cells of the
mucosal epithelial and the nasal associated lymphoid tissue (NALT) may promote
the induction of tolerance [536, 549].
To date, this is the first study investigating chitosan as a vehicle for peptide
delivery. Many questions remain to be answered but chitosan may have therapeutic




This thesis addresses a number of hypotheses. Firstly, we have shown that it
is possible to induce an allergen-specific Th2 response with accompanying lung
inflammation by challenging the airways with allergen after previous systemic
sensitisation. Traditionally, Th2 induction in mice has involved the use of alum
adjuvant to drive strong T and B cell-mediated responses, however, in this study, we
were able to induce allergen-specific responses of a similar magnitude without the
use of adjuvant, thus creating a more physiological system.
However, the main aim of this thesis was to investigate different approaches
for the modulation of Th2 immunity to the major house dust mite allergen Der p 1.
This was targeted in two ways: either by the induction of antigen-specific tolerance
or inhibiting the synthesis ofTh2 cytokine production by inducing Thl immunity.
The administration ofmicroencapsulated Der p 1 and the immunodominant
epitope Der p 1 ;p 111 -139 peptide was investigated. Microencapsulated Der p 1
failed to induce tolerance or a shift in cytokine production to that of the Thl/ThO
phenotype. However, the intranasal administration of microencapsulated Der p
l;pl 11-139 suppressed both systemic and local inflammatory responses to intact Der
p 1. This was shown by a reduction in IL-4, IL-5 and IL-13 accompanied with a
reduction in eosinophilia. The exact mechanism of Th2 suppression was not
determined although it was hypothesised that IL-10 played a part. However, further
studies would need to be undertaken in order to determine whether IL-10 played a
critical role in suppressing Th2 responses.
Furthermore, we showed that IL-10 played a critical role in suppressing Th2
responses, including production of the cytokines IL-4, IL-5 and IL-13 which are
associated with the pathology of asthma.
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The effects of administering Der p 1 ;pl 11 -139 peptide with chitosan, an
enhancer of epithelial permeability was also investigated. By using a murine model
of pulmonary allergic inflammation, we demonstrated that the mucosal delivery of
Der p 1 ;pl 11-139 could protect against the induction of Th2-mediated airway
inflammation and eosinophilia, in mice challenged with whole Der p 1 allergen. The
suppression of airway inflammation by intranasal administration of peptide antigen
was found to be initiated by T cell hyperactivation and maintained by the production
of IL-10 antigen-specific T cells in the draining lymph nodes.
In conclusion, we have described two possible methods of regulating the
immune response in a murine model of allergic disease. Further work needs to be
undertaken to elucidate the exact mechanisms involved in this immunoregulation but
these studies provide exciting new evidence of possible immune therapies that may
be utilised in the future.
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Kinetics and mode of peptide delivery
via the respiratory mucosa determine the
outcome of activation versus TH2
immunity in allergic inflammation of the
airways
Gillian Hall, BSc,a Lise Lund, PhD,b Jonathan R. Lamb, PhD,a and
Elizabeth R. Jarman, PhDa t> Edinburgh, United Kingdom, and H0rsholm, Denmark
Background: Specific immunotherapy involving systemic
injection of allergen, though highly effective, can cause severe
side effects due to IgE-mediated activation of effector cells.
Allergen-derived peptides might provide a safer alternative.
We have investigated the use of mucosally delivered peptide to
induce CD4+ TH2 cell tolerance and thus protect against aller¬
gen-induced airway inflammation.
Objective: The purpose of this study was to investigate
whether intranasal administration of an allergen-derived pep¬
tide, either alone or adsorbed to chitosan, can prevent the
induction of TH2-mediated pulmonary inflammation after sen¬
sitization and challenge of the airways with allergen.
Methods: Mice were given (intranasally) a peptide containing
an immunodominant epitope of the Dermatophagoides
pteronyssinus (Der p) 1 allergen, either as soluble antigen or
adsorbed to chitosan, before sensitization and allergen chal¬
lenge. Pulmonary inflammation, antigen-specific (1)4' T-cell
responses, and antibody levels in sera were then determined.
Results: Mice given peptide adsorbed to chitosan had signifi¬
cant reductions in airway eosinophilia, which correlated with
reduced levels of IL-4 and IL-5 in the bronchoalveolar lavage
fluid. There was decreased recruitment of activated CD4+ T
cells into the airways after allergen challenge, which correlated
with a loss of Der p 1-specific T-cell cytokine responses in the
periphery and the localized production of IL-10 by antigen-
specific T cells in bronchial lymph nodes. Induction of periph¬
eral T-cell tolerance was preceded by transient T-cell activation
and IFN-y production.
Conclusion: Our data demonstrate that suppression of airway
inflammation by intranasal administration of peptide antigen
adsorbed to chitosan is initiated by transient T-cell activation
and maintained by the production of IL-10 by antigen-specific
T cells in the draining lymph nodes. (J Allergy Clin Immunol
2002;110:883-90.)
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Allergic asthma is characterized by elevated serum
IgE levels, airway hyperresponsiveness, and bronchial
inflammation after exposure of the airways to inhaled
allergens. CD4+ TH2 cells expressing an activated mem¬
ory phenotype and the cytokines IL-4, IL-5, IL-9, and IL-
13 have been isolated from the bronchoalveolar lavage
fluid (BALF) of acute allergic asthmatic individuals and
are associated with the disease pathology.1'2
The type of effector T-cell response generated in vivo
is determined by antigen concentration, route of delivery,
and the presence of inflammatory signals, which influ¬
ence antigen-presenting cell (APC) activation, upregula-
tion of costimulatory molecules, and cytokine produc¬
tion. Inflammatory signals are required for maturation of
dendritic cells (DCs) in the airway mucosa, upregulation
of MHC class II proteins, the costimulatory molecules
(CD80 and CD86), and chemokine receptor CCR7,
which is critical for migration of DCs to the draining
lymph nodes.3'4 The interaction between APCs and
CD4+ T cells during antigen presentation and the
cytokine milieu influence the primary response generat¬
ed.5 CD4+ T-cell activation involves ligation of the spe¬
cific T-cell receptor (TCR) by MHC class II peptide com¬
plexes. In the absence of APC-derived costimulatory
signals, TCR ligation leads to functional inactivation and
ancrgy.6 As in activation, a critical threshold level of sig¬
naling needs to be reached for induction of T-cell toler¬
ance, which is preceded by and critically dependent on
an initial state of transient activation, upregulation of
TCR and CD69 expression, and increased proliferative
and cytokine responses, after antigen-specific TCR liga¬
tion.7 Peripheral T-cell tolerance can be induced by the
mucosal delivery of soluble antigen.8 Studies in animal
models have demonstrated that intranasal administration
of allergens to the upper respiratory tract before par¬
enteral immunization can suppress the induction of
peripheral allergen-specific lymphoproliferative T-cell
responses and IgE production.911 The effect on T
cell-mediated inflammatory responses of the lower air¬
ways requires further investigation. Clinical studies have
demonstrated that subcutaneous immunotherapy using
peptides can induce peripheral T-cell tolerance with










BALF: Bronchoalveolar lavage fluid
DC: Dendritic cell
Der p 1: Group 1 allergen derived from Dermatophagoides
pteronyssinus species
pDC: Pulmonary dendritic cell
TCR: T-cell receptor
not asthmatic, reactions.12 In this study, we investigated
whether intranasal administration of a peptide encoding
an immunodominant T-cell epitope of Der p 1,13 a major
aeroallergen of house dust mite, can suppress induction
of CD4+ T-cell responses and airway eosinophilia after
allergen challenge in a murine model of pulmonary
inflammation.
Peptide absorption across the nasal mucosa occurs
principally by passive diffusion across intercellular barri¬
ers formed by tight junctions. To reach a critical TCR
activation threshold for tolerance induction, we adminis¬
tered Der p 1; pi 11-139, the immunodominant T-cell epi¬
tope of Der p 1, as a soluble peptide adsorbed to chitosan.
Chitosan is a nontoxic, biocompatible, and biodegrad¬
able mucopolysaccharide that enhances the level of
absorption of compounds delivered via the nasal
mucosa.I4d5 This is due in part to the bioadhesive prop¬
erties of chitosan but is also due to the transient opening
of the tight junctions between epithelial cells, which
form a barrier to the external environment. Because this
increase in absorption occurs in the absence of tissue
damage or inflammation, the delivery of peptide
adsorbed to chitosan could facilitate tolerance induction
by increasing the level of peptide released systemically.16
METHODS
Animals
C57BL/6 mice, 6 to 8 weeks of age, were used. Animals were
purchased from Harlan. Animal care and experimental procedures
were conducted in accord with the animal ethics regulations of the
Home Office in the United Kingdom.
Antigens
The house dust mite allergen Der p 1 was affinity-purified from
spent mite medium through use of the monoclonal antibody 4C1
(Indoor Biotechnologies Ltd). The synthetic peptide Der p 1 pi 11-
139 (FGISNYCQIYPPNANKIRELAQPQRYCR) was synthesized
with a free carboxyl terminus and HPLC-purified (Advanced
Biotechnology Centre, Imperial College School ofMedicine, Char¬
ing Cross Hospital, London). The chitosan-Der p 1 pi 11-139 pep¬
tide solution was made up as follows: 2% chitosan in acetic acid
(0.5% w/v; Vanson Inc) was dissolved by sonication, diluted further
in d H20 (0.4% w/v), and filter-sterilized. The chitosan was used at
a final concentration of 0.25% w/v adsorbed to a minimum of 5
mg/mL peptide.
Immunization and tolerance induction
The following optimized treatment regimes were used: Mice
were lightly anesthetized under ether, and groups of mice were
treated by the intranasal administration, on each of 5 consecutive
days, of a 20-pL volume of endotoxin-free saline solution contain¬
ing 100 pg of either Der p 1 pi 11-139 peptide or chitosan adsorbed
to Der p 1 pi 11-139 peptide. The control groups received either
saline solution or chitosan alone. Mice were immunized 14 and 16
days after the last intranasal treatment by the intraperitoneal injec¬
tion of Der p 1 (10 pg) in saline solution absorbed to an equal vol¬
ume of aluminum hydroxide adjuvant (Imject Alum; Pierce). On
days 41 and 43, mice were challenged by intratracheal instillation
of Der p 1 (20 pg) into the airways in 50 pL saline solution and
killed after 24 hours by means of a lethal dose of Avertin. To deter¬
mine antibody levels in sera, mice were bled from the tail vein
before being killed. Blood samples were centrifuged at 2000g; sera
were collected and stored at -70°C. For the mechanistic studies,
mice were treated intranasally for 3 consecutive days with saline
solution, peptide, or peptide adsorbed to chitosan; after either 48 or
96 hours, the mice were killed and their cervical lymph nodes were
removed.
T-cell proliferative responses
We prepared single-cell suspensions from the spleen or lymph
nodes by teasing the tissue apart and passing it through a fine wire
mesh to remove cell debris after red blood cell lysis. Whole cell
populations were cultured in RPMI 1640 medium (Gibco) supple¬
mented with 5% FCS, 50 |imol/L 2-mercaptoethanol, 2 mmol/L
L-glutamine, and 10 U penicillin/streptomycin (Gibco). To mea¬
sure specific T-cell proliferative responses, cells (1 x 105/well)
were cultured in round-bottomed, 96-well microtiter plates
(Costar, Corning Incorporated) in medium with Der p 1 pi 11 -139
peptide (5, 20 |ig/mL) or Der p 1 (10 jig/mL). To control for T-cell
viability, cells were polyclonally stimulated by being cultured in
wells containing immobilized anti-CD3 (145-2C11) and anti-
CD28 (37.51; 5 pg/mL). After 72 hours, cells were pulsed with
3H-thymidine (1 pCi/well) and the levels were incorporated after
a further 16 hours of culture, as determined by liquid scintillation
counting.
Cytokine production
Single-cell suspensions prepared from spleen or lymph nodes
were cultured (5 x 106/mL) in complete media containing eitherDer
p 1 or Der p 1 pi 11-139 peptide (10 pg/mL). Control wells con¬
tained (a) medium alone or (b) an irrelevant antigen;OVA (10
pg/mL), or wells were coated with anti-CD3 and anti-CD28 (5
pg/mL) antibodies. After 72 hours supematants were collected; they
were stored at -70°C and later assayed in duplicate for the presence
of the cytokines IL-4, IL-5, IL-10, IL-13, and IFN-y through use of
ELISA. Antibodies were purchased and used according to the
instructions of the manufacturer (IL-4, IL-10, and IL-13, R& D Sys¬
tems; IL-5 and IFN-y, Pharmingen).
Measurement of eosinophil and cytokine
levels in BALF
Immediately after sacrifice, the trachea were exposed and can-
nulated with 27-gauge silicon tubing attached to a needle and
syringe. The lungs were instilled through the trachea with 500 pL
cold PBS, and the BALF was withdrawn. The volume of BALF col¬
lected was measured for each sample. To determine BALF cell
numbers and composition, samples were centrifuged (700g, 5 min¬
utes, 4°C) and cells were washed (PBS/10% FCS), counted, and
resuspended at 1 X 106/mL. BALF (1 X 105) cells in 100 pL were
cytospun onto poly(L-lysine)-coated slides (3 minutes at 300 rpm
by means of a cytocentrifuge). The slides were air-dried, fixed in
methanol, and stained through use of Diff-Quik (Dade-Behring). To
determine cytokine levels in BALF, samples were stored at -70°C.
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Determination of Der p 1-specific antibody
levels in sera
Antibody levels in sera were determined through use of ELISA.
Unless otherwise indicated, serum samples and antibodies were
diluted in PBS/1% BSA and wells were washed between incubation
steps with PBS/0.05% Tween-20. Round-bottomed, 96-well
microtiter plates (Costar) were coated overnight at 4°C either with
rat antimouse IgE (R35-72; Pharmingen) for detection of specific
IgE levels or with Der p 1 (5 pg/mL) diluted in carbonate buffer (0.1
mmol/L NaHC03, pH 8.2) for detection of specific IgGl and
IgG2a. After washing, nonspecific binding was blocked by incubat¬
ing with PBS/3% BSA for 2 hours at 37°C. Plates were washed, and
serial dilutions of serum samples were added in duplicates (IgE,
1:5, 1:10, and 1:20; IgGl, 1:50, 1:100, and 1:500; IgG2a, 1:10,
1:20, and 1:50). The plates were incubated overnight at 4°C. After
washing, biotinylated rat antimouse IgGl (LO-MG1-2; Serotec) or
rat antimouse IgG2a (Lo-MG2a-7; Serotec) was added at 1000
ng/mL; plates were then incubated for 2 hours at room temperature.
To determine Der p 1-specific IgE levels in sera, Der p 1 (10
pg/mL) was added and plates were incubated at 37°C for 60 min¬
utes. After washing, plates were incubated for an additional 45 min¬
utes with biotinylated anti-Der p 1 mAb 4C1 (1:1000 dilution).
Bound biotinylated antibodies were detected by being incubated
with streptavidin-peroxidase for 45 minutes at room temperature
and visualized through use of the TMB substrate. Plates were read
in a microtiter reader at 450 nm through use of the MRX microplate
reader (Dynatech) and Revelation software.
Statistical analysis
The data represent mean values ± SEMs. There were 5 mice in
each group. Differences between mean values were analyzed by 1-
way ANOVA through use of either the Dunnett multiple comparison
parametric test or the 2-tailed Student t test (antibody levels) with
InStat (GraphPad Software). P values less than or equal to .05 were
considered statistically significant.
RESULTS
Cytokine production by allergen-reactiveT
cells isolated from mice treated
prophylactically by intranasal administration
of peptide before sensitization and challenge
with allergen
We investigated whether intranasal administration of
peptide leads to the induction of tolerance and a loss of
cytokine production or aTHl/TH0 shift in the phenotype
of the effector T-cell populations. For this purpose, cells
isolated from the spleens (Fig 1, A) or lymph nodes
draining the airways (Fig 1, B) of Der p 1-sensitized and
-challenged mice were restimulated in vitro with Der p
1; levels of IL-5, IL-13, IL-10, and IFN-y in culture
supernatants were then determined through use of
ELISA. Investigation of systemic responses revealed
reductions in both TH2 (IL-5 [65%] and IL-13 [62%])
and Th1 (IFN-y [75%]) cytokines in peptide-
chitosan-treated mice compared with control mice, sug¬
gesting that Der pl-reactive T cells in the spleen were
tolerized (Fig 1, A). Systemic cytokine responses were
not suppressed in mice treated with peptide alone. Fur¬
thermore, these mice exhibited marked increases in lev¬
els of the Th2 cytokines IL-5 (3-fold) and IL-13 (7-fold)
on stimulation of cells obtained from draining lymph
nodes with Der p 1. The differential effect of peptide and
peptide adsorbed to chitosan on recall responses in
lymph node cultures suggest that the kinetics of mucosal
delivery might influence the extent to which naive T cells
are primed at sites of antigen exposure.
There is increasing evidence that tolerance induced
by mucosal administration of soluble antigen is main¬
tained by antigen-specific T regulatory cells through the
production of immunosuppressive cytokines. Increases
in IL-10 production in lymph node cultures were
observed on restimulation with Der p 1 in mice treated
with peptide (70%) or peptide adsorbed to chitosan
(51%) compared with control mice. IL-10 production
was antigen-dependent. Nevertheless, reductions in
TH2-mediated eosinophilia on rechallenge with antigen
were associated with increases in the ratio of IL-10 to
IL-5 produced (Fig 1, Q rather than with increases in
IL-10 alone or increases in the ratio of IFN-y to IL-5
(data not shown), suggesting that in the context of a
TH2-driven response, mechanisms influencing the initial
state of T-cell tolerance induction might play a role in
maintaining a state of antigen-specific nonresponsive-
ness. IL-10 levels produced by cells isolated from the
spleen did not differ markedly between groups, suggest¬
ing that IL-10 might play a greater role in maintaining
tolerance at sites of T-cell priming.
Effect of intranasal peptide treatment on
antigen-specific immunoglobulin levels
induced after systemic immunization
Because the induction of IgE and IgGl synthesis by B
cells requires a cognate interaction with antigen-specific
CD4+ Th2 cells, we investigated whether the tolerization
of T cells reactive with an immunodominant region of
Der p 1 by intranasal administration of Der p 1; pi 11-139
peptide was sufficient to inhibit antibody production
after immunization with the intact Der p 1 allergen. Mice
given peptide intranasally showed minor reductions in
Der p 1-reactive IgGl and IgG2a levels in sera compared
with control mice given PBS. IgE levels, however, were
not reduced (Fig 2). Mice given peptide-chitosan showed
no reductions in serum IgG levels, though IgE produc¬
tion was increased (P < .05). Comparable increases in
IgE production were observed in mice given chitosan
alone. These increases might reflect the inhibitory effect
of chitosan on IFN-y production (Fig 1, A and B) and
consequently an upregulation of IL-4-dependent
humoral responses. This suggests that chitosan might not
be the most appropriate vehicle for allergen therapy.
Effect of intranasal peptide administration
on eosinophil levels in Der p 1 allergen-
challenged airways
The infiltration of eosinophils into the airways after
allergen challenge is a major pathologic feature of aller¬
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FIG 1. The induction of peripheral T-cell tolerance by the mucosal exposure to antigen is associated with a
reduction in both TH1 and TH2 responses but also with an increase in IL-10 production. Mice tolerized by the
intranasal instillation of peptide alone or peptide adsorbed to chitosan were sensitized and challenged with
Der p 1. After 24 hours, cells isolated from spleen (A) or pooled bronchial lymph nodes (B) were restimu-
lated in vitro with Der p 1 (10 pg/mL); supernatants were collected after 72 hours, and the cytokines IL-5, IL-
13, IL-10, and IFN-ywere measured by ELISA. Results are expressed for each group of mice as mean ± SEM
(n = 5; Fig 1, A), as pooled data (Fig 1, B), or as a ratio of IL-10 to IL-5 production (C).
of peptide was sufficient to suppress TH2-mediated air¬
way inflammatory responses to allergen challenge, we
assessed the extent of eosinophil infiltration into the
BALF. For this purpose, the lungs of Der p 1-challenged
mice were lavaged 24 hours after antigen exposure.
There was a significant (P < .05) reduction of 94% in the
extent of eosinophil recruitment into the lungs of mice
pretreated intranasally with Der p 1 ;pl 11-139 peptide
adsorbed to chitosan compared to the control mice treat¬
ed with saline solution. No reductions in eosinophil
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The effect of intranasal peptide treatment on
suppression ofTH2 activation and cytokine
production in the airways
The Th2 cytokines IL-4 and IL-5 are associated with
eosinophil recruitment and survival in the lungs of
allergic asthmatic individuals. We determined whether
the loss of eosinophil recruitment was a direct effect of
the reduction in levels of these cytokines in the lungs of
tolerized mice after allergen challenge. Groups of mice
receiving chitosan-adsorbed Der p 1 ;pl 11-139 peptide
intranasally before systemic immunization showed sig¬
nificant reductions in BALF levels of 73% (P < .01) and
65% (P < .05) in IL-4 and IL-5, respectively, compared
with control mice treated with saline solution. There
was no reduction in IL-4 levels and there was a non¬
significant reduction of 48% in IL-5 levels in BALF
obtained from mice treated with peptide alone.
Intranasal administration of chitosan alone had no
effect (Fig 3, B and C). Eosinophils are also a source of
IL-5 in the airways. Reductions in the TH2 cell cytokine
IL-4. which initiates the influx of eosinophils into the
airways through upregulation of adhesion molecules on
endothelial cells, might more closely reflect changes in
eosinophil levels in BALF.
The induction of sustained T-cell tolerance is
preceded by transient activation marked by
an increase in the levels of IFN-y production
In several experimental models it has been reported
that antigen-specific T-cell activation precedes the induc¬
tion of peripheral tolerance. We investigated whether the
differential effects of intranasally administered soluble
peptide and peptide adsorbed to chitosan on the induc¬
tion of tolerance was due to a failure to prime naive T
cells or was instead due to differential effects on T-cell
effector function. For this purpose, cervical lymph nodes
draining the nasal cavity were removed either 48 or 96
hours after intranasal administration of peptide or pep-
tide-chitosan and cells stimulated with increasing doses
of Der p 1 pi 11-139 peptide. Peptide antigen-reactive T
cells isolated from mice treated with peptide or peptide-
chitosan were highly activated at 48 hours, showing
dose-dependent increases in proliferation on in vitro
stimulation with peptide. However, in mice given pep-
tide-chitosan, reactive T cells exhibited 2- to 3-fold
increases in IFN-y production on stimulation with
equimolar concentrations of peptide compared to pep-
tide-treated mice. This was consistent over a dose range
of peptide, indicating that it was not due to differences in
TCR activation thresholds. Furthermore, at lower con¬
centrations of peptide, IL-5 production was suppressed in
T cells isolated from peptide-chitosan-treated mice (Fig
4, A). By 96 hours, T cells obtained from all groups of
mice were nonresponsive to in vitro restimulation with
peptide; there was a loss in both proliferative and
cytokine responses (Fig 4, B). Chitosan itself failed to
activate T cells.
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FIG 2. The induction of peripheral T-cell tolerance by mucosal
peptide delivery has little effect on Der p 1 specific antibody lev¬
els in sera. Levels of Der p 1-specific IgE, lgG1, and lgG2a in sera
were determined through use of ELISA. Serial dilutions of sera
were set up in duplicate, and the results are presented as mean ±
SEM (n = 5) for each group of mice; significant differences
between treatment and control groups are indicated (*P< .05).
DISCUSSION
Here we have investigated, using a murine model of
pulmonary inflammation, whether the intranasal adminis¬
tration of Der p 1 ;pl 11-139, a peptide covering an
immunodominant T-cell epitope of Der p 1, could protect
against the induction of TH2-mediated airway inflamma¬
tory responses to the Der p 1 allergen. A previous study
demonstrated that intranasal administration of Der p 1
p 111-139 peptide protected against THl-mediated
delayed-type hypersensitivity responses.17 We demon¬
strate that peptide alone was insufficient to prevent induc¬
tion of TH2-mediated airway inflammatory responses
unless it was adsorbed to chitosan, a compound that
enhances uptake of antigen across the airway mucosa.
The induction of tolerance in the antigen-specific TH2
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FIG 3. Effect of mucosal delivery of peptide on eosinophil recruit¬
ment and cytokine levels in BALF 24 hours after final challenge of
the airways with Der p 1. Eosinophil levels in BALF were deter¬
mined by Diff-Quik staining, and each number was calculated as a
percentage of the total cell population per milliliter of BALF (A).
Levels of the TH2 cytokines IL-4 (B) and IL-5 (C) in BALF were mea¬
sured through use of quantitative ELISA. These data are presented
as means ± SEMs (n = 5) and significant differences between the
treatment and control groups are indicated (*P< .05; **P< .01).
population was preceded by transient increases in prolif¬
eration and IFN-y production with suppression of IL-5.
Changes in the rate and dose of antigen delivery might
affect the type of effector T-cell responses generated. The
use of peptide adsorbed to chitosan, a compound widely
used for controlled mucosal drug delivery,18 might influ¬
ence the kinetics of APC activation in the mucosa.5-19
Changes in the density and affinity of MHC peptide
complexes, the expression of costimulatory molecules
and cytokines produced by the APCs during T-cell prim¬
ing, differentially regulate the induction of TH1 and TH2
responses.20-21
In vitro studies have demonstrated that qualitative and
quantitative differences in antigen recognition might
affect the affinity of interactions between the TCRs and
their ligands and, consequently, the effector response gen¬
erated. High-affinity TCR-MHC class II peptide interac¬
tions prime TH1 responses, whereas low-affinity interac¬
tions prime TH2 responses.22 The selective priming of
Th2 responses to inhalant allergens by pulmonary DCs23
(pDCs) might therefore reflect not only differences in the
cytokine milieu in the airways but also the low levels of
antigen exposure and consequentially lower-affinity
TCR-MHC class II-peptide interactions. Desensitization
therapy, which involves the administration of increasing
doses of allergen to allergic patients, is associated with
both a shift in cytokine profile of allergen-reactive T cells
from a TH2-like to a THl-like response and a shift in the
induction of T-cell tolerance.24"26 The transient increase
in IFN-y levels produced by hyperactive T cells isolated
from peptide-chitosan-treated mice might be influential
in the initial phase of tolerance induction. IFN-y has been
shown to play a protective role in the initial phase of tol¬
erance induction in naive animals to inhalant antigen.27
Mice that were given (intranasally) peptide adsorbed
to chitosan exhibited a reduction in airway eosinophilia,
associated with a fall in levels of the TH2 cytokines IL-4
and IL-5 in BALF, which is suggestive of a loss of CD4+
effector T-cell recruitment and activation in the airways
on allergen challenge. This correlated with a loss of IL-
5, IL-13, and IFN-y produced systemically and an
increase in the ratio of IL-10 to IL-5 produced locally in
the bronchial lymph nodes, on recall with the Der p 1
allergen. This suggests that attenuation of airway
eosinophilia was a consequence of tolerance induction in
the Der p 1-reactive effector TH2 population rather than
a TH2/TH0 to Th1/Th0 shift in cytokines.
Eosinophils are principal effector cells in the patho¬
physiology of allergic asthma.28 The induction of airway
inflammatory responses and recruitment of eosinophils
into the airways after allergen exposure is largely initiat¬
ed by CD4+ Th2 cells through the production of IL-4 and
IL-5. Both mast cells and eosinophils are also respective
sources of these cytokines. The localized production of
IL-4 in the airways has been shown to enhance expression
of adhesion molecules such as VCAM-1 on endothelial
cells, leading to the recruitment of eosinophils along a
chemotactic gradient. IL-5 is a principal growth factor
and chemoattractant for eosinophils, stimulating recruit¬
ment of progenitor cells from the bone marrow and stim¬
ulating their differentiation, maturation, and survival in
the airways.29-30A loss of antigen-specific priming ofTH2
effector responses in the bronchial lymph nodes and a
reduction in IL-4 and IL-5 levels in the airways might
account for attenuation of airway eosinophilia.31
In some patients, successful immunotherapy is associ¬
ated with a shift in effector phenotype from a TH2/TH0 to
a Th1/Th0 cytokine response, which might be achieved
either by promoting TH1 cytokines or by tolerizing TH2
effector cells, both of which could shift the balance of
cytokines. Studies in patients receiving bee venom
J ALLERGY CLIN IMMUNOL
VOLUME 110, NUMBER 6
Hall et al 889








Chitosan Per p 1; p111-139
20 >igAnl
Th2: L-5 -O- Chitosan
-V-Darpl; pi 11-139



















Per p1; pi 11-139 (jigSmf)
FIG 4. T-cell tolerance induced by mucosal delivery of antigen is preceded by transient activation. Groups
of mice that were given (intranasally) peptide, peptide adsorbed to chitosan, or chitosan for 3 consecutive
days were killed after 48 (A) or 96 (B) hours. Cervical lymph nodes were removed and cells were cultured
in media or with Der p 1; p111-139 peptide (at 5 or 20 pg/mL); proliferation was determined as 3H TdR incor¬
poration after 72 hours. Culture supernatants were assayed for IL-5 and IFN-y. These data are expressed as
means ± SEMs (n = 5) for each treatment group.
immunotherapy demonstrate that suppression of antigen-
specific T-cell proliferation and cytokine production is
associated with T-cell anergy induction. Antigen-specific
proliferation and TH1 (IFN-y) cytokine synthesis, but not
Th2 (IL-4, IL-5, IL-13) cytokine synthesis, could be
restored by exogenous IL-2 and IL-15.26 T-cell anergy
was associated with increased levels of IL-10 production,
primarily by antigen-specific CD4+CD25+ T cells in the
periphery and subsequently by B cells and monocytes.32
IL-10 is an immunoregulatory cytokine that has been
implicated in the reversal of TH2-mediated pathology,
inhibiting both expansion and cytokine production by
effector TH2 cells and the recruitment of eosinophils into
the airways. A potential role for IL-10 in mucosal toler¬
ance induction was first suggested by studies that demon¬
strated an increase in IL-10 produced by antigen-specific
T cells after the intranasal administration of an immu¬
nodominant epitope of myelin basic protein.33 However,
until now a role for IL-10-producing T regulatory cells in
the induction and maintenance of peripheral tolerance to
inhalant aeroallergen had not been shown. The
immunoregulatory cytokine IL-10, produced by pDCs
after exposure of the airways to soluble antigen, might
play a role in downregulating airway inflammatory
responses. Production of IL-10, in conjunction with the
expression of a mature phenotype by pDCs on migration
to the bronchial lymph nodes where antigen is presented
to naive T cells, might be instrumental in the induction
and maintenance of tolerance to environmental antigens
encountered in the respiratory mucosa. pDCs obtained
after mucosal exposure to soluble antigen from wild-type
mice, but not from IL-10 knockout mice, were shown to
adoptively transfer tolerance to naive mice and, in vitro,
to prime IL-10-producing CD4+ Trl cells.34 IL-10 is now
recognized as a growth factor for a population of
CD4+CD25+ Trl cells,35 originally identified in the thy¬
mus, and is now thought to play a critical role in main¬
taining peripheral tolerance.36 There is considerable evi¬
dence that pDCs play a critical role in the induction of
tolerance to inhalant antigen and in the generation of Trl






cells. Our data suggest that these antigen-specific Trl
cells might play an important role in maintaining toler¬
ance through production of IL-10 in lymph nodes drain¬
ing the airways after antigen challenge. IL-10 induces a
tolerogenic phenotype in DCs, which correlated with a
failure to undergo maturation and upregulation of the co-
stimulatory molecules CD80, CD86, and CD40.37 The
production of IL-10 might therefore account for the
observed bystander suppression with a loss of responses
not only to the Der p 1 ;pl 11-139 epitope but also to minor
T-cell epitopes within Der p 1.
In conclusion, we demonstrate that the mode of pep¬
tide delivery to the airway mucosa might be fundamental
to the induction of sustained TH2 tolerance to inhalant
allergen and reductions in airway eosinophilia. The
increase in IFN y production and suppression of IL-5
during the initial activation phase and the production of
IL-10 in the bronchial lymph nodes following antigen
exposure might be instrumental in maintaining a tolero¬
genic state. Within the limitations of the model system
used, these studies give some indication of parameters
that might be of importance in designing immunothera-
peutic approaches for allergy.
We thank Dr Henrik Jacobi for helpful discussions and critical
reading of the manuscript of this article.
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Abstract
The potential to induce systemic tolerance following exposure of the airway mucosa to soluble antigen, may be applied therapeutically
for the treatment of allergic disease. Since the use of allergen can trigger IgE mediated inflammation, we investigated whether mucosal
delivery of a peptide, containing an immunodominant epitope of the Der pi allergen of house dust mite, can lead to CD4+ Th2 cell
tolerance and thus protect against airway inflammatory responses to inhalant allergen. The administration of microencapsulated peptide
to the nasal mucosa ofmice, protected against airway inflammation, with significant reductions in eosinophil infiltration into the airways
following allergen challenge. Der pi specific antibody levels in sera were not modulated. Allergen reactive CD4+ T cells expressed a
tolerized phenotype, with reduction in levels of the cytokines, IL-5, IL-13 and IFN-y although IL-10 levels were increased. The mucosal
administration of a peptide containing an immunodominant region of an allergen can protect against the induction of systemic and local
inflammatory responses to allergen challenge.
© 2002 Published by Elsevier Science Ltd.
Keywords: Allergy; In vivo animal models; Microencapsulated antigen; Immunoregulation
1. Introduction
Allergic asthma is a disease characterized by elevated
serum IgE levels and the development of chronic bronchial
inflammation, airway hyper-responsiveness and mucus hy¬
persecretion. CD4+ T cells expressing the Th2 cytokines
IL-4, IL-5, IL-9 and IL-13 have been identified in the
airways of asthmatics [1], These cytokines are primarily
responsible for the disease pathology, which is caused by
Abbreviations: AHR: airway hyper-responsiveness; BAL (F): bron-
choalveolar lavage (fluids); LN: lymph node; Der pi: Dermatophagoides
pteronyssius spp.; EPO: eosinophil peroxidase; i.n.: intranasal (ly); PAMP:
pathogen associated molecular patterns; SIT: specific immunotherapy
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ALK-Abello A/S, Boege Aue 6-8, DK-2970 Horsholm, Denmark.
Tel.: +45-4574-7793; fax: +45-4574-8642.
E-mail addresses: eja@dk.alk-abello.com, eja@dk.alk.abello.com
(E.R. Jarman).
the influx of mast cells and eosinophils into the airways
following exposure to environmental allergens [2].
Specific immunotherapy (SIT), which involves the injec¬
tion of increasing doses of allergen, can lead to a reduc¬
tion in clinical symptoms and prevent disease progression.
However, the inherent risk of inducing potentially lethal
anaphylactic reactions has limited the use of SIT in patients
with allergic inhalant asthma. Cross-linking of FceR on
effector cells by IgE-allergen complexes causes the release
of preformed mediators responsible for acute immediate
inflammatory responses. This has lead to an interest in
identifying alternative approaches towards immunotherapy.
Successful therapy is associated with increasing levels of
IgG4 blocking antibodies and reductions in numbers ofmast
cells and eosinophils at sites of inflammation [3,4], The un¬
derlying mechanism leading to desensitization is less clearly
understood. Recent studies demonstrating augmented levels
in IL-10 production, suggest a role for immune regulation
and tolerance, rather than the induction of Thl cytokines.
0264-410X/02/S - see front matter © 2002 Published by Elsevier Science Ltd.
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Peripheral tolerance would account for reductions in antigen
specific lympho-proliferative responses and IL-4 production.
This may result in a subsequent shift in the cytokine milieu
with a relative increase in levels of the Th 1 cytokines, lead¬
ing to further reductions in Th2 mediated responses [5-7].
In an effort to enhance the efficacy of therapy, studies
have attempted to address the use of different routes of al¬
lergen administration, which influence the immune response
generated. Studies on autoimmune disease have demon¬
strated that the mucosal administration of antigen via either
the oral or intranasal route, in the absence of inflammatory
signals, can protect against disease induction or exacerba¬
tion following parenteral challenge with antigen [8,9], The
mechanisms underlying mucosal tolerance in Thl disease
models differ depending on the route of administration.
Whereas, oral delivery leads to the induction of a regulatory
population of Th3 cells secreting TGF-y and IL-4, admin¬
istration of antigen via the intranasal mucosa is thought to
lead to the induction of a regulatory Trl population, which
produce IL-10. Clinical studies are currently addressing the
efficacy of sublingual (oral) immunotherapy in the treat¬
ment of allergies [10]. However, little is understood about
the effect of localized intranasal administration of allergen
on targeting airway inflammatory responses. In most indi¬
viduals, soluble proteins delivered to the nasal mucosa do
not invoke an immune response, but induce a state of tol¬
erance. This phenomena has been demonstrated by earlier
studies which demonstrated that exposure of naive mice to
aerosolized allergen protects against induction of asthma
[11]. Studies using murine models of asthma have shown
that the prophylactic intranasal administration of a recom¬
binant allergen of birch pollen or long peptides covering the
major allergen of bee venom, prior to parenteral immuniza¬
tion with allergen, suppressed systemic Th2 responses and
IgE production [12,13]. These studies did not investigate
airway inflammatory responses, which may be exacerbated
following cross-linking of effector cell bound IgE by al¬
lergens, and release of inflammatory mediators. To reduce
the risk of eliciting IgE mediated inflammatory responses,
clinical studies have addressed the use of peptides in ther¬
apy. While clinical studies have demonstrated success in the
use of this approach, the induction of late phase asthmatic
responses in a proportion of patients following intradermal
injection of peptides is a concern [14-16],
To understand the mechanism underlying mucosal toler¬
ance, we have investigated whether Th2 mediated airway
inflammation can be modulated by the intranasal adminis¬
tration of peptides. We demonstrate, using a murine model
of pulmonary allergic inflammation, that the mucosal deliv¬
ery of an immunodominant peptide of Der pi, can protect
against the induction of Th2 mediated airway inflammation
and eosinophilia, in mice challenged with the whole Der pi
allergen. Furthermore, we show that IL-10 plays a critical
role in suppressing Th2 responses, including production of
the cytokines IL-4, IL-5 and IL-13, which are associated
with the pathology of asthma.
2. Materials and methods
2.1. Animals
C57BL/6 mice, 6-8 weeks of age, were used. Animals
were purchased from Harlan, UK. Animal care and exper¬
imental procedures were conduced in accordance with the
animal ethics regulations of the Home Office, UK.
2.2. Antigens
The house dust mite allergen Der pi was affinity purified
from spentmite medium using the monoclonal antibody 4C1
(INDOOR biotechnologies Ltd., UK) [17]. The synthetic
peptide Der pi; pi 11-139 (FGISNYCQIYPPNANKIRE-
LAQPQRYCR) were synthesized with a free carboxyl
terminus and HPLC purified (Advanced Biotechnology
Centre, Imperial College School of Medicine at Charing
Cross Hospital, London). MEA-pl 11-139 particles were
kindly provided by ALK-Abello (Horsholm, Denmark).
2.3. Immunization and tolerance induction
The following treatment regimes were used. Mice were
lightly anaesthetized under ether and treated by the in¬
tranasal (i.n.) administration, on five consecutive days, of a
20 p.1 volume of endotoxin free saline containing 100 p.g of
either peptide Derpl; pi 11-139, orMEA-Derpl; pi 11-139
particles (Fig. 1). The control groups received either saline
alone or empty MEA particles. In the prophylactic regime,
mice were immunized 14 and 16 days after the last i.n. treat¬
ment by the intraperitoneal injection of Der pi (10p.g) in
saline absorbed to an equal volume of aluminum hydroxide
adjuvant (Imject Alum; Pierce, Rockford, IL). On days 41
and 43, mice were challenged by intratracheal instillation
of Der pi (20 p,g) into the airways in 50 p.1 saline. For the
therapeutic regimen, mice were primed by a subcutaneous
injection, followed by seven intraperitoneal injections, at
2 day intervals of Der pi (10p.g in saline). Eight days
after the last injection, groups of mice were treated by the
intranasal administration of a 20 p.1 volume of endotoxin
free saline containing 100p,g of either peptide Der pi;
pi 11-139, MEA-Derpl; pi 11-139 particles, Derpl aller¬
gen, or MEA-Der pi (Fig. 1). The control groups received
either saline alone or empty MEA particles. After 2 weeks,
the airways were challenged three times, by instillation of
Der pi (20 p.g in 50 p.1 saline) at 2 day intervals. Mice were
sacrificed after 24 h, using a lethal dose of avertin. To de¬
termine antibody levels in sera, mice were bleed from the
tail vein prior to sacrifice. Blood samples were centrifuged
at 2000 x g, sera collected and stored at —70°C.
2.4. Cytokine production
Single-cell suspensions were prepared from spleen or
lymph nodes by teasing the tissue apart and passing it
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Fig. 1. (I) Prophylactic immunization regimen; groups of naive mice were treated intranasally on five consecutive days with 20 p,l saline containing
100pug Der pi; pi 11-139 peptide either alone, or encapsulated in MEA particles. Control mice received saline or MEA particles alone. On days 19 and
21, mice were immunized with Der pl/alum and after 20 days, challenged twice by instillation of 20|xg Der pi into the airways. After 24h mice were
sacrificed. (II) Therapeutic regimen; mice were sensitised as shown by multiple intraperitoneal injections with Der pi in saline. After 7 days, mice were
treated intranasally with either Der pi or the Der pi; pi 11-139 peptide either alone or encapsulated in MEA particles. Controls received MEA particles
or saline. Mice were then challenged by instillation of Der pi directly into the airways and sacrificed 24 h later.
through a fine wire mesh to remove cell debris. Cells were
cultured in RPMI 1640 medium supplemented with 5%
foetal calf serum (FCS; GIBCO), 50 |xM 2-mercaptoethanol,
2mM L-glutamine and 10 U penicillin/streptomycin
(GIBCO, Paisley, UK). Cells (5 x 105 per well) were cul¬
tured in 96-well flat-bottomed plates (Costar) with either
Der pi or peptide Der pi; pi 11-139 (10p,g/ml). Control
wells contained medium alone, OVA (10 p-g/ml) or were
coated with anti-CD3 and anti-CD28 (5 p,g/ml). After 72 h
supernatants were collected, stored at —70°C and assayed
in duplicate for the presence of the cytokines; IL-4, IL-5,
IL-10, IL-13 and IFN-y using ELISA. Antibodies were
purchased and used according to the instructions of the
manufacturer (IL-4, IL-10, IL-13; R& D Systems, UK, or
IL-5, IFN-y Pharmingen, San Diego, CA).
2.5. Measurement of eosinophil levels in
bronchoalveolar lavage
Immediately after sacrifice, the trachea were exposed and
cannulated with 27-gauge silicon tubing attached to a needle
and syringe. The lungs were instilled through the trachea
with 500 p.1 of cold PBS and the BAL fluid withdrawn.
The volume of BAL fluid collected was measured for each
sample. To determine BALF cell numbers and composi¬
tion, samples were centrifuged (700 x g, 5 min, 4 °C), cells
were washed (PBS/10% FCS), counted and re-suspended at
I x 106 ml-1. BALF (1 x 105) cells in 100 p,l were cytospun
onto poly(L-lysine)-coated slides (3 min at 300 rpm). The
slides were air-dried, fixed in methanol and stained using
Diff/Quick. To determine cytokine levels in BALF, samples
were stored at —70°C. All cytokines were analyzed by
ELISA.
2.6. Extraction and measurement of eosinophils
numbers in lung tissue
Lungs were weighted and homogenized in Hanks balan¬
ced salt solution (HBSS; Gibco) containing lOmM HEPES
(pH 7.4). Following red blood cell lysis, cells were re-homo¬
genized in HBSS containing 0.5% hexadeclytrimethylam-
monium bromide (HTAB; pH 7.4) and freeze thawed in
liquid nitrogen. Levels of eosinophil peroxidase in lung ho-
mogenates were determined using the O-phenylenediamine
substrate (Sigma; OPD 1.5 mM, H2O2 6.6 mM; pH 8). The
reaction was stopped using H2SO4 (4M) and plates read in
a MRX microplate reader at 490. Data was analyzed using
Revelation software.
2.7. Determination ofDer pi specific antibody
levels in sera
Antibody levels in sera, were determined by ELISA.
Unless otherwise indicated serum samples and antibodies
were diluted in PBS/1% BSA and wells washed between
each incubation step with PBS/0.05% Tween-20. Round
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bottomed 96-well microtitre plates (Costar) were coated
overnight at 4°C with either rat anti-mouse IgE (R35-72;
Pharmingen), or with Der pi (5 pg/ml), diluted in car¬
bonate buffer (0.1 mM NaHCCh, pH 8.2). After washing,
non-specific binding was blocked by incubating wells
PBS/3% BSA for 2h at 37 °C. Plates were washed and
serial dilutions of serum samples added in duplicates (IgE
1:5, 1:10, 1:20; IgGl 1:50, 1:100, 1:500; IgG2a 1:10, 1:20,
1:50). The plates were incubated overnight at 4°C. After
washing, biotinylated rat anti-mouse IgGl (LO-MG1-2;
Serotec) or rat anti-mouse IgG2a (Lo-MG2a-7; Serotec)
was added at lOOOng/ml and plates incubated for 2h at
room temperature. To determine Der pi specific IgE levels
in sera, Der pi (10 p.g/ml) was added and plates incubated
at 37 °C for 60min. After washing, plates were incubated
for a further 45 min with biotinylated 4C1 (1:1000 dilution).
Bound biotinylated antibodies were detected by incubating
with streptavidin-peroxidase for 45 min at room temperature
and visualized using the TMB substrate. Plates were read
in a microtitre reader at 450 nm using the MRX microplate
reader and Revelation software.
2.8. Statistics
Data represents mean values ± S.E.M., with five mice per
group. Differences between mean values were analyzed by
one way analysis of variance (ANOVA) using the Dunnett
Multiple comparison parametric test and Instat software.
P < 0.05 were considered statistically significant.
3. Results
3.1. Prophylactic effects of intranasal administration of
an immunodominant peptide on Der pi allergen induced
airway eosinophilia
Eosinophil infiltration of the airways is a predominant
feature of allergic asthma. To investigate whether the in¬
tranasal administration of a peptide covering an immun¬
odominant T cell epitope of Der pi; pi 11-139, could
protect against the induction of Th2 mediated airway in¬
flammatory responses to Der pi, eosinophil numbers in the
BAL and lung tissue were determined. Groups ofmice were
administered intranasally either Der pi; pi 11-139 peptide
(5 x 100 pug) alone or encapsulated in MEA particles on five
consecutive days. Mice were then immunized systemically
and challenged by instillation of Der pi into the airways
(Fig. 1). Eosinophil numbers in the lung tissue and BAL
were determined 24h after allergen challenge. A significant
reduction (P < 0.05) of 66.3% in eosinophil numbers in
the BALF was observed in mice treated intranasally with
MEA encapsulated Der pi; pi 11-139 peptide, as compared
with the control group receiving PBS (Fig. 2A). This cor¬
related with a significant (P < 0.01) reduction of 54.4%
in eosinophil numbers in the lung tissue (Fig. 2B). No
reduction in eosinophil levels in the BAL or lung tissue
were observed in mice administered Der pi; pi 11-139
peptide alone (Fig. 2). The suppression of eosinophilia was
antigen dependent since empty MEA particles had no effect.
Preferential uptake of MEA-peptide by immunosuppressive
APC such as pulmonary dendritic cells (DC) or alveolar
macrophages may account for reductions in Th2 mediated
inflammation. Alternatively, the kinetics of peptide released
systemically from MEA particles may, by altering the fre¬
quency and duration of TCR ligation, reduce the activation
threshold required for T cell tolerance induction.
3.2. Cytokine levels in the BALF
Allergic asthmatics have elevated levels of the cytokines
IL-4 and IL-5 present in the BALF [1]. These cytokines play
a critical role in initiating and sustaining airway inflamma¬
tion and eosinophilia. To determine whether reductions in
eosinophil numbers in the lung and BALF of MEA-peptide
intranasally treated mice, were due to a loss of allergen reac¬
tive CD4+ T helper activity, levels of these cytokines were
measured in BALF of mice 24 h after challenge with Der
pi. Marked reductions in levels of IL-4 (35%) and IL-5
(62%) were observed in the BALF of mice treated i.n. with
MEA encapsulated Der pi; pi 11-139, as compared with
control PBS treated mice. Reductions in IL-5 levels (48%),
were also observed in mice treated intranasally with Der p 1;
pi 11-139 peptide alone. No parallel reduction was observed
in IL-4 levels, suggesting that other factors in addition to
IL-5 influenced eosinophil levels (Fig. 3).
3.3. Mucosal tolerance leads to reductions in antigen
specific production of both Thl and Th2 cytokines,
produced systemically
To investigate whether reductions in eosinophilia was due
to a Th2 to Thl cytokine shift, splenocytes obtained from
individual mice were cultured in the presence of Der pi or
the immunodominant peptide Der pi; pi 11-139. Cytokine
levels in the supernatants were assayed after 72 h (Fig. 4).
In comparison with the control saline treated group, Der pi
reactive T cells obtained form mice administered MEA-Der
pi; pi 11-139 had reduced levels of both the Th2 (IL-5
(69%), IL-13 (67%)) and Thl (IFN-y (82%)) cytokines.
Reductions in airway eosinophila were, therefore, due to a
loss of antigen specific T cell responsiveness and eosinophil
recruitment, rather than a Thl shift in cytokine production.
The loss ofT cell responsiveness to intact Der pi, following
mucosal tolerance induction with an immunodominant T
cell epitope (Der pi; pi 11-139), may be due to linked sup¬
pression resulting in a loss of responsiveness to minor T cell
epitopes within Der pi. Peptide alone, failed to tolerize Der
pi reactive T cells, suggesting that MEA particles enhanced
the tolerogenicity of the peptide. Whereas, the inhibitory
effect of MEA-peptide on Der pi specific responses is
antigen dependent, the significant reduction in IFN--y levels
G. Hall el al.l Vaccine 21 (2003) 549-561 553
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Fig. 2. The effect of i.n. treatment with Der pi; plll-139 on levels of eosinophils in BALF and lung tissue of mice sensitised and challenged with Der
pi. (A) Eosinophil numbers in BALF were determined by Diff/Quick staining of cytospins. For each treatment group, cell number were determined as
a percentage of total cell numbers per ml BALF and expressed as mean ± S.E.M. Differences in means were significant (*P < 0.05). (B) Eosinophil
numbers in lung tissue were determined by measuring eosinophil peroxidase levels in lung homogenates. The data is presented as mean eosinophil
numbers ± S.E.M. for each group of mice. Differences in means were significant (** P < 0.01).
(P < 0.001) may be largely due to a non-specific effect of
MEA particles. Background cytokine levels were negligible
(Fig. 4).
3.4. Antibody levels and isotype are not significantly
suppressed by intranasal peptide treatment
To determine whether the i.n. administration of a single T
cell epitope peptide could influence B cell responses, Der pi
specific antibody levels in sera were measured by ELISA.
Der pi specific IgE, IgGl and IgG2a levels were not reduced
in mice receiving MEA-peptide as compared with control
mice, although there was a 42% reduction in Der pi specific
IgGl levels, in sera obtained from Der pi; pi 11-139 treated
mice. Mice treated with MEA particles alone, had increased
levels of specific IgE in sera, which may be linked to the
non-specific reduction in IFN-y production (Fig. 5).
3.5. Pulmonary eosinophilia is reducedfollowing local
allergen challenge and correlates with an increase in the
ratio ofantigen induced IL-10. IL-5
We investigated whether or not IL-10 plays a role in the
intranasal peptide induced Th2 tolerance to Der pi aller¬
gen. Supernatants obtained form spleen or pooled bronchial
lymph node cells, were cultured with Der pi or Der pi;
pill—139 and assayed for IL-10 production by ELISA.
There was an increase in levels of IL-10 production by anti¬
gen specific T cells obtained from the draining lymph nodes
ofmice treated i.n. with MEA-Der pi; pi 11-139 or peptide
Der pi; pi 11-139 alone, as compared with cells obtained
from control mice. IL-10 levels produced by splenocytes
obtained from intranasally tolerized mice were not signifi¬
cantly greater than in the control group. Comparisons of the
ratio of IL-10 to IL-5, revealed a significant increase in the
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Fig. 3. Reduction in levels of the Th2 cytokines IL-4 and 1L-5 in BALF of mice treated with MEA-peptide (Der pi; pi 11-139), correlated with reduced
numbers of eosinophils in BALF and lung tissue. IL-4 (A) and 1L-5 (B) in BALF obtained from mice 24h after challenge of the airways with Der pi
were determined by ELISA. The data is presented as mean ± S.E.M. for each treatment group.
ratio of IL-10, which correlated with a reductions in lung
eosinophilia. Increases were observed in cultures of spleen
and draining lymph node cells obtained from MEA-peptide
treated mice (Fig. 6).
3.6. Effect of the therapeutic intranasal administration of
Derpi; plll-139 peptide to Derpi sensitized mice
Studies have demonstrated that the intranasal admin¬
istration of allergen to mice sensitized systemically, can
lead to airway inflammation. We investigated whether the
intranasal administration of a Der 1 peptide, using the thera¬
peutic regimen (Fig. 1), leads to reductions or exacerbations
in established Th2 mediated response to Der pi. For this
purpose, groups of mice primed by systemic immunization
with Der pi, were treated intranasaly with peptide (Der pi;
pi 10-131) alone or encapsulated into MEA particles. Ther¬
apeutic administration ofMEA-peptide or peptide alone did
not exacerbate airway eosinophilia in sensitised mice. In
contrast, the intranasal administration of Der pi allergen to
sensitised mice, lead to increases in airway eosinophilia of
70% and an increase of55% in Der pi specific IgGl levels in
sera (P < 0.01). Increases in eosinophilia and specific IgGl
in pre-sensitised mice were not elevated on intranasal admin¬
istration of Der pi adsorbed to MEA. Fig. 7A). In contrast,
administration ofDer p 1; p 110-131 peptide orMEA-peptide
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Fig. 4. Reduction in both Th2 (IL-5) and Thl (IFN-y) cytokine levels. Splenocytes obtained from individual mice were cultured (5 x 106 per ml)
in the presence of either Der pi or the peptide Der pi; plll-139 (10p,g/ml). Supernatants were collected after 72h and cytokine levels assayed by
ELISA. Cytokines in the supematants of splenocytes cultured in media alone or an irrelevant antigen were at baseline levels. The data is presented as
mean ± S.E.M. for each group of mice. Differences in means were significant (* P < 0.001).
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saline plll-139 MEA-pl 11-139 MEA
Fig. 5. Der pi specific IgE and IgG levels in sera. Der pi specific antibodies in sera were determined on day 45. Antibody levels, measured by ELISA
are presented for the following dilutions; specific IgE (1/20 dilution), IgGl (1/100 dilution) and IgG2a (1/10 dilution). The data is presented as OD
405 nm (mean ± S.E.M.) for each group.
to systemically sensitised mice, lead to non-specific reduc¬
tions in Der pi specific IgGl (60%, 52%) and IgG2 (47%,
59%) levels in sera, as compared to control mice (Fig. 7).
4. Discussion
Allergic asthma is thought to arise following a loss of tol¬
erance to inhaled allergen. The exposure of naive mice to
aerosolized allergen has been shown to protect against the
induction of allergic responses [11]. A number of groups
have demonstrated that exposure of the airway mucosa to
soluble allergen by intranasal administration can lead to the
induction of tolerance. However, concerns about the po¬
tential for triggering IgE mediated inflammatory responses,
have prompted investigations on the use of peptides, which
contain T cell epitopes in therapy.
Previous studies demonstrated that residues plll-139
of Der pi contained an immunodominant T cell epitope.
Stimulation with a peptide covering this region induced































Saline plll-139 MEA-plll-139 MEA
Fig. 6. Intranasal MEA-peptide treatment results in an increase in the ratio of IL-10 to IL-5 produced by Der pi reactive T cells in vitro. IL-10 and IL-5
levels in supernatants obtained from Der pi (10p,g/ml) stimulated cells obtained from the spleen or bronchial lymph nodes, were assayed by ELISA.
Mean values from individual spleen and pooled lymph node cells were used for each group. The data is presented as the ratio of IL-10 to IL-5 produced
by each treatment group.
558 G. Hall et al. / Vaccine 21 (2003) 549—561
0 50 100 150 200 250 300 350 400 450 500
Eosinophil numbers (x 10 2V mg lung
20 40 60 80 100
Derpl specific IgGl in sera (pg/ml)
120
20 40 60 80 100 120 140
Derpl specific IgG2a in sera (ng/ml)
160 180
Fig. 7. Therapeutic intranasal administration of Der pi peptide to sensitised mice causes in reduction in systemic humoral responses but not in airway
eosinophilia, following challenge with Der pi. Groups of mice sensitised systemically to Der pi, received three consecutive intranasal administrations
of either peptide or Der pi, alone or encapsulated in MEA particles. Control mice received PBS or MEA alone. Eosinophil numbers in the lung were
determined using the quantitative eosinophil peroxidase assay (A), Der pi specific IgGl (B) and IgG2a (C) levels in sera were determined by ELISA.
The data is presented here as mean±S.E.M. for each treatment group. Differences in mean between the treatment and control saline group are significant
(* P < 0.05, ** P < 0.01) using Dunnett multiple comparison test.
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lympho-proliferative responses in human T cell clones,
and murine T cell lines obtained from Der pi immunized
mice expressing the H-2b haplotype [17,18]. The intranasal
administration of peptide Der pi; pi 11-139 to naive mice
protected against the induction of Thl mediated DTH re¬
sponses, following immunization with Der pi in CFA [19].
In this study, we demonstrate, using a murine model of
pulmonary inflammation that the intranasal delivery of an
immunodominant T cell epitope peptide can also protect
against the induction of Th2 mediated eosinophilia, which
is a principal feature of allergic asthma. Mice administered
MEA encapsulated peptide intranasally had significantly re¬
duced numbers of eosinophils in the BAL and lung tissues
after inhalation of the Der pi allergen. Mucosal tolerance
is linked to the degree to which the CD4+ T cell popula¬
tion is initially activated, since the intranasal administration
of peptide alone, failed to protect against the induction of
eosinophilia. Antigen concentration and TCR affinity are
critical in determining the strength of initial activation sig¬
nals that precede T cell tolerance [20,21], Our data suggest
that by using MEA encapsulated peptide, we were able
to increase the concentration of peptide released systemi-
cally thus strengthening the initial TCR mediated activation
signal.
Eosinophil infiltration of the airways is a characteristic
feature of allergic asthma. Eosinophils contribute towards
airway inflammation not only by the release of inflamma¬
tory mediators, but also as antigen presenting cells, capable
of amplifying localized Th2 mediated responses [22]. The
recruitment and differentiation of eosinophil progenitor
cells in the bone marrow as well as the infiltration and sur¬
vival ofeosinophils at sites of inflammation are all regulated
by IL-5. Signaling by IL-4 or IL-13 through the IL-4Ra
chain is also critical for development of an allergic asthma
phenotype [23], Reductions in levels of the cytokines IL^4
and IL-5 in the BAL fluid of mice challenged with Der pi,
may account for reduced eosinophil numbers in the airways
of mice administered MEA-peptide intranasally. However,
a decrease in levels of IL-5 in the BALF did not result in
a reduction in airway eosinophilia in peptide treated mice,
suggesting that other factors contributed to the reduction
in eosinophil numbers. A separate study, investigating sys¬
temic responses generated by the intranasal administration
of overlapping peptides from PLA2, demonstrated a shift
in cytokine profile, with an increase in the ratio of IFN-y
to IL-4 [13]. Here we fail to demonstrate a Th2 to Thl
shift in cytokine profile by antigen specific cells following
successful intranasal therapy. Comparison of levels of cy¬
tokines produced by spleen and draining lymph node (data
not shown) cells obtained from control or MEA-peptide
treated mice, revealed a reduction in levels of the Th2 (IL-5,
IL-13) as well as the Thl (IFN-y) cytokines. Reductions in
allergen specific production of both Thl and Th2 cytokines
were also observed in a separate study using a recombinant
allergen of Bet vl [12], The general view that Thl cy¬
tokines, by suppressing Th2 responses may protect against
progression of allergic disease, is not supported by data,
which indicates that elevated IFN-y levels can exacerbate
airway inflammatory responses to allergen [24,25].
Studies involving the intranasal administration of whole
allergen, demonstrated that the induction ofperipheral T cell
tolerance was accompanied by modified B cell responses,
with reductions in specific IgE and changes in the ratio of
IgGl to IgG2a levels in sera [12,13]. Data obtained from
this study, demonstrate that the prophylactic use of a short
linear T cell epitope peptide, while suppressing local Th2
dependent inflammatory responses in the airways, did not
greatly influence B cell dependent responses such as anti¬
body levels in sera or isotype. In contrast, the intranasal ad¬
ministration of a T cell epitope peptide pi 10-131, to mice
systemically sensitised with Der pi, lead to a reduction in
B cell dependent antibody responses, but failed to suppress
airway eosinophilia. There is considerable data from ani¬
mal models of asthma, which demonstrate that many of the
processes of asthma, including eosinophil infiltration of the
bronchial mucosa and bronchial hyper-responsiveness are
elicited independently of the presence of B cells and IgE,
but are dependent on the presence of T cells [26,27]. The
induction of tolerance in the allergen specific T cell pop¬
ulation by mucosal delivery of peptide containing a T cell
epitope is sufficient to cause a reduction in eosinophil lev¬
els in the airways, independently of any effect on B cell
responses. Failure to significantly downregulate allergen in¬
duced eosinophilia following mucosal delivery of peptide
to sensitised mice, suggests that it may be more difficult to
suppress established Th2 mediated responses, by tolerance
induction. This view is supported by a recent publication
demonstrating that ongoing Th2 responses in the lungs of
mice prevented induction of tolerance to aerosolized OVA
[28],
We have attempted to address the mechanism under¬
lying the induction of Th2 tolerance. Linked suppression
is thought to account for the loss of responsiveness to
all epitopes within a protein, following the induction of
T cell tolerance using a single immunodominant epitope.
This form of suppression may be mediated via an antigen
non-specific cognate interaction with APC [29], possibly in¬
volving signaling through Notch ligands and their receptors
[30] and/or through the production of immunosuppressive
cytokines such as IL-10 and TGF-(3. There has been con¬
siderable evidence demonstrating that TGF-(3 plays a role
in the loss of responsiveness arising due to the induction of
mucosal tolerance [12,31]. Animal studies have indicated
that the immunoregulatory cytokine IL-10 is a critical fac¬
tor in the induction of mucosal tolerance to a Thl response
to autoantigen [32], Clinical studies have demonstrated an
increase in IL-10 production by allergen reactive CD4+ T
cells in the periphery following SIT [33]. However, until
now, a role for IL-10 in the induction of tolerance to allergen
and consequently a reduction in Th2 mediated airway in¬
flammation has not been demonstrated using in vivo models.
In this study, we have shown that after prophylactic ther-
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apy with peptide alone or encapsulated in MEA particles,
there is an increase in levels of IL-10 production following
antigen stimulation of cells obtained from lymph nodes
draining the airways. Reductions in eosinophil numbers cor¬
related with a parallel reduction in IL-5 production. IL-5 is
a critical differentiation and survival factor for eosinophils
as well as a major chemoattractant. It is therefore, likely
that IL-10 induced tolerance in the allergen reactive CD4+
Th2 population, possibly during antigen presentation in the
draining lymph nodes, would result in a loss of localized
IL-5 production and consequently in eosinophil levels in
the airways. Recent evidence suggests that the production
of IL-10 by pulmonary DC may be critical for the induction
of mucosal tolerance [34]. IL-10 is a critical growth factor
for a population of antigen specific CD4+ CD45RB low
CD25+ T regulatory type 1 (Trl) cells, which are thought
to be central to the induction and maintenance of periph¬
eral tolerance [35,36]. The transfer of Trl T cell clones,
but not Thl or Th2 clones, at the time of OVA immuniza¬
tion inhibited antigen specific serum IgE responses [37].
Although originally described as a murine Th2 factor, it is
now recognized that IL-10 inhibits Th2 mediated responses,
including airway eosinophilia [38]. The ability of IL-10
to suppress DC maturation may be central to the induc¬
tion of T cell tolerance and immunoregulation by Trl cells
[39,40],
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